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General Introduction 
1.1 Haemostasis and Venous Thrombosis
Haemostasis refers to a physiologic process whereby bleeding is halted (reviewed in (1-3)).
When a blood vessel is damaged, several processes occur to staunch the flow of blood. Firstly,
vasoconstriction narrows the blood vessel, reducing vessel diameter and slowing bleeding. 
Then, during primary haemostasis blood platelets bind to collagen in the exposed sub-
endothelium to form a haemostatic plug within seconds after an injury. This is followed by 
secondary haemostasis or coagulation, which involves the activation of a complex cascade of
coagulation factors, ultimately resulting in the conversion of fibrinogen into polymerized
fibrin, making a clot. Finally, the clot attracts and stimulates the growth of fibroblasts and
smooth muscle cells within the vessel wall, and initiates the repair process, which ultimately
results in the dissolution of the clot through fibrinolysis (tertiary haemostasis). Disorders of
haemostasis can be roughly divided into platelet disorders, such as Glanzmann
thrombasthenia and Bernard-Soulier syndrome, and disorders of coagulation, such as
haemophilia or thrombosis.
Most coagulation factors circulate as the zymogen of a serine protease. The coagulation
cascade is a series of reactions in which the zymogens and their glycoprotein cofactors are
activated and then catalyze the next reaction in the cascade. Coagulation is initiated mainly in 
response to the interaction between factor VII (FVII) and exposed tissue factor (TF) from the 
vascular sub-endothelium. The TF-activated FVII (FVIIa) complex activates coagulation
factors IX (FIX) and X (FX) (4), thereby activating the coagulation cascade (Figure 1). The
final product of the cascade, thrombin, increases its own production by activating other
components of the coagulation cascade, amongst which factors V (FV), VIII (FVIII), and XI
(FXI) and so the cycle continues. The primary role of thrombin is the conversion of 
fibrinogen into fibrin fibres, the main component of the blood clot together with the platelets.
Activated clotting factors are the driving force of the coagulation cascade. To prevent
excessive clotting, activated coagulation factors are inactivated by the circulating blood
protease inhibitors; antithrombin (5) and heparin cofactor II (6), by tissue factor pathway
inhibitor (TFPI) (7) and by Activated protein C (APC), the end product of the protein C
anticoagulant pathway (8). Whereas blood protease inhibitors and TFPI bind to the activated
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clotting factors and/or clotting factor complexes thereby rendering them inactive, APC 
inhibits the coagulation cascade through the proteolytic degradation of the two key
coagulation factors activated FV (FVa) and activated FVIII (FVIIIa). 
The coagulation cascade is tightly regulated since excessive production of fibrin would lead 
to the occlusion of blood vessels and thrombosis, whereas too little fibrin would cause
(excessive) bleeding and impaired wound healing. When clots are formed in the venous
system we refer to venous thrombo-embolism. These clots most often occlude veins in the 
extremities (e.g. legs; deep vein thrombosis), and may form emboli, which travel through the
blood to the narrow pulmonary arteries, where they may cause life-threatening obstructions
(pulmonary embolism). The annual incidence of venous thrombosis is 1-3 per 1000 
individuals (9;10). A predisposition towards this disease may be genetic or acquired. Acquired
risk factors include a.o. aging, immobilisation, trauma, pregnancy, and use of female hormones
(11). Genetic risk factors include loss of function mutations in the genes coding for 
antithrombin, protein C, and protein S (PS) and gain of function mutations in the FV and
prothrombin gene (12). The most common genetic risk factor is a mutation in the gene 
encoding FV, causing an amino acid substitution, R506Q, which renders this coagulation
factor resistant to inactivation by APC (13). FV-R506Q is referred to as FVLeiden and occurs in
almost 50% of the patients with a family history of venous thrombosis (14).
1.2 The Protein C Anticoagulant Pathway
The protein C anticoagulant pathway is initiated by the activation of protein C to APC by a 
complex of thrombin and the transmembrane glycoprotein thrombomodulin.
Thrombomodulin present in the membranes of vascular endothelial cells amplifies protein C 
activation more than 1000 fold (15), and when protein C is bound to the Endothelial Protein 
C Receptor (EPCR), this process is stimulated another 20-fold (16). Upon its generation, APC
inactivates F Va and FVIIIa (Figure 1) thus inactivating the prothrombinase and tenase
complexes (17;18). Both proteolytic reactions are greatly enhanced by the negatively charged
phospholipids present on activated platelets and vascular endothelium, and by PS, the non-
enzymatic cofactor to APC (19).
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PS forms a complex with APC on the phospholipid surface and increases the affinity of 
APC for negatively charged phospholipids (17;20;21). Moreover, PS relocates the APC active
site closer to the membrane surface, which contains the activated coagulation factors (22). In
the inactivation of FVIIIa, PS and FV act as synergistic cofactors to APC (23). PS also has 
direct anticoagulant properties independent from APC. It was shown to directly inhibit the
activity of the tenase and prothrombinase complexes, presumably by binding to factors VIIIa
(24), Va and Xa (25-27). The physiological implications of these findings are the subject of 
active research (28-31).
FIXa
Figure 1 Schematic representation of the coagulation cascade and the protein C 
anticoagulant pathway. Blunted arrows represent inhibitory reactions.
Next to inhibiting the formation of thrombin, APC also has profibrinolytic properties.
During fibrinolysis cross-linked fibrin, the main component of a blood clot, is solubilized by
plasmin. Plasmin is generated from its precursor, plasminogen, by tissue-type plasminogen
activator (t-PA). t-PA however, is strongly inhibited by plasminogen activator inhibitor-1 
(PAI-1). APC is thought to stimulate fibrinolysis through binding and inhibition of PAI-1 
(Figure 2) (32-34). The APC-PAI-1 interaction is greatly enhanced upon binding of the



























Figure 2 Schematic representation of the proposed role for APC in fibrinolysis. Blunted
arrows represent inhibitory reactions. 
In addition to their anticoagulant role, both APC and PS have been implicated in other
major physiological processes. APC has been shown to have both anti-inflammatory and anti-
apoptotic effects (36-38), and successful clinical trials have been conducted for development
of its use in the treatment of sepsis (39;40). Similar functions have been allocated to PS (41).
The emphasis of the research into a role beyond coagulation for this protein has focused
mainly on its mitogenic properties (42;43) and its potential role in the regulation of cell 
survival (44-47). 
Just as the coagulation cascade is under strict regulation by several inhibitory pathways, so 
are the main components of the protein C anticoagulant pathway. APC anticoagulant activity 
is inhibited after binding to protein C inhibitor (PCI) and �1-antitrypsin, both members of the
serpin family of blood protease inhibitors (48-50). Moreover, PCI prevents the formation of
APC by inhibiting the thrombin-thrombomodulin complex (51). The PAI-1-vitronectin
complex was also suggested to be important in limiting APC anticoagulant activity on the















DiScipio and Davie in Seattle first isolated and named protein S(eattle) in 1977 (52). Not
much later Walker described PS as the non-enzymatic cofactor to APC (17;19). PS (Figure 3) 
is a vitamin K-dependent glycoprotein with a molecular weight of 75 kilo Dalton that is 
present in plasma at a concentration of ~ 0.35 µM (53-55). The structure and function of its
individual domains are well-documented and reviewed elsewhere (56-59) and will therefore 
not be covered here. Regretfully, a crystal structure of PS has not yet been successfully
generated.
Figure 3 Schematic representation of human Protein S. (A) Immature PS. AS: aromatic
stack, EGF: epidermal growth factor-like domain (B) Mature post-translationally modified PS. �:
carboxylated carboxyglutamic (Gla) residues, : glycosylation sites, illustration (B) taken from
(60).
PS is produced and secreted mainly by hepatocytes (61) in the liver but also at low levels by
various other cell types, such as megakaryocytes (62), endothelial cells (63;64), Leydig cells 
(65), osteoblasts (66) and cells of the nervous system (67). In addition, a small portion 
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(~2.5%) is stored in the �-granules of blood platelets (68). That extra-hepatically produced PS
is an important source of plasma PS, is illustrated by the fact that in patients with liver disease 
PS levels are reduced but not to the same low levels as other vitamin K-dependent coagulation
factors (69;70). The anticoagulant reactions in which PS participates (Figure 1), take place on
the surface of endothelial cells and activated platelets, cell types that both produce and/or can
release PS.
PS can bind to the surface of (endothelial) cells not only through its interaction with 
negatively charged phospholipids (71), but also by binding to a specific family of membrane
receptor tyrosine kinases (Tyro/Axl) (67;72-74). This interaction was first shown for growth
arrest-specific 6 (GAS6) (75), a protein structurally related to PS (76). The relevance of this
finding is questionable though since in contrast to GAS6, which binds to and stimulates its
receptor, PS seems to only bind, not activate, the receptor at physiological relevant
concentrations (77). 
Functional PS levels in plasma are mainly regulated in two different ways. Firstly, PS can be
inactivated by proteolytic cleavage in the thrombin-sensitive region. In vitro PS is cleaved by
thrombin after Arg 49 and Arg 70 in the thrombin-sensitive region (78). In vivo PS is protected
against thrombin-mediated cleavage by the binding of calcium ions to the Gla-domain (79).
Nevertheless, increased cleaved PS levels were found in patients with disseminated
intravascular coagulation (DIC) (80). Long et al. demonstrated that in vitro PS is cleaved after
Arg 60 by FXa (81). This cleavage site was later shown to be the actual cleavage site in vivo
(82;83). It is therefore assumed that it is FXa that inactivates PS by proteolytic cleavage in vivo.
Secondly, PS circulates in plasma in two forms; a free form (40%) and in complex with the
complement inhibitor, C4b-binding protein (C4BP) (53-55). Multiple binding sites for C4BP
are located in the SHBG domain of PS (84-87). The C4BP protein contains 6 or 7 identical �-
chains and a single �-chain, although 17% of the C4BP molecules lack the �-chain (55). PS 
binds with high affinity to C4BP via the �-chain (Figure 4a) (88). Unbound PS circulating in 
plasma represents the molar excess of PS over C4BP� (53;55).
Whereas only free PS functions as a cofactor to APC, the APC-independent anticoagulant
properties of PS do not seem to be negatively influenced by complexation to C4BP (24;27;31).
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Moreover, the newly proposed role for PS in the phagocytosis (44;45) and/or rescue (43;47)
of early apoptotic cells is thought to be mediated at least in part by directing C4BP to the
surface of apoptotic cells (Figure 4b).
Figure 4 Interaction of PS with C4BP. (A) Schematic representation of binding sites on C4BP�+.
PS binds to the �-chain of C4BP. The binding of other proteins at their specific binding sites
does not affect PS binding to C4BP (89;90). C3b: activated complement factor 3, C4b:
activated complement factor 4, LRP: low-density lipoprotein receptor-related protein, SAP:
Serum Amyloid P component. Illustration adapted from (59). (B) Properties of PS on the cell
surface. Illustration adapted from (91).
1.3.2 Gene
Two copies of the gene for PS, PROS1 and PROS2, are located near the centromeric
region of chromosome 3 (3p11.1-3q11.2) (92;93). PROS mRNA (94-96) is produced only 
from the PROS1 gene, which spans a length of 80 kb and contains 15 exons and 14 introns
(97-99). This is because PROS2 is a pseudogene that lacks the promoter and the first exon. It
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contains several frame-shift deletions leading to premature stopcodons that render this gene
inactive. PROS2 most likely originated from the functional gene, PROS1, through partial
duplication (98). As with promoter regions from other genes coding for vitamin K-dependent
coagulation proteins (100-106), a distinct TATA-box is absent from the PROS1 promoter
region. The finding of various transcription start sites reported for both published (94-96) and 
unpublished (NCBI-dbEST database entries (107)) PROS1 cDNA sequences, suggests that
transcription is initiated through multiple transcription start sites. In addition, the presence of
an alternative promoter and first exon was postulated by Ploos van Amstel et al (98) upon
their finding of two distinct start sites by primer extension analysis and the identification of
two putative splice acceptor sites in the promoter region. This last hypothesis was, however,
never borne out by experimental data. 
In contrast to the coding region of the PROS1 gene, which has been thoroughly
investigated (reviewed in (108;109)), the promoter region has been poorly investigated. A
promising abstract on the regulation of the PROS1 promoter by various transcription factors, 
which was presented at a meeting of the International Society of Thrombosis and 
Haemostasis (ISTH) in 1995, was never followed by a paper in a peer reviewed journal (110). 
Since then, only a single report on the regulation of the promoter region has been published
(111). In this last report, transcription directed from PROS1 promoter-reporter gene
constructs was stimulated in hepatoma HepG2 cells in vitro by binding of the ubiquitous 
transcription factor, Sp1. The liver-specific transcription factor, forkhead box A2 (FOXA2,
HNF3�), also bound to the PROS1 promoter, but trans-activation studies were not conducted
with this transcription factor.
On a completely different level, Hooper and coworkers (112-114) measured PS levels after 
stimulation of cultured human hepatoma cell line HepG2, primary Human Umbilical Vein
Endothelial Cells (HUVEC), and the human microvascular endothelial cell line, HMEC-1,
with interleukin 6 (IL6), a mediator of the acute phase response during inflammation (115). 
IL6 stimulated PS production by all cell types and this could be suppressed by the addition of 
tumor necrosis factor � (TNF�). Although these authors did not directly investigate
transcriptional regulation of PROS1, the results allude to the possible binding of the nuclear
factors, which are induced by IL6 such as the signal transducer and activator of transcription 3 
(STAT3) (116) and the CCAAT/enhancer-binding protein � (C/EBP�) (117). In Figure 5 the
24
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data from the various studies are combined and putative binding sites for STAT3 and
C/EBP� are included.
All in all, the components that determine (normal) variation in PS levels at the
transcriptional level are still largely unknown. 
-299  GCTGGTGAAG AAGGATGTCT CAGCAGTGTT TACTAGGCCT CCAACACTAG 
-249 AGCCCATCCC CCAGCTCCGA AAAGCTTCCT GGAAATGTCC TTGTTATCAC
-199  TTCCCCTCTC GGGCTGGGCG CTGGGAGCGG GCGGTCTCCT CCGCCCCCGG
-149  CTGTTCCGCC GAGGCTCGCT GGGTCGCTGG CGCCGCCGCG CAGCACGGCT
-99   CAGACCGAGG CGCACAGGCT CGCAGCTCCG CGGCGCCTAG CGCTCCGGTC
-49   CCCGCCGCGA CGCGCCACCG TCCCTGCCGG CGCCTCCGCG CGCTTCGAAA
+2 TG
Sp1                C/EBP�/STAT3?
FOXA2
Figure 5 Partial PROS1 5’ sequence. FOXA2 and Sp1 bind the PROS1 promoter at the 
underlined regions (111). A putative binding site for C/EBP� and STAT3 binding is depicted. 
The arrows indicate published transcription start sites derived from cDNA libraries (65;95;96).
+1 is the first nucleotide of the translational startcodon, ATG.
1.4 Protein S Deficiencies
1.4.1 Hereditary PS deficiency 
Partial PS deficiency was first reported to be associated with venous thrombotic disease in
1984 (118). In subsequent years it was established that in thrombophilic families heterozygous
PS deficiency was associated with an increased risk of venous thrombosis. Homozygous or
compound heterozygous PS deficiency is extremely rare and associated with severe purpura
fulminans in the neonatal period. Hereditary PS deficiency is classified in three types (119). 
Type I deficiency corresponds to low levels of both free and complexed PS, type II PS 
deficiency is characterized by normal total and free PS levels but reduced PS activity, and type
25
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III is defined by normal total PS levels but low free PS levels and activity. The disorder
inherits as an autosomal dominant trait with incomplete penetrance (120) and is present in
about 2% to 8% of families with hereditary thrombophilia (121;122). Many abnormalities in
PROS1 underlying hereditary PS deficiency have been described (reviewed in (108;109)). More
recently Johansson et al reported a high incidence of large PS gene deletions in a group of
Swedish PS deficient families (123). Not all familial PS deficiencies are explained by an
abnormality in PROS1 though (124). In this respect it must be noted that intronic sequences 
and 5’, and 3’ sequences are not routinely included in the investigation of familial PS 
deficiency and that possible functional mutations and polymorphisms in these regions are 
therefore not found. Of course, the remainder of unexplained inherited PS deficiencies may
also be caused by variations in other genes. The Spanish Genetic Analysis of Idiopathic
Thrombophilia (GAIT) project described the genetic linkage between free PS levels and the 
1q32 genetic locus, which contains both genes for C4BP� and C4BP� (125). This was not a
surprising finding since PS binds to the C4BP�-chain present in most C4BP molecules. This 
binding is of a 1:1 stoichiometric nature, which means that all C4BP-�+ molecules are bound 
by one PS molecule. A drop or rise in C4BP-�+ protein levels thus directly influences free PS 
levels either positively or negatively, respectively.
An example of a genetic abnormality/polymorphism is the relatively rare Ser 460 to Pro
change in PSHeerlen (126) which, in some families, is associated with a type III PS deficiency
(127;128). The anticoagulant properties of PS are not negatively affected by this amino acid
change (29;31). A recent publication shows that instead, free PSHeerlen is cleared more rapidly
than wild type PS from the circulation in mice (129). 
1.4.2 Acquired PS deficiency 
Whereas hereditary PS deficiency is relatively rare, many circumstances can lead to
acquired deficiency, in which case it may be transient. Several non-genetic and environmental
factors such as liver disease (130), DIC (80;130), and hormonal status (gender, contraceptive
use, pregnancy) (131-133) influence PS levels. In liver disease PS levels as well as C4BP levels
are decreased. Patients with DIC have decreased PS activity most likely due to increased
cleavage of PS (80). Total PS levels remain similar as in controls and reports on the levels of 
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free PS in this hypercoagulable state are inconclusive (69;130). PS levels were shown to 
decrease with age (134), but when these data are corrected for gender the effect appears
specific for females (135). It is evident from several studies that PS levels (total and free) are
downregulated by female sex hormones, but the mechanism of this effect has not been
clarified and would form an interesting area of research. 
A more controversial issue is the regulation of PS levels during inflammation. C4BP is an
established acute phase reactant with 2-3 fold elevated plasma levels during inflammation 
(136-139). Although PS levels are upregulated by the acute phase cytokine, IL6, in vitro (112),
this finding was not confirmed by in vivo data. Several studies have demonstrated similar or
only slightly increased total plasma PS levels (140-144). A controversy surrounds the levels of
free PS during inflammation, with some studies showing reduced free PS levels in patient
plasma (140-142), whilst others report stable free PS levels (143;144). A difference in the
regulation of C4BP �- and �-chains in patient populations during the acute phase may explain
the observed discrepancy (145). 
1.5 Aim of this thesis
Overall the components that determine variations in PS levels at the transcriptional level 
are still largely unknown and the promoter region of PROS1 has been poorly investigated. 
Knowledge of the PROS1 promoter structure and the proteins regulating its transcriptional
activity may help in acquiring a greater understanding of PS levels and PS function since;
a. Transcription factors that regulate PROS1 transcription may be tissue-specific (e.g.
liver-specific transcription factors), thereby explaining PS production in certain cell 
types,
b. Mutations or polymorphisms in the PROS1 5’ sequence may lead to deficiencies if they
are located in important binding sites for transcription factors or for the basal
transcriptional machinery,
c. Deficiencies (qualitative or quantitative) in the regulatory factors of PROS1
transcription may explain idiopathic hereditary PS deficiencies,
d. Transcription factors that upregulate PROS1 transcription may themselves be triggered 
by a specific physiological process, thereby linking PS to this process.
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The aim of this thesis was to identify the factors regulating PROS1 transcription, to determine whether
PROS1 transcriptional regulation has a tissue/cell-specific component and to elucidate the underlying
mechanisms.
In Chapter 2 the transcriptional initiation of endogenous human PROS1 is examined in 
liver and the relevant cell types that are exposed to the blood stream. Since PS is produced
primarily by hepatocytes and to a lesser extent also by endothelial cells and megakaryocytes,
we hypothesized that PS transcription might be regulated in a cell type-dependent manner. 
Cell-specific transcription may be regulated through a difference in the location of 
transcription start sites. Four major endogenous start sites were identified, the usage of which 
differed slightly between cell types. Furthermore, a minimal promoter with optimal
transcriptional activity was identified in basal expression studies with PROS1 promoter-
reporter constructs in all cell types. It is this promoter construct that, in Chapter 3, was used
in a pilot study in which the effect of a range of transcription factors on PROS1 promoter
activity was tested. Phylogenetic footprinting further provided a solid basis on which to select
certain conserved regions within the human PROS1 promoter for further research. Chapter 4
expands the data presented in chapter 3 with a large scale investigation into the possible 
binding of nuclear proteins to the sequence contained in the PROS1 promoter. Sp1 is
identified as a transcription factor with multiple binding sites within the PROS1 promoter.
From further functional studies it became apparent that Sp1, and possibly also the related 
transcription factor Sp3, is almost solely responsible for the basal transcriptional activity of the
PROS1 promoter.
Previously published reports suggest that IL6 has a direct effect on PROS1 transcription.
In Chapter 5 the IL6 responsive element within the PROS1 promoter is identified. STAT3
binding to this element was essential for induction of PROS1 transcription, which is illustrated 
by the absence of STAT3 binding and IL6 induction of PROS1 transcriptional activity when
this region is mutated. Major stimulatory effects on PROS1 transcription were also observed
upon cotransfection of another mediator of IL6 signalling, C/EBP�. However, the role for




Chapter 6 describes a classic case of serendipity. During the development of a real-time
rtPCR analysis (QPCR) for the accurate measurement of PROS1 transcipt levels, an additional
unexpected PCR product was identified. The product was sequenced and resulted in the
identification of a relatively abundant alternatively spliced PROS1 mRNA. The alternative PS
product from this alternative mRNA is compared to that of normal recombinant PROS1 in
COS1 cells in vitro.
In Chapter 7 the results described in this thesis are discussed and related to insights from
the literature.
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Initiation of Protein S mRNA synthesis
Summary
Protein S (PS), a cofactor of activated protein C (APC), is a vitamin K-dependent
anticoagulant plasma protein, which is produced mainly in the liver but which is also produced
extrahepatically. Therefore, the production of this protein may be regulated in a tissue-specific
manner. Upon analysis we found that the 5’-flanking region of the human PS gene (PROS1)
lacks characteristic “CCAAT” and “TATA” boxes. To determine the sites of transcriptional
initiation PROS1 transcripts from HepG2, HuH7, HeLa, HUVEC, and Meg01 cells and
human liver were subjected to transcription start site (TSS) analysis by using 5’-rapid
amplification of cDNA ends. In all cell types, as well as in human liver, transcription is 
initiated most frequently at one of three TSSs located 100 bp, 117 bp or 147 bp upstream 
from the translational startcodon. HUVEC cells contained an additional TSS at –200 bp. In all 
cell lines, reporter constructs containing a minimal promoter of 370 bp upstream of the
translational startcodon demonstrated maximal promoter activity. Whereas three distinct TSSs
were identified for the endogenous PROS1 transcripts, no preferred TSSs could be
determined for transiently transfected PROS1 promoter luciferase constructs. This is
consistent with our finding that deletion of the first 181 bp proximal to the translational start 
in these constructs did not result in complete deterioration of promoter activity. This suggests




Reduced plasma Protein S (PS) levels were first reported to be involved in the
development of venous thrombo-embolism (VTE) in 1984 (1-3). PS deficiency has been well
established as a risk factor for VTE since then (4-7). PS is a vitamin K-dependent plasma
protein that displays anticoagulant properties by acting as a non-enzymatic cofactor for
activated Protein C (APC) in the proteolytic degradation of blood clotting factors Va and
VIIIa (8-11). In human plasma, PS circulates in an active free form (40%) and a C4b-binding 
protein (C4BP)-bound inactive form (60%) (12-14). The major source of circulating plasma
PS is the hepatocyte (15). However, PS is also known to be produced by a variety of other cell 
types such as megakaryocytes (16;17), endothelial cells (18;19), Leydig cells (20), osteoblasts
(21) and cells of the nervous system (22). In mammals, PS mRNA was found in virtually all
tissues and organs examined (23).
Two copies of the PS gene are located on chromosome 3. The active PS gene (PROS1)
shares 96% homology with the inactive pseudogene (PROS2). The pseudogene, which lacks
the promoter and the first exon also contains several frame-shift deletions leading to
premature stopcodons that render this gene inactive (24-26). Mutational analysis of the exons
of PROS1 in patients with PS deficiency has shown various mutations within the PS gene to
be responsible for low PS levels in plasma [reviewed by Gandrille et al (27;28)]. In contrast to
the coding regions of the PROS1 gene, the promoter region has been poorly investigated. As
with other promoter regions from genes coding for vitamin K-dependent coagulation
proteins, a distinct TATA-box is absent from the PROS1 promoter region (29;30). The
literature to date describes one primer extension assay (25) and multiple cDNAs derived from 
cDNA libraries (31-33). The databases at the National Center for Biotechnology Information
(NCBI) provide multiple direct submissions of PROS1 cDNAs (34). However, none of these
cDNAs are necessarily full-length, whereas primer extension studies are notoriously difficult
to interpret.
In the present study, we describe an analysis of the transcriptional control region of 
PROS1. To our knowledge for the first time we provide a transcription start site (TSS)
distribution after analysis of multiple full-length PROS1 cDNAs from various cell lines and
human liver. Using a method that targets capped mRNA for reverse transcription we show
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that there are a number of major start sites in the promoter of the endogenous PROS1 gene.
The cell types that were tested displayed small differences in TSS usage. In addition, we show
that this preference for specific positions is lost in luciferase reporter constructs. The
implications of these findings are discussed. 
Experimental procedures 
Plasmids --- The PROS1 promoter reporter constructs used in this study, originated from a 7
kb EcoRI promoter fragment which was isolated from BAC clone #2513H18 from the
CITBI-E1 genomic library (Research Genetics, Invitrogen, Carlsbad, CA) and ligated into the
EcoRI site in the multiple cloning site region (MCS) of the pcDNA3 cloning vector
(Invitrogen). This pcDNA3-PROS1 construct contained 716 bp of sequence downstream
from the translational startcodon. The complete sequence was determined through automated
sequencing (ABI PRISM and Beckman CEQ2000 sequencers) and deposited in Genbank 
under accession number AY605182. Subsequently, pcDNA3- PROS1 was modified to contain
nucleotides -5948 to -1 from the translational startcodon as follows. First, the construct was
digested with BamHI and EcoRI (all restriction enzymes were obtained from New England
Biolabs, Hertfordshire, UK) resulting in two fragments. Fragment -5948/-410 contained a 
pcDNA3-BamHI and a PROS1-BamHI terminus, and fragment -410/+716 contained a 
PROS1-BamHI and a pcDNA3-EcoRI terminus. Fragment -410/+716 was ligated into
pcDNA3, which had been linearized by digestion with BamHI and EcoRI. The pcDNA3-
PROS1-410/+716 was used to generate a product spanning from bp -410 to -1 by polymerase
chain reaction (PCR) using the T7 primer in pcDNA3 and a mutant reverse gene-specific 
primer (GSP), PSstart, in which the initiation methionine was modified into an EcoRI site 
(Table 1). After digestion with BamHI and EcoRI this PCR product was ligated into pcDNA3,
which had been linearized by digestion with the same enzymes. PROS1 fragment -5948/-410
was then religated into the BamHI site connecting the 5’ terminus of PROS1-410/-1 and 
pcDNA3. The resulting PROS1 fragment (-5948/-1) was cloned directly 5’ to the luciferase 
reporter gene in the pGL3basic vector (pGL3b, Promega, Madison, WI) after digestion with 
MCS restriction sites KpnI and XhoI. This construct was named PS5948. PS5948 was 
linearized with KpnI and NdeI (located at position –5798) and subsequently subjected to
exonuclease III digestion (Erase a Base kit, Promega). The size of the resulting 5’ deletion was
determined by sequence analysis. The 5’-deletion constructs were used for transient
transfection assays. After digestion of construct PS1062 with PstI and EcoRI, exonuclease III
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digestion was also used to obtain 3’-deletion fragments from this construct. Additional 3’-
deletion constructs, PS-370/-181, PS-1062/-256 and PS-370/-256, were created using 
restriction enzymes. PS-370/-181 was created by combination of constructs PS-370 and PS-
1062/-181 after digestion with HindIII. PS-1062/-256 and PS-370/-256 originated from the
original PS370 and PS1062 constructs by religation after excision of a StuI-EcoRI PS fragment
(-256/-1). An overview of all luciferase reporter constructs is given in Figure 1.
Figure 1 PROS1 promoter-luciferase constructs in pGL3basic. The numbers indicate the
length of the PROS1 5’ flanking region proximal to the luciferase gene in pGL3basic.
Constructs PS1062 and PS370 were also used in 3’ deletion studies. The length of the 3’ 
indentation is shown at the 3’ end of the construct.
Human liver, cell lines and media --- A human liver sample was obtained from a deceased
healthy donor and was a kind gift from E. de Wit at TNO Center for Prevention and Health,
Leiden (TNO). The human hepatoblastoma cell line HepG2, and cervical adenocarcinoma cell
line HeLa were purchased from the American Type Culture Collection (ATCC, Manassas,
VA). Megakaryocytic cell line Meg01 was a kind gift from G. van Willigen from the Utrecht 
Medical Centre. The hepatoma cell line HuH7 was a kind gift from M. Verschuur (TNO).
Primary human umbilical vein endothelial cells, HUVEC cells, were a kind gift from J.
Grimbergen (TNO). HepG2, HuH7, HeLa cells were grown in Minimal essential medium
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(MEM), 10% Fetal Bovine Serum (FBS), 100 g/ml penicillin, 100 g/ml streptomycin, and
1x MEM non-essential amino acids (all purchased from Gibco, Invitrogen). HUVECs were
grown in M199-medium (BioWhittaker, Walkersville, MD), 10% heat inactivated human
serum (local bloodbank), 10% Newborn Calf Serum (home made), 10 IE/ml heparin
(BioWhittaker), 150 U/ml endothelial cell growth factor, 100 g/ml penicillin (BioWhittaker)
and 100 g/ml streptomycin (BioWhittaker). 24 hrs before transfection the medium was 
replaced with heparin-free medium to prevent interference with the transfection assay. For PS
antigen level measurements HUVEC cells were grown in serum-free EBM medium
(BioWhittaker). Meg01 cells were grown in RPMI 1640 medium, 20% FBS, 100 g/ml
penicillin, 100 g/ml streptomycin (all purchased from Gibco, Invitrogen). For PS antigen
level measurements Meg01 cells were suspended at 1*106 cells/ml in RPMI 1640 medium 
with 10% FBS. 
Reporter gene assays --- 1*106 Meg01 suspension cells were used per transfection. All adherent
cell lines (HepG2, HuH7, HeLa, HUVEC) were transfected at 60-80% confluency. HUVEC
cells were transfected in passage 2-3, whereas the other cell types were used up to passage 25.
Each transfection was performed in triplicate in 12-wells plates, all assays were conducted
with two different DNA preparations of each construct. Transfections with HepG2, HeLa,
HUVEC and HuH7 cell lines were carried out using 3 l Tfx-20 lipids (Promega) per g
transfected DNA. Meg01 cells were transfected using 10 g DAC-30 (Eurogentec, Seraing,
Belgium) per 2 g DNA. In each transfection an equimolar concentration of construct was 
used supplemented with pUC13-MCS vector to obtain a fixed amount of transfected DNA. 
In pUC13-MCS the MCS had been removed by digestion with PvuII and religation. Control 
vector pRL-SV40 (Promega), expressing the Renilla luciferase, was co-transfected for 
correction of transfection efficiency in a 1:500 ratio to total transfected DNA in HepG2,
HuH7 and HeLa cell lines, a 1:100 ratio in transfections with HUVEC and Meg01 cells. The
cell extracts were harvested at either 24 hours (HepG2, HuH7) or 48 hours (Meg01, HUVEC,
HeLa) after transfection. Luciferase activity was measured according to the Dual Luciferase
Assay System Protocol (Promega). All cell lines were lysed in 250 l Passive Lysis Buffer/well,
after which 20 l was used to measure luciferase activity in HepG2 and HuH7 cells, 100 l
was used for HeLa, HUVEC and Meg01 cells. Activity was measured using a Lumat LB9507 
luminometer (Berthold, Bad Wildbad, Germany).
PS measurements --- Total PS antigen levels in culture media were determined by enzyme-
linked immunosorbent assay (ELISA) as described previously (35), with the following
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modifications. ELISA plates were coated with goat anti-human PS IgG (Kordia, Leiden, The
Netherlands) overnight at 4oC. A second coating with 2.5% ovalbumin (Sigma-Aldrich, St.
Louis, MO) at 37oC for 1 hour was performed to reduce background absorbance. Complexes
were detected with horseradish peroxidase-conjugated rabbit anti-human IgG (Dako, 
Glostrup, Denmark). Absorbance at 450 nm was determined with an Organon Teknika plate 
reader (Turnhout, Belgium).
RNA-assays --- Total RNA was isolated from cell culture or frozen tissue using Trizol 
reagent (Invitrogen) according to the manufacturers recommendations. Samples were treated
with RNAse-free DNAse I (Amersham, Roosendaal, The Netherlands) after which RNA was
purified with the RNeasy mini kit (Qiagen, Hilden, Germany). For 5’ RACE (Rapid
Amplification of cDNA Ends) experiments polyA RNA was isolated from total RNA
preparations with a PolyA isolation kit (Ambion, Austin, TX). PROS1 RNA levels were
determined by quantitative real-time PCR analysis (QPCR). First, 1g total RNA from each
cell line was reverse transcribed using Superscript II reverse transcriptase and random
hexamers (Invitrogen). 1/20th of the obtained cDNA was subsequently used in a QPCR 
reaction with primers and probes specific for PROS1. The primers and probe sequence
locations and lengths were determined by using the ABI Primer Express Program (Applied
Biosystems, Foster City, CA), and custom synthesized at Eurogentec. PROS1 QPCR reactions
(Eurogentec) were performed in 0.5 ml thin-walled, optical-grade PCR tubes (Applied 
Biosystems) in a 50 l final volume, by addition of the following components: 0.25 U
AmpliTaq Gold DNA polymerase, 160 nM TaqMan probe, 300 nM of each primer, and 3 
mM MgCl2. A QPCR of the internal standard, the porphobilinogen deaminase gene (PBGD),
was carried out in a similar fashion for each RNA sample with 4 mM MgCl2. An Applied 
Biosystems Prism model 7700 sequence detection instrument monitored the reactions. 
Thermal cycling conditions consisted of 10 min at 95oC followed by 50 cycles of 15 s at 95oC
and 1 min at 60oC. Determinations of cycle threshold (CT) were performed automatically by
the instrument. The results are expressed as fold transcript relative to the internal standard
PBGD (=2�Ct).
Determination of the TSS --- TSS analysis was performed on polyA RNA isolated from 
untransfected and transfected cell lines and human liver. The procedure was carried out using
the Gene RacerTM kit (Invitrogen). The amount of polyA RNA used for the experiment varied
from 300 to 2000 ng and was dependent on the amount of protein and mRNA detected in
ELISA and QPCR analysis. After selection of full-length mRNA with the Gene Racer Kit,
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first strand cDNA synthesis was performed with Superscript II reverse transcriptase and
random hexamers (Invitrogen). For the untransfected cell lines and human liver the gene-
specific amplification of full-length cDNA was performed with a 5’-primer provided in the
Gene Racer kit and a 3’ GSP located in the first exon of the PROS1 mRNA (PSex1). For the
cell lines transfected with a PROS1 promoter reporter construct, the GL2 primer (Promega)
was used as GSP. A PROS1 primer in exon 2 was used for amplification of PROS1 transcripts
from a more downstream position (PSex2). The sequence and location of all non-
commercially available primers are depicted in Table 1. The PROS1 PCR cycle conditions
were as follows; 5 cycles with an annealing temperature (Ta) of 72oC, 5 cycles with Ta 70oC, 25 
cycles with Ta 68oC. After 20 cycles an equal volume of fresh PCR mix was added. For the
construct PCR the annealing temperatures were, 68oC, 66oC, and 64oC respectively. The
elongation time was set to 1.5 minutes to ensure complete elongation of all possible
transcripts. After amplification of full-length PROS1 transcripts all PCR products were ligated 
into sequencing vector pCR4.0. Approximately 40 clones of each cell type were analysed
resulting in a TSS distribution estimate. The positional indications used throughout this article,
are respective to the translational startcodon.
Target Namea Assay Location Primer/Probe sequence 5’-3’ 
PS PS-F QPCR +32/+51 ex1 TGCTGGCGTGTCTCCTCCTA
PS-R QPCR +109/+85 ex2 CAGTTCTTCGATGCATTCTCTTTCA
PS-P QPCR +55ex1/+7ex2 CTCCCCGTCTCAGAGGCAAACTTTTTGTC
PBGD PBGD-F QPCR +13/+28 ex1 GGCAATGCGGCTGCAA
PBGD-R QPCR +25/+43 ex2 GGGTACCCACGCGAATCAC
PBGD-P QPCR +30ex1/+23ex2 CTCATCTTTGGGCTGTTTTCTTCCGCC
PS PSstart GR -1/-21 GAATTCGAAGCGCGCGGAGGCGCC
PS PSex1 GR +62/+33 ACGGGAAGCACTAGGAGGAGACACGCCAG
PS PSex2 GR +40/+21 CTTCCTAACCAGGACTTGTG
Table 1 Primer and probe sequences. F, forward primer; R, reverse primer; P, probe. All
Taqman probes contain the reporter dye, 6-carboxy-4,7,2’,7’-tetrachlorofluorescein, TET, and




PROS1 mRNA and PS protein are produced by HepG2, HuH7, HeLa, HUVEC, Meg01 and
human liver --- PS circulates in normal plasma at a concentration of 0.33 M (14). Hepatocytes
are the largest contributor to the systemic concentration (15), but other cell types have also
been shown to produce PS (16-18;20). ELISA analysis demonstrated that all cell lines used in
this study produce PS (Figure 2). HepG2, and HuH7 cell lines were most productive whereas 
Meg01, HeLa, and HUVEC cells expressed smaller amounts of PS. Since mature
megakaryocytes (platelets) are known to contain storage pools of coagulation factors in their
�-granules, cell lysates were also analysed for PS antigen levels (36). Very low and comparable
levels of PS antigen were found in lysates from all cell types including Meg01 (<10 fmol per 
107 cells). PROS1 transcript levels were determined by QPCR of total RNA from each cell 
line. All cell lines were found to contain PROS1 transcripts, indicating de novo production of 
PS. The relative level of PROS1 transcript in the various cell types correlated with the PS
protein level found in each cell type, i.e. HepG2 and HuH7 cells produced high amounts of 
PS protein and contained high relative levels of PROS1 transcript.
PROS1 mRNA contains multiple start sites --- For TSS determination, full-length PROS1
transcripts were isolated from polyA RNA samples from all cell lines and from a human liver 
sample. Figure 3a shows the PCR products obtained after selection and amplification of full-
length PROS1 mRNA products. Specificity of the amplified products was confirmed with a
nested PROS1 PCR, in which an internal GSP was used on the PCR mix (Figure 3b). The size
of the resulting PROS1 fragments decreased by the expected number of base pairs (62 bp).
Sequence analysis of the cloned cDNAs revealed the presence of multiple TSSs in PROS1
mRNA in all cell types. The start site distributions (Figure 3c) generated from these data
revealed that four distinct start sites, located at -200, -147, -117 and -100 bp upstream from
the translational start, can be defined for PROS1. Other start sites were found, but most were
encountered only once. HUVEC and HuH7 cells do not use the TSS at -100 bp, whereas all 
other mRNA samples do contain this starting point. Also, HUVEC cells use the initiation site
at -200 bp more frequently than other cell types. Long transcripts commencing at -340 bp,
-347 bp, and -360 bp were found for Meg01, HeLa and HuH7, respectively.
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Figure 2 PS antigen and mRNA levels in various cell lines. (A) PS antigen levels were
measured over time in media from cell culture. Cells were seeded in 12 well plates and
incubated with 1 ml medium. Experiments were started at 80% confluency or, in the case of
Meg01, at 1*106 cells/ml. HepG2, HeLa, Meg01 and HuH7 medium included 10% FBS, 
HUVEC medium was serum-free. Fresh media in the appropriate dilutions were used as 
blanks to correct for background interference in the ELISA. Media and total RNA from
triplicate samples were pooled. (B) PS mRNA levels are expressed as fold transcript relative to




Cell type 5’ start site distribution (%) Total (n) L
-100 -117 -147 -200-210 Other
HL 32 25 22 2 18 100 59 -267
HepG2 17 18 33 0 32 100 60 -177
HuH7 2 33 31 2 32 100 51 -360
Meg01 24 11 34 0 31 100 38 -340
HUVEC 2 12 45 12 29 100 42 -210
HeLa 24 12 24 2 37 100 41 -347
Figure 3 PROS1 transcription is directed from multiple start sites. (A) Full-length 
PROS1 cDNAs were amplified using the GeneRacerTM technique. M; DNA size standard, �-
actin; positive 5’ RACE control, -; negative PCR control, e.g. the reaction without cDNA, +; 
PS positive PCR control with primers spanning from exon 2 to exon 5. The PS primer is 
located in exon 1 at +62 to +32 (PSex1) (B) Nested PCR on the PCR mix which is depicted
in Figure 3A. The PS primer is located in the 5’ UTR at -1 to -21 (PSstart). M; DNA size
standard. (C) Observed start site frequencies are given as percentage of the total. TSS
numbering is relative to the translational startcodon. “other” indicates start sites different
from the ones denoted, start sites in this category occurred no more than twice. (n) equals the
number of PCR clones sequenced. L; longest transcript.
No evidence for an alternative promoter --- In 1986 Lundwall et al reported the presence of a 
PROS1 transcript that starts in intron A (33). This could indicate the presence of an alternative
promoter in intron A. The transcript has an intronic sequence of 236 bp and commences
approximately 14.9 kb downstream from the first exon and 31.1 kb upstream from the second 
exon. This transcript is not prominently present in our HepG2 mRNA population. Figure 4
shows a 5’ RACE PCR, which was conducted with a PS-specific primer in exon 2. The
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products were not digested by MseI, a restriction enzyme with a site in the alternative
transcript that was found by Lundwall and co-workers (33). Moreover, all PCR products were
digested by AvaII, for which restriction sites are present in exon 1. 
Figure 4 PROS1 transcripts with a start in intron A are not present. Full-length PROS1
transcripts were amplified from HepG2 mRNA using the GeneRacerTM technique. PSex2 was
used as GSP for PS in the second exon. M; DNA size standard. The arrow indicates the
specific digestion products after digestion with AvaII.
A minimal promoter of 370bp confers maximal transcriptional activity
5’ deletion experiments --- Transient transfection studies were conducted in unstimulated cells 
with equimolar amounts of PROS1 promoter constructs cloned upstream from the luciferase
reporter gene (Figure 5a). Luciferase levels differed widely per transfected cell type and are
dependent on transfection efficiency of the cell type and on the presence of the correct
combination of nuclear transcription factors by which transcription is regulated. For
comparison purposes, promoteractivity of the most active promoter construct in each cell 
type was adjusted to 100% after which the activity of the other constructs in the same cell type 
was normalised to this 100%. These studies pointed out that the first 370 bp of the PROS1 5’ 
flanking region are sufficient for optimal promoter activity in all cell types. This activity was 
maintained up to a 5’ region of 1062 bp. A marked difference in activity for longer constructs
was observed among the various cell lines. In HuH7 and Meg01 cells promoter activity
decreased only slightly with increasing construct size, whereas in HepG2 and HeLa cells 
promoter activity decreased more rapidly with increasing construct size.
3’ deletion experiments --- Transient transfection experiments in HepG2 with PROS1 3’ 
deletion reporter constructs confirmed the importance of the transcription start sites located 
at -100 bp and -117 bp. Deletion of the first 131 bp upstream from the startcodon decreased
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promoter activity by approximately 50% (Figure 5b). The importance of the -147 bp TSS 
could not be confirmed in these experiments since promoter activity remained at a similar
level after further deletion up to -181 bp. Transcriptional activity decreased significantly after 
deletion of the 5’ region up to -256 bp from the startcodon, and deletion up to -806 bp 
completely reduced the level of activity to that of pGL3basic. Comparable results were
obtained in all cell lines (results not shown). Since the -147 bp start site was one of the three 
most prominently found endogenous TSSs in all cell lines, we set out to validate the TSS 
usage in the transfected PROS1-luciferase constructs.
Construct start site determination --- The transcription start sites that were used in PROS1
promoter constructs, PS370, PS1062, and PS5948 were determined after transfection in 
HepG2 cells. If the transfection system reflects the in vivo situation, the TSSs from the
transfected constructs should be identical to those of the endogenous PROS1 gene.
Surprisingly, a large range of mostly unique TSSs was found for the three constructs tested
(Table 2). Start sites -100 and -117, which were shown to be important sites in endogenous
PROS1 transcriptional initiation, were also used by the constructs. However, these sites were
not used more frequently than the other TSSs.
Discussion
The experiments described in this study provide a more detailed understanding of the
transcription start site usage during the initiation of PROS1 transcription in various cell lines
and human liver. Our results show that human liver has three prominent start sites, namely
-100 bp, -117 bp and -147 bp upstream from the translational start. These TSSs were found in 
most cell types tested. Whereas hepatoma cell line HepG2 uses TSS -100 bp, this TSS was not
found for the related cell line HuH7. Since human liver does contain this TSS we conclude
that, for PROS1 transcription, HepG2 cells are more representative of the in situ situation than
HuH7 cells. HUVEC cells also do not use the aforementioned start site, moreover in this cell
type transcription is regularly initiated from -200 bp. This TSS is rare in the other cell types 
suggesting that, in HUVEC, a different array of regulatory nuclear proteins may be present.
Even though human liver, HepG2, HeLa, and Meg01 cell types all contain the same start sites,
the contribution of the three main start sites to the total PROS1 mRNA pool was different
(Figure 3c).
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Figure 5 A minimal promoter of 370 bp is sufficient for maximal promoter activity. Cell
lines were transiently transfected with the pGL3basic vector carrying PROS1 promoter-
luciferase gene constructs. Bars represent a mean of 2 triplicate assays with 2 different
preparations of each plasmid (n = 12). (A) Luciferase activity is relative to the activity of
construct PS370, which was designated as 100%. Note that the activity for PS370 was 
different for each cell line. Luciferase activities can therefore not be compared among cell
lines, as they are also dependent on transfection efficiency in addition to promoter activity (B)
HepG2 cells were transfected with 3’ deletion constructs. Luciferase activity is relative to the
activity of the 5’ parent construct, i. e. PS1062 or PS370. 
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Construct 5’ start position of cDNA 
-1-100 -100-200 -200-300 -300-400 >-400
370 -36,-60,-73 -100,-115 -238,-242 -308,-320,-356






5948 -2 -100*,-119 -230,-238,
-247, -290 
-302,-318*, -332* -424
Table 2 PS construct start site distribution. Full-length luciferase cDNAs were amplified
from mRNA isolated from transfected HepG2 cells using the GeneRacerTM technique. Primer
GL2 was used as GSP for luciferase mRNA. TSS numbering is relative to the luciferase 
translational startcodon. The start sites were all unique with exception of those with an 
asterisk (*), for these TSSs n=2.
Published and unpublished (NCBI database entries) PROS1 cDNA sequences suggest the
presence of multiple TSSs. To our knowledge for the first time, our results pinpoint exactly 
which TSSs are used for PS transcription in human liver and various cell lines. In accordance
with some database entries we show that transcriptional initiation can take place from sites
located more than 300 bp upstream from the translational start. However, these start sites are 
not used frequently. One can conclude that for GC-rich promoters, such as the PROS1
promoter, the longest reported transcript does not necessarily represent the most abundantly
used TSS.
The transcriptional regulation of the PROS1 gene has, to date, been poorly investigated.
According to a recent review this may be due to the presence of an additional exon 5’ to what
currently is considered exon 1 (37). Ploos van Amstel et al (25) identified two TSSs by primer
extension analysis at -174 bp and -286 bp, respectively. Based on these findings and on the
presence of a putative splice acceptor site, they postulated the presence of an alternative
promoter and first exon. Also, Lundwall et al reported the presence of a PROS1 transcript that
starts in intron A (33). In our studies we found only uninterrupted PROS1 sequences
stretching from the 5’ flanking region into exon 1. Also, restriction analysis of GeneRacer
products generated with a GSP in exon 2 provided no support for the hypothesis of an 
alternative promoter.
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At present, two DNA elements have been found to be involved in core promoter function
in the transcriptional regulation from TATA-less promoters: the initiator (Inr), and the
downstream promoter element (DPE)(38). The DPE is located precisely 28-30 nucleotides
downstream from the transcription start site (for review see (39)). TSSs -200 bp, and -100 bp,
form the center of an Inr consensus sequence (YYA+1NWYY). However, the consensus
sequence (RGWYV) for the DPE was not detected in the PROS1 promoter at the designated
positions. A schematic presentation of the TSSs and their interspecies conservation, is shown
in Table 3. Phylogenetic footprinting revealed that the region surrounding the -100 bp TSS is
poorly conserved, whereas the other regions have a higher degree of conservation.
Species -200 -147 -117 -100
Human .TATCACTTCC. .CGGCTGTTCC. .GGCGCCGCCG. .GCTCAGACCG.
Chimpanzee .TATCACTTCC. .CGGCTGTTCC. .GGCGCCGCCG. .GCTCAGACCG.
Rhesus monkey .TATCACTTCC. .CGGCTGTTCC. .GGCGCCGCCG. .GCTCAGACCG.
Dog .TATCACTTCC. .CGGC(*)TGTTGG. .GGCGCCGCCG. .CCTCGGAGAG.
Pig .TATCACTTCC. .CGGCTCGGCA. .GGCGCCGCTG. .CTTCAGAGAG.
Mouse .CACCGCTTCC. .TGGCTGCTCC. .GG.GCCGCCG. .GCTGGGAGAG.
Rat .CGCCGCTTC.. .TGACTGCTCC. .GG.GCCGCAG. .GTTGGGAGAG.
Cow .TATCACTTCC. .CGGCTCCGCT. .GGCGCCCCCG. .CCTTAC.TAG.
Table 3 Phylogenetic footprint for the most prominent PROS1 TSSs. Gaps introduced
to maximize alignment are indicated by dots. The TSS is underlined.
A region up to 370 bp upstream from the translational start is sufficient for optimal
promoter expression in our model transfection system. We show that this activity is 
maintained up to a length of 1062 bp upstream. The subtle differences between the cell lines
in these transfection studies do not allow a firm conclusion regarding tissue-specific regulation
of the PROS1 promoter under basal culture conditions. However, it can be concluded that the
promoter region apparently does not contain additional upstream regulatory elements, e.g.
enhancers and repressors that can be detected in our model system. Surprisingly, only a 60%
decrease of promoter activity was shown after deletion of the three most prominent start sites
in the 3’ deletion experiments. This led us to investigate the TSS usage in three of the PROS1
promoter constructs that were used in our transfection studies. The TSSs at -100 bp and -117
55
Chapter 2 
bp were observed for all constructs but the -147 bp and -200 bp start sites were not found
amongst the cloned mRNAs derived from the transfected constructs. Moreover, even though
similar TSSs were found for the three constructs that were tested, most identified transcripts
were rare, indicating a relaxation of the transcriptional machinery (Table 2). A reduction to
10% of original promoter activity was obtained after deletion of the first 256 bp proximal to
the translational start. The deleted region contained all of the endogenously important TSSs
(-100, -117, -147 and -200). However, the absence of these sites is most likely not the sole
cause of the abrogation of promoter activity. By deletion of this region also essential 
transcription factor binding sites may have been deleted. For instance, Tatewaki and co-
workers (40) have recently shown transcription factor Sp1 to bind within the deleted region, at 
-247 to -238 bp. Since Sp1 is a major component in the transcriptional regulation from many
genes with GC-rich promoters (41), deletion of this site may well be, at least in part, 
responsible for abrogation of promoter activity. A similar argument probably applies to the
PS-1062/-806 construct, which has lost all promoter activity.
Our findings suggest that the mechanism of transcriptional initiation in this model system 
differs from the in vivo situation. A possible explanation for this phenomenon may be that
transfected DNA is in plasmid form and not in a chromosomal form. It therefore may lack
necessary structural elements that are present in normal genomic DNA. Based on our results,
researchers should express great caution to use this model system for determining TSSs. We
believe that even though transcriptional initiation is directed differently, i.e. more relaxed, this 
system remains a valuable tool for examining promoter regulation as the binding of essential
transcription factors and their role in transcriptional activation is in general not affected as has
been shown in numerous publications. However, it is clear from our results that transient
transfection of luciferase reporter gene constructs may not be a suitable tool for dissecting
subtle differences in promoter activity and TSS usage.
Acknowledgements
We would like to thank Jos Grimbergen and Erna Peters from the TNO Center for
Prevention and Health for their generous donation of HUVEC cells and for technical
assistance with HUVEC transfection experiments. This work was financially supported by the 
Dutch Thrombosis Foundation (grant application number TSN 98.002). 
56
Initiation of Protein S mRNA synthesis
References
1. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with
recurrent thrombosis. J.Clin.Invest 1984;74:2082-8.
2. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of
protein S. N.Engl.J.Med. 1984;311:1525-8.
3. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in
familial thrombotic disease. Blood 1984;64:1297-300.
4. Kamiya T, Sugihara T, Ogata K, Saito H, Suzuki K, Nishioka J et al. Inherited deficiency of protein
S in a Japanese family with recurrent venous thrombosis: a study of three generations. Blood
1986;67:406-10.
5. Engesser L, Broekmans AW, Briët E, Brommer EJ, Bertina RM. Hereditary protein S deficiency:
clinical manifestations. Ann.Intern.Med. 1987;106:677-82.
6. Bosson JL, Francois P, Pernod G, Carpentier P. [Venous thromboembolic disease in children
related to transient protein S deficiency following varicella]. Presse Med. 1995;24:415.
7. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes,
and management. Blood 1996;87:3531-44.
8. Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine
protein S. J.Biol.Chem. 1980;255:5521-4.
9. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor
VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood
1984;63:486-9.
10. Walker FJ. Protein S and the regulation of activated protein C. Semin.Thromb.Hemost.
1984;10:131-8.
11. Walker FJ, Chavin SI, Fay PJ. Inactivation of factor VIII by activated protein C and protein S. 
Arch.Biochem.Biophys. 1987;252:322-8.
12. Dahlbäck B, Stenflo J. High molecular weight complex in human plasma between vitamin K-
dependent protein S and complement component C4b-binding protein. Proc.Natl.Acad.Sci.U.S.A
1981;78:2512-6.
13. Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-
binding protein. J.Biol.Chem. 1986;261:12022-7.
14. Griffin JH, Gruber A, Fernandez JA. Reevaluation of total, free, and bound protein S and C4b-
binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992;79:3203-11.
15. Fair DS, Marlar RA. Biosynthesis and secretion of factor VII, protein C, protein S, and the Protein
C inhibitor from a human hepatoma cell line. Blood 1986;67:64-70.
16. Schwarz HP, Heeb MJ, Wencel-Drake JD, Griffin JH. Identification and quantitation of protein S
in human platelets. Blood 1985;66:1452-5.
17. Ogura M, Tanabe N, Nishioka J, Suzuki K, Saito H. Biosynthesis and secretion of functional
protein S by a human megakaryoblastic cell line (MEG-01). Blood 1987;70:301-6.
18. Fair DS, Marlar RA, Levin EG. Human endothelial cells synthesize protein S. Blood 1986;67:1168-
71.
19. Stern D, Brett J, Harris K, Nawroth P. Participation of endothelial cells in the protein C-protein S 
anticoagulant pathway: the synthesis and release of protein S. J.Cell Biol. 1986;102:1971-8.
57
Chapter 2 
20. Malm J, He XH, Bjartell A, Shen L, Abrahamsson PA, Dahlbäck B. Vitamin K-dependent protein S
in Leydig cells of human testis. Biochem.J. 1994;302(Pt 3):845-50. 
21. Maillard C, Berruyer M, Serre CM, Dechavanne M, Delmas PD. Protein S, a vitamin K-dependent
protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology
1992;130:1599-604.
22. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C et al. The anticoagulation factor protein
S and its relative, GAS6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 
1995;80:661-70.
23. Shimokawa T, Yamamoto K, Yamafuji E, Kojima T, Saito H. Expression of protein S in the
murine heart and cultured mouse cardiomyocytes is down-regulated by cytokines.
Thromb.Haemost. 2001;86:623-9.
24. Schmidel DK, Tatro AV, Phelps LG, Tomczak JA, Long GL. Organization of the human protein S 
genes. Biochemistry 1990;29:7845-52.
25. Ploos van Amstel HK, Reitsma PH, van der Logt CP, Bertina RM. Intron-exon organization of the
active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during
primate evolution. Biochemistry 1990;29:7853-61.
26. Edenbrandt CM, Lundwall A, Wydro R, Stenflo J. Molecular analysis of the gene for vitamin K 
dependent protein S and its pseudogene. Cloning and partial gene organization. Biochemistry
1990;29:7861-8.
27. Gandrille S, Borgel D, Ireland H, Lane DA, Simmonds R, Reitsma PH et al. Protein S deficiency: a 
database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and 
Standardization Committee of the International Society on Thrombosis and Haemostasis.
Thromb.Haemost. 1997;77:1201-14.
28. Gandrille S, Borgel D, Sala N, Espinosa-Parrilla Y, Simmonds R, Rezende S et al. Protein S
deficiency: a database of mutations--summary of the first update. Thromb.Haemost. 2000;84:918.
29. Pollak ES, Hung HL, Godin W, Overton GC, High KA. Functional characterization of the human
factor VII 5'-flanking region. J.Biol.Chem. 1996;271:1738-47.
30. Huang MN, Hung HL, Stanfield-Oakley SA, High KA. Characterization of the human blood
coagulation factor X promoter. J.Biol.Chem. 1992;267:15440-6.
31. Ploos van Amstel HK, van der Zanden AL, Reitsma PH, Bertina RM. Human protein S cDNA
encodes Phe-16 and Tyr 222 in consensus sequences for the post-translational processing. FEBS 
Lett. 1987;222:186-90.
32. Hoskins J, Norman DK, Beckmann RJ, Long GL. Cloning and characterization of human liver
cDNA encoding a protein S precursor. Proc.Natl.Acad.Sci.U.S.A 1987;84:349-53.
33. Lundwall A, Dackowski W, Cohen E, Shaffer M, Mahr A, Dahlbäck B et al. Isolation and sequence
of the cDNA for human protein S, a regulator of blood coagulation. Proc.Natl.Acad.Sci.U.S.A
1986;83:6716-20.
34. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W et al. Gapped BLAST and PSI-
BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389-
402.
35. Deutz-Terlouw PP, Ballering L, van Wijngaarden A, Bertina RM. Two ELISA's for measurement
of protein S, and their use in the laboratory diagnosis of protein S deficiency. Clin Chim Acta
1990;186:321-4.
36. Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev. 1993;7:52-62. 
58
Initiation of Protein S mRNA synthesis
37. Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles 
for protein S and the protein S-C4b binding protein complex. Blood 2004;103:1192-201.
38. Smale ST, Baltimore D. The "initiator" as a transcription control element. Cell 1989;57:103-13.
39. Smale ST, Kadonaga JT. The RNA polymerase II core promoter. Annu.Rev.Biochem. 2003;72:449-
79.
40. Tatewaki H, Tsuda H, Kanaji T, Yokoyama K, Hamasaki N. Characterization of the human protein
S gene promoter: a possible role of transcription factors Sp1 and HNF3 in liver. Thromb.Haemost.
2003;90:1029-39.




Regulators of PROS1 transcription, a pilot study 
De Wolf CJF, Bertina RM, and Vos HL 

Regulators of PROS1 transcription, a pilot study
Summary
The function of anticoagulant protein S (PS) as a cofactor for activated protein C in the
inactivation of coagulation factors Va and VIIIa has been well described. A deficiency in PS
may either be hereditary or acquired and is associated with an increased risk for venous
thrombosis. It is for this reason that much research has been conducted into the genetic
structure of the gene encoding PS; PROS1. Many mutations in the exons encoding for the PS
protein have been found to contribute to lowered plasma PS levels. On the other hand, the 
PROS1 promoter through which transcription is regulated has been poorly investigated. We
set out to tackle this outstanding issue by analysing the PROS1 promoter sequence through
phylogenetic footprinting. The promoter sequences of six different species were compared
with the human PROS1 sequence and the compiled data were analysed for conserved regions.
Especially the region between base pairs -300 and -100 upstream from the translational 
startcodon showed a high degree of similarity amongst species. In this region sites were found
for DNA-binding proteins such as the Sp-family of transcription factors and C/EBP�.
Transfection into HeLa cells of a PROS1 promoter-reporter gene construct with a
promoter length of 370 bp and candidate transcription factors confirmed that both Sp1 and
C/EBP� are potent activators of the PROS1 promoter. PROS1 promoter activity was also 
influenced, either positively or negatively, by FOXA2, AP2 and AP1 and the androgen
receptor. The results of this study provide indications as to which effectors may play a role in
PROS1 transcriptional regulation in vivo and therefore provide a starting point for future 




Anticoagulant Protein S (PS) is a vitamin K-dependent plasma glycoprotein which
functions as a non-enzymatic cofactor to activated protein C (APC) in the protein C
anticoagulant pathway (1-3). PS is produced mainly by the hepatocytes in the liver (4), but also
at low levels by many other cell types in the body (5-11). In patients with liver disease PS
plasma levels are not reduced to the same extent as those of the structurally related vitamin-K
dependent coagulation factors (12). In these circumstances significant amounts of PS are 
thought to be produced and released by megakaryocytes (6;7;13) and the vascular endothelium
(5;8).
Protein S mRNA is transcribed from the PROS1 gene on chromosome 3 (14-17). Early
studies into the transcriptional initiation of PROS1 indicated that transcription is generated
from multiple start sites within the TATA box-less promoter of this gene (17-20). We recently 
confirmed and extended these assumptions by demonstrating that PROS1 transcription is
generally directed from one of four major transcription start sites located 100 bp, 117 bp, 147
bp, and 200 bp upstream from the translational startcodon, respectively (21). Hall and
coworkers presented an abstract at the meeting of the International Society of Thrombosis
and Haemostasis (ISTH) in 1995 reporting the regulation of PROS1 transcription by multiple
transcription factors (22). An induction of PROS1 promoter activity in vitro was demonstrated
in cotransfections of PROS1 promoter-reporter gene constructs with expression vectors 
containing cDNAs for CCAAT/Enhancer-Binding Protein (C/EBP) �, D-Binding Protein
(DBP), Forkhead Box A (FOXA), Hepatocyte Nuclear Factor (HNF) 4, androgen receptor
(AR), estrogen receptor (ER) and glucocorticoid receptor (GR). The only other study that
investigated the regulation of the PROS1 promoter, showed binding to and induction of the
PROS1 promoter by Sp1 and binding of FOXA (23).
In this pilot study, we tested selected candidate transcription factors for the ability to 
influence PROS1 promoter activity in vitro. Cotransfections of epithelial carcinoma cell line
HeLa with a PROS1 promoter-reporter gene construct and expression vectors containing the
cDNA for C/EBP�, FOXA2 (HNF3�), HNF6 (Onecut1), DBP, p49, Activator Protein (AP)
2, Specificity protein (Sp) 1 and Sp3 resulted in increased promoter activity. In contrast, 
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promoter activity was decreased in the presence of FOXA3 (HNF3�), HNF4, jun, fos, p65 
and the AR.
Experimental procedures 
Phylogenetic footprinting and promoter predictions for the PROS1 promoter region --- The 5’ upstream
sequences for PROS1 from human, chimpanzee, rhesus monkey, dog, mouse, rat, pig and cow
were either generated by automated sequencing (human) or assembled through alignment of
known sequences with the nucleotide and trace databases at the National Center for 
Biothechnology Information (NCBI) (www.ncbi.nlm.nih.gov). The sequences were aligned
and analyzed with the VISTA software (genome.lbl.gov/vista), where necessary the
alignments were adjusted manually. Additional transcription factor binding site analyses were 
done with the IFTI mirage software (www.ifti.org) and MatInspector professional
(www.genomatix.de). Promoter predictions were done with the proscan software at the
bimas.dcrt.nih.gov web site.
Plasmids --- The PROS1 promoter-reporter gene (luciferase) construct, PS370, was 
described previously (Chapter 2 of this thesis). The expression vectors containing cDNAs for 
transcription factors of murine origin; pSCT-C/EBP� (24), pMSV-C/EBP� (25), pECE-
HNF6 (26), pCMV-DBP (27), pcDNA3-FOXA (1, 2, 3) (HNF3�, �, �) (28;29), were
described previously. pcDNA3-HNF4 was generated from pLEN4S-HNF4 (30) and
pcDNA3-HNF1� was generated from pBJ5-HNF1� (31). The expression vectors containing 
cDNAs for transcription factors of human origin; pSV-ARO (32), pCMV-AP2 (33), pCMV4-
Sp1 (34) and pCMV4-Sp3 (35), pRSV-cjun and pRSV-cfos (36), pCMV-p49 (37), pCMV-p50
and pCMV-p65 (38), were previously described. pTracer-GR was generated from pRSV-GR
(39) and pcDNA3-HNF1� was generated by insertion of the original HNF1� cDNA (40) into
pcDNA3. The cDNAs for constitutively active human ER� and ER� in expression vector
pShuttle were generated at the Human and Clinical Genetics department of the Leiden
University Medical Centre and were kindly provided by Dr Willems van Dijk. 
Cell culture --- The human cervix epithelial carcinoma cell line HeLa was purchased from 
the American Type Culture Collection (ATCC, Manassas, VA). Cells were grown in Minimal 
essential medium (MEM), 10% Fetal Bovine Serum (FBS), 100 g/ml penicillin, 100 g/ml
streptomycin, and 1x MEM non-essential amino acids (all purchased from Gibco, Invitrogen).
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Reporter gene assays --- Cells were transfected at 60-80% confluency. Each transfection was
performed in triplicate in 12-wells plates. Transfections were carried out using 3 l Tfx-20 
lipids (Promega) per g transfected DNA. In each transfection 500 ng PS370 and 500 ng 
transcription factor expression vector was used. Control vector pRL-SV40 (Promega),
expressing the Renilla luciferase, was co-transfected for correction of transfection efficiency in
a 1:500 ratio to total transfected DNA. The cell extracts were harvested 48 hours after
transfection. Luciferase levels were measured with the dual-luciferase assay kit (Promega,
Leiden, the Netherlands) in the LB9507 luminometer (Berthold, Bundoora, Australia) 
according to the manufacturers recommendations.
Results
Conserved sequences in the PROS1 promoter region --- The 370 bp 5’ upstream sequences for 
PROS1 from human, chimpanzee, rhesus monkey, dog, mouse, rat, pig and cow were aligned
with the mVISTA software and analysed for putative transcription factor binding sites (Figure
1). A high degree of conservation amongst all species was found in a region approximately
encompassing bp -230 to -100. Upstream from this point the PROS1 promoter sequence from
mouse and rat deviated from the other species, which kept a high homology up to -300 bp.
Sequences from rhesus monkey, chimpanzee and human were highly homologous throughout
the examined region.
In the first region (-230/-100) two stretches of sequence with a very high homology were 
found, namely -240/-205 and -185/-155. GC-boxes are located at -170 and -155 bp and are
putative binding sites for the Sp-family of transcription factors, the consensus sequence being
KGGGCGGRRY (5’-3’) (41). At positions -230 through -210 sites for STAT (42), consensus
TT(n)4-5AA, and C/EBP� (24), consensus RNRTKNNGMAAK, were identified. Since these
sites have remained in the PROS1 promoter throughout evolution it may be assumed that they
areimportant in the regulation of the transcriptional activity of the PROS1 promoter.
Therefore, these sites are obvious candidates for future studies.
Further computational analyses were done for the PROS1 promoter region also taking into 
account the location of transcription start sites. The proscan software calculated a putative
promoter with a start site at -148 but did not identify the other start sites that were
66
Regulators of PROS1 transcription, a pilot study
Figure 1 Phylogenetic alignment of the PROS1 promoter sequence. Sequences from
human, chimpanzee, rhesus monkey, cow, dog, mouse and rat were retrieved from the
archives at the NCBI. Numbering is according to the human sequence with the first
nucleotide of the translational startcodon being +1. Cons; 100% conserved sequence. The
enboxed nucleotides are the transcription start sites found in reference 21.
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experimentally found by us previously (21). Table 1 gives the consensus, binding site and
conservation level of selected transcription factor binding sites within the -370/-1 PROS1
sequence using various programs.
TF Location Consensus Conservation Software
AP2 -360 YCSCCMNSSS h,ch,r 3, 4
Sp1 -360/-345 KGGGCGGRRY h,ch,r 2, 4
CREB/ATF -340/-325 TGACGTMA h,ch,r 2, 3, 4 





All 1, 2, 4 
GR -215 TGTNCT All 1
Sp1 -190 KGGGCGGRRY All 1
AP2 -190/-180 CCCMNSSS All 1, 3, 4 
Sp1 -170 KGGGCGGRRY All 1, 2, 3, 4 
Sp1 -160/-150 KGGGCGGRRY All 1, 2, 3, 4 
Table 1 Putative transcription factor binding sites in the PROS1 promoter. Software: 1;
rVISTA, 2; Matinspector professional matrix library, 3; proscan, 4; ifti mirage. Abbreviations:
TF: Transcription factor, h; human, ch; chimpanzee, r; rhesus monkey, co; cow, d; dog, GR:
glucocorticoid receptor. For consensus binding sites, see the Transfac public database at
www.gene-regulation.com.
Many more possible binding sites are routinely found by computational analysis, however
most can be ruled out because of tissue-specific expression of the transcription factor or an
incomplete consensus. On the other hand, when an incomplete binding site is preserved 
throughout evolution it may nevertheless be functional. For instance, incomplete sites were
found for AP1 (fos), C/EBP�, NF�B and the neurally expressed silencer NSRF. These sites
are not included in the table. On the other hand, the GR-site, which is also incomplete, ís 
mentioned because it is in a highly conserved region.
Rationale for the selection of transcription factors --- Transcription factors were selected on basis of 
the presence of a putative binding site in the -370/-1 PROS1 sequence (Sp1, Sp3, FOXA2,
C/EBP�, AP2, GR), on their relation to the prior category (FOXA1, FOXA3, C/EBP�, ER,
AR) or their liver-specific expression (HNF1, HNF4, HNF6, FOXA1, FOXA2, FOXA3,
C/EBP�, DBP). An additional argument for including the steroid receptors ER and AR is
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given by the fact that plasma PS levels are negatively influenced by female steroid hormones 
(43-45). The mechanism by which this downregulation of PS levels occurs is unknown. 
The major pro-inflammatory cytokines interleukin 1 (IL1) and Tumor Necrosis Factor �
(TNF�) activate transcription factors AP1 (jun and fos), and NF�B (p49, p50, p65) (46;47).
Incomplete binding sites for these DNA-binding proteins are located in the PS370 sequence.
Even though the consensuses are incomplete we included the expression vectors for these
transcription factors in our study mainly for two reasons. Firstly, PS levels in hepatoma 
(HepG2) and endothelial (MVEC, HUVEC) cell culture are upregulated by interleukin 6 (IL6)
and downregulated by TNF� thus linking PS to the inflammatory response (48;49). Secondly,
recent publications indicate that free plasma PS may act on inflammation by facilitating the 
uptake of early apoptotic cells by macrophages (50) and that PS in complex with complement
4b binding protein (C4BP) directs complement to the surface of apoptotic cells (51;52). 
PROS1 promoter activity is modulated by various liver-specific and ubiquitous transcription factors --- 
HeLa epithelial carcinoma cells were co-transfected with PROS1 promoter-reporter construct,
PS370, and a transcription factor expression vector (Figure 2). Transcription factors Sp1 and
Sp3 upregulated PROS1 promoter activity 23- and 15-fold, respectively. Lower, but also
significant, stimulatory effects were shown for C/EBP� (7-fold), FOXA2 (4-fold), HNF6 (2-
fold), p49 (2-fold) and AP2 (2-fold). Negative effectors were the components of AP1 (jun and
fos), the p65 subunit of the NF�B complex and the AR. FOXA3 and HNF4 slightly 
downregulated PROS1 promoter activity, the measured reduction in promoter activity was 
significant but the effect was marginal.
Identical transfection assays were also carried out with hepatocytes (HepG2 cells), which 
are the main source of plasma PS in vivo, resulting in a similar albeit less-pronounced pattern
of promoter induction (results not shown). Because endogenous liver-specific transcription
factors are already present in the nucleus of hepatocytes, possibly in sufficient levels for 
maximal PROS1 promoter regulation, the effect of this category of transcription factors on 
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Discussion
This pilot study is a good example of the added value of phylogenetic footprinting in 
locating and identifying potential transcriptional effectors in promoter studies. In our species
comparison for the PS370 PROS1 promoter two major sites, at -230/-200 and -190/-155, 
proved to be highly conserved throughout evolution (Figure 1). The factors C/EBP� and 
Sp1/Sp3 that have consensus binding sites within these regions were subsequently found to
be the major transcriptional activators of the PS370 promoter-reporter gene construct (Figure 
2). Most likely Sp1 trans-activates the PROS1 promoter by binding to multiple sites within the 
promoter, whereas only a single binding site for C/EBP� is contained in the PS370 sequence
(Table 1). Sp1 is a ubiquitously present transcription factor (41) and may therefore be involved 
in the constitutive expression of PROS1. On the other hand, C/EBP� is restricted to certain
tissues, amongst which the liver (24;53), and is probably involved in tissue-specific regulation
of PS levels. The same holds for the liver-specific transcription factor FOXA2 (54) of which
the binding site is also highly conserved and which also upregulated PS370 promoter activity. 
HNF6 mildly induced PS370 activity. We did not find the consensus for HNF6 (5’-AARTCA
ATAW-3’) in the PS370 promoter region. 
The AP1 proteins jun and fos as well as the trans-activation subunit p65 of NFkB
negatively influenced PS370 activity (Fig 2). On the other hand, C/EBP�, a known mediater 
of IL6 signalling, enhanced PS370 activity. The stimulatory and inhibitory effects on PS levels
in vitro described for IL6 and TNF�, respectively, may thus be mediated through these
proteins (48;49). Interestingly, APC was shown to inhibit the activation and translocation of 
the NF�B complex and AP1 to the nucleus thereby inhibiting TNF� production and release 
by monocytes (55). Although there is no evidence to suggest a regulation of PS levels by APC, 
it is tempting to speculate that APC could positively influence PROS1 transcription through a 
similar mechanism.
What has been clearly shown is that PS plasma levels are downregulated by female
hormones. The mechanism by which this occurs has not been studied, thus cotransfections of
PS370 with the steroid receptors were of special interest. We did not find a good consensus
for any nuclear steroid receptors in the PROS1 -370/-1 sequence (the GR-site in Table 1 is 
rather weak/poor), but nevertheless included expression vectors for the constitutively active
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ER� and ER�, the GR, and the AR in our pilot study. In contrast to the results obtained by
Hall and coworkers (22) we found that the AR downregulated PS370 activity, whereas the GR
and ER had no influence. Although the ER was long considered to be the sole mediator of 
estrogen action, several findings show that estrogen can directly activate AR function (56-58).
Our results for the AR are thus in line with the inhibitory influence of female steroid
hormones on PS plasma levels, however we had expected to see an effect with the ER as well.
As a cell differentiation factor, the transcription factor AP2 is imperative for the normal 
development of the neural crest in embryogenesis (59). In adulthood AP2 mRNA is present in 
several tissues with highest levels occurring in female reproductive organs, eye, skin and liver
(http://harvester.embl.de/harvester). The PROS1 promoter has a conserved AP2 binding site
and, in cotransfections, AP2 enhanced PROS1 promoter activity, albeit marginally (2 fold).
This is of interest since PS is present in brain (60-62) and has been shown to protect against
neuronal cell death upon ischemic injury (63). 
In conclusion, transcription factors affecting PROS1 transcription were found amongst 
ubiquitously expressed factors, as well as amongst tissue-specific transcription factors. The
results of this pilot study give a sneak preview into the regulation of PS protein levels at the
transcriptional level and provide a starting point for in depth research into the regulation of 
PROS1 promoter activity.
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Sp1 and Sp3 binding to and regulation of the Protein S gene promotor
Summary
Protein S (PS) is a vitamin K-dependent plasma protein that inhibits blood coagulation by 
serving as a non-enzymatic cofactor for activated protein C in the Protein C anticoagulant
pathway. Low PS levels are a risk factor for the development of deep venous thrombosis. The 
regulation of PS protein levels through transcriptional regulation of the PS gene was
investigated in this report. A minimal PS gene promoter of 370 base pairs upstream from the
translational initiation codon was sufficient for maximal promoter activity in transient
transfections regardless of the cell type. A pivotal role for Sp1 in the constitutive expression
of the PS gene was demonstrated through EMSA experiments, transient expression of mutant 
PS promoter-reporter gene constructs and chromatin immunoprecipitations in HepG2 cells. 
A total of at least four Sp-binding sites were identified. The two sites most proximal to the
translational startcodon were found to be indispensable for PS promoter activity, whereas
mutation of the two most distal Sp-binding sites had a negligible influence on basal promoter
activity. In addition, all other major promoter-binding proteins that were found by EMSA
could be positively identified in supershift assays. We identified binding sites for the
hepatocyte-specific forkhead transcription factor FOXA2, nuclear factor Y (NFY), and the
cAMP-response element (CRE)-binding protein (CREB)/activating transcription factor (ATF)





The coagulation cascade is a complex system in which the consecutive activation of 
multiple coagulation factors leads to the production of thrombin and ultimately to the
formation of fibrin polymers, the primary component of blood clots (for a recent review (1)).
Protein S (PS) is a vitamin K-dependent plasma protein that functions as a nonenzymatic
cofactor for Activated Protein C (APC) in the downregulation of the coagulation cascade via 
proteolytic inactivation of coagulant factors Va and VIIIa (2-5). PS has also been shown to 
display APC-independent anticoagulant activity in purified systems as well as in plasma (6-8). 
Recent studies indicate that PS may have a second function unrelated to coagulation in the 
clearance of apoptotic cells (9;10).
Over the past two decades low PS plasma levels have become a well-established risk factor 
for the development of deep venous thrombosis (11-13). However, not all mechanisms
underlying low plasma PS levels have been fully characterized. Hereditary PS deficiency has
been shown to be an autosomal dominant trait and many causative genetic mutations have
been described in the PS gene (14;15). On the other hand, PS deficiency can also be acquired
during life through conditions such as oral contraceptive use and liver disease (16). To better
understand the different functions of PS and the possible causes of PS deficiency, more
information on the regulation of the PS gene, mRNA and protein is needed. 
The major source of circulating plasma PS is the hepatocyte (17), but PS is also produced
constitutively at low levels by a variety of other cell types throughout the body (18-25). PS 
circulates in human plasma at a concentration of approximately 0.35 µM in a free form (40%)
and a C4b-binding protein-bound form (60%) (26-28). The PS genetic locus, PROS, consists 
of an active PS gene (PROS1) and an inactive pseudogene (PROS2) which share 96% 
homology in their coding sequence. The promoter and the first exon are absent from the
PROS2 gene, however (29-31). Transcription from the PROS1 promoter is directed from 
multiple start sites (32; Chapter 2), and recently the PROS1 promoter was shown to contain a
forkhead box A2 (FOXA2) binding site and an Sp1 binding site (33).
In this report, we further characterized the transcriptional regulation of the PROS1
promoter. We identified binding sites for various transcription factors within the first 400 bp
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proximal to the PROS1 translational startcodon, among which multiple binding sites for the
ubiquitous transcription factors Sp1 and Sp3, and single sites for nuclear factor Y (NFY), and
the cAMP-response element-binding protein/activating transcription factor (CREB/ATF)
family of transcription factors. Chromatin immunoprecipitations of chromatin from
hepatocytic cell line HepG2 with an Sp1 antibody demonstrated the in vivo relevance of our 
findings. The results presented here show that Sp1 and Sp3 have a crucial role in the basal 
expression of the PS gene, whereas transcription factors FOXA2, NFY and CREB/ATF do
not.
Experimental procedures 
Plasmids --- The PROS1 promoter-reporter constructs used in this study originated from a 7
kb EcoRI promoter fragment which was isolated from BAC clone #2513H18 from the
CITBI-E1 genomic library (Research Genetics, Invitrogen, Carlsbad, CA). Their construction
is described in Chapter 2 of this thesis.
Mutation of putative transcription factor binding sites --- Mutant constructs were generated by use 
of the QuikChange XL Site-Directed Mutagenesis kit from Stratagene (La Jolla, CA). The
sequence of the mutant oligonucleotides is depicted in Table 1. Successful incorporation of









Table 1 Mutant oligonucleotides for site-directed mutagenesis. Nucleotide sequences of 
the primers used for site-directed mutagenesis of putative transcription factor binding sites
within the PROS1 promoter. * Numbering of the position is relative to the PROS1
translational startcodon. ‡ Underlining of nucleotides denotes mutations.
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Expression vectors --- Expression vectors containing human Sp1 and Sp3 (pCMV-Sp)
transcription factors were a kind gift from J. Horowitz (Roswell Park Cancer Institute, USA)
(34;35), and the expression vector containing murine FOXA2 (pcDNA3-FOXA2) was a kind
gift from P. Holthuizen (University of Utrecht, NL). The pcDNA3-FOXA2 vector was 
created by inserting the cDNA for FOXA2, as reported by Lai and coworkers (36), into the
EcoRI cloning site of vector pcDNA3.
Cell culture --- Leukocytes isolated from blood obtained from healthy donors (Sanquin 
Bloodbank, Leiden, NL) were a kind gift from E. Paffen (Leiden University Medical Center,
Leiden, NL). The human hepatoblastoma cell line HepG2, and cervical adenocarcinoma cell
line HeLa were purchased from the American Type Culture Collection (ATCC, Manassas,
VA). Megakaryocytic cell line Meg01 was a kind gift from G. van Willigen (Utrecht Medical 
Center, Utrecht, NL). The hepatoma cell line HuH7 was a kind gift from M. Verschuur (TNO
Prevention and Health, Leiden, NL). Primary human umbilical vein endothelial (HUVEC)
cells were a kind gift from J. Grimbergen (TNO Prevention and Health, Leiden, NL). HepG2,
HeLa and HuH7 cells were grown in Minimal essential medium (MEM), 10% Fetal Bovine
Serum (FBS), 100 g/ml penicillin, 100 g/ml streptomycin, and 1x MEM non-essential
amino acids (all purchased from Invitrogen). Meg01 cells were grown in RPMI 1640 medium, 
20% FBS, 100 g/ml penicillin, 100 g/ml streptomycin (all purchased from Invitrogen).
HUVECs were grown in M199-medium (BioWhittaker, Walkersville, MD), 10% heat 
inactivated human serum (Sanquin Bloodbank), 10% Newborn Calf Serum (TNO Prevention
and Health), 10 U/ml heparin (BioWhittaker), 150 U/ml endothelial cell growth factor, 100 
g/ml penicillin (BioWhittaker) and 100 g/ml streptomycin (BioWhittaker). 24 hrs before
transfection HUVEC medium was replaced with heparin-free medium to prevent interference
with the transfection.
Reporter gene assays --- 1*106 Meg01 suspension cells were used per transfection. All adherent
cells (HepG2, HuH7, HeLa, HUVEC) were transfected at 60-80% confluency. HUVEC cells
were transfected in passage 2-3, whereas the other cell types were used up to passage 25. Each
transfection was performed in triplicate in 12-wells plates. All assays were conducted with two
different DNA preparations of each construct. Transfections in HepG2, HeLa, HUVEC and
HuH7 cells were carried out using 3 l Tfx-20 lipids (Promega) per g transfected DNA.
Meg01 cells were transfected using 5 g DAC-30 (Eurogentec, Seraing, BE) per g DNA. In
each transfection an equimolar concentration of construct was used, supplemented with 
pUC13-MCS vector to obtain a fixed amount of transfected DNA. In pUC13-MCS the MCS
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had been removed by digestion with PvuII and recircularisation. Control vector pRL-SV40
(Promega), expressing the Renilla luciferase, was co-transfected to correct for transfection
efficiency in a 1:500 ratio to the total transfected amount (g) of DNA in HepG2, HuH7 and
HeLa cell lines, and a 1:100 ratio in transfections with HUVEC and Meg01 cells. 250 ng
transcription factor expression vector was used for cotransfections, expression vector without
the transcription factor cDNA was used as a negative control. Cell extracts were harvested at 
either 24 hours (HepG2, HuH7) or 48 hours (Meg01, HUVEC, HeLa) after transfection. Cells
were lysed in 250 l Passive Lysis Buffer (Promega) per well, after which 20-100 l was used
to measure luciferase activity. Luciferase activity was measured according to the Dual
Luciferase Assay System Protocol (Promega) using a Lumat LB9507 luminometer (Berthold,
Bad Wildbad, DE).
Preparation of nuclear extracts --- Nuclear extracts (NE) were prepared according to the
method of Dignam et al (37). Nuclear extract buffer contained 20 mM Hepes (pH 7.9), 0.2
mM EDTA, 100 mM KCl, 0.5 mM DTT, 0.2 mM PMSF and the EDTA-free protease
inhibitor cocktail (Roche, Mannheim, DE). NEs were aliquoted and frozen at -80oC until 
further use. Protein concentration of the NE was measured with the BCA assay (Pierce
Biotech, Rockford, IL). 
Electrophoretic Mobility Shift Assays (EMSA) --- EMSAs were performed in a 13 l binding 
reaction containing 10 g NE and 195 ng denatured herring sperm DNA. EMSA buffers were
purchased from Active Motif (Carlsbad, CA) and used according to the manufacturers
recommendations. Double-stranded (ds) oligonucleotides were end-labeled using �32P-ATP
and T4 polynucleotide kinase. The position numbers for the oligonucleotides in Figure 2 show
their location respective to the PROS1 translational startcodon. Reaction mixtures were 
incubated on ice for 20 min with or without an unlabeled competitor. Subsequently, the 32P-
labeled ds probe was added and the incubation was continued for another 20 min. In
supershift experiments, NE was incubated on ice for 10 min with the 32P-labeled ds probe
after which an anti-Sp1 (sc59x), anti-Sp3 (sc664x), anti-NFYA (sc7711x), anti-CREB/ATF
(sc270x) or anti-FOXA2 antibody (sc6554x) (Santa Cruz Biotechnology, Santa Cruz, CA) was 
added and the incubation was allowed to continue for another 10 min. Samples were loaded
on a 3% or 5% non-denaturing polyacrylamide gel, which was electrophoresed for 2 hrs at 
200V, after which gels were vacuum-dried and exposed to x-ray film.
Chromatin Immunoprecipitation Assay (ChIP) --- Chromatin immunoprecipitation assays were
conducted with chromatin isolated from HepG2 cells with the Chip-IT kit (Active Motif,
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Rixensart, Belgium) according to the manufacturers instructions. Briefly, HepG2 cells were
grown to 80% confluency in 75 cm2 flasks after which chromatin was fixed in vivo by addition
of 1% formaldehyde in culture medium. Fixed chromatin was isolated and sheared for 5 x 20
seconds to an average fragment size of 500 bp using a Soniprep 150 homogenizer (MSE,
Kent, UK) at 25% power. Approximately 20 µg sheared chromatin was incubated for 4 hours
with 3 µg transcription factor-specific antibody at 4oC with gentle rotation, after which 
Protein G beads were added and the incubation was continued overnight. An antibody against
TFIIB was used as a positive control, non-specific IgG was used as a negative control (both
antibodies are included in the Chip-IT kit). The same Sp1 antibody was used for the ChIP
experiments as for the supershift assays. The antibody-chromatin complexes on the Protein G
beads were pelleted, washed extensively, eluted from the protein G beads, and treated with
proteinase K and RNAse A. DNA was purified over a mini-column and resuspended in 100
l H2O. 3 l was used as a template for PCR using primers surrounding the suspected 
transcription factor binding site. For the PROS1-specific PCR the following primers were 
used: -322/-299 (sense) 5’-GGAGGAAAAGCAGCAACTAGGGAG-3’, -91/-106 (antisense) 5’-
TCGGTCTGAGCCGTG-3’. For the positive control primers located in the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) promoter were used. The background control consisted
of a PCR with primers located in the chromosome condensation-related SMC-associated
protein (CNAP1) gene.
PS levels (nM)
Cell Type 24 hr 48 hr 72 hr 96 hr 
HepG2 0.315 0.498 0.752 1.064
HuH7 0.343 0.709 1.166 1.391
HeLa 0.171 0.189 0.268 0.405
HUVEC 0.042 0.072 0.089 0.112
Meg01 0.065 0.126 0.149 0.185
Table 2 PS protein levels over time in cell culture. PS levels were measured by ELISA 
analysis of cell culture medium at various time points. Cells were seeded in 12 wells plates and 
incubated with 2 ml medium. Experiments were started at 80% confluency of cell culture or,
in the case of Meg01, at 1*106 cells/ml. HepG2, HeLa, Meg01 and HuH7 medium included
10% FBS, HUVEC medium was serum-free. Fresh media were used as a blank to correct for
background interference in the ELISA. Data are shown in graph format in Chapter 2. 
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Results
Protein S expression in cell lines --- Protein S levels in cell culture medium were determined by 
ELISA analysis for HepG2, HuH7, HeLa, Meg01, HUVEC cells (Table 2). Hepatocytic cell
types HuH7 and HepG2 had the highest PS production. PS levels in HeLa and Meg01 cell
culture were low when compared to levels in HepG2 and HuH7 culture medium. PS levels
were lowest in medium from HUVEC cell culture.
PROS1 promoter activity in transient transfection of various cell types --- Transient transfection
studies were conducted in unstimulated HepG2, HuH7, HeLa, HUVEC, and Meg01 cells with
equimolar amounts of PROS1 promoter constructs cloned upstream from the firefly luciferase
reporter gene (Figure 1). These studies pointed out that the first 370 bp of the PROS1 5’-
flanking region were necessary for maximal promoter activity in all cell lines. When compared
with expression in other cell types, the shortest PROS1 construct, PS197, had relatively high 
activity in HeLa and HuH7 cells. However, background pGL3basic activity was also higher in 
these cells. Optimal promoter activity was maintained up to a 5’ region with a length of 1062 
bp. Constructs longer than 1062 bp had reduced activity in transfections in HepG2 and HeLa 
cells, whereas in HuH7 and Meg01 cells promoter activity remained at a high level. This 
difference in expression indicates that tissue-specific expression of transcription factors that 
bind to sites in this region may play a role in the regulation of PROS1 activity. Computational
analysis of the PROS1 promoter sequence with the MatInspector professional software (38) 
did not reveal the presence of distinct upstream inhibitory or stimulatory elements, however. 
Multiple transcription factors bind to the PS promoter --- In a previous study we determined that
PROS1 transcription is driven from three possible start sites, namely -100, -117, and -147 (32).
Here we show that maximal promoter activity is reached with a minimal PROS1 promoter of
370 bp. On basis of these observations we investigated transcription factor binding to the
PROS1 region encompassing bp 100 to 370 upstream from the translational start. For this 
purpose, a series of overlapping ds oligonucleotides covering the aforementioned region was
designed. The duplexes were all 24 bp long, each having a 12 bp overlap with its neighbouring
oligonucleotides. The liver cell line HepG2 was chosen for these more detailed experiments,




Figure 1 Transient expression of PROS1 promoter-reporter gene constructs in cultured 
cells. Promoter activity of a series of 5’ PROS1 deletion constructs was measured as luciferase
expression and is expressed as a percentage of the most active construct PS370. Note that the
activity of PS370 was different for each cell line. Luciferase activities can therefore not be
compared among cell lines, as they are also dependent on transfection efficiency in addition to 
promoter activity. The data are presented as the means (± SD) of at least two different
experiments in triplicate with two independent plasmid preparations. Luc; luciferase.
Numbering of the construct is relative to the PROS1 translational startcodon. The data in this 
figure are also used in Chapter 2.
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Figure 2 Primer walking: incubations of HepG2 Nuclear Extract and 24 consecutive 
ds oligonucleotide probes. 10 µg HepG2 Nuclear Extract was incubated with a single ds
oligonucleotide probe for 20 minutes. Protein-DNA complexes were separated on 3-5% 
PAGE. The dried gel was exposed to film. Numbering of the nucleotide positions was as in 
Figure 1.
Incubation of HepG2 nuclear extracts with radio-labeled oligonucleotide duplexes located
between positions -93 to -152 upstream from the PROS1 translational start did not result in 
the formation of protein-DNA complexes (Figure 2). In contrast, almost all ds oligonucleotide
probes from duplex -152/-129 up to -382/-359 were complexed with nuclear protein. In
further experiments we focussed on the more pronounced complexes found with primer 
walking. Upon computational analysis of the first 400 bp of the PROS1 promoter sequence
with the MatInspector professional software (38), consensus binding sites for various
transcription factors were found (Figure 3). A high degree (>60%) of interspecies
conservation (human, chimpanzee, rhesus monkey, dog, bovine, pig, mouse, and rat 
comparison) was found from ~250 bp to ~100 bp upstream of the PROS1 translational 
startcodon with the VISTA alignment tools (Chapter 3 this thesis) (39;40). Binding sites for
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-400  TCTTGAACCC TGGAAGTTGT CTTGACCAGT CAGAGAACTG CGTTCCCCAC
-350  CCCTTCCCCT TTGGAAACGT CACACTGTGG AGGAAAAGCA GCAACTAGGG 
-300  AGCTGGTGAA GAAGGATGTC TCAGCAGTGT TTACTAGGCC TCCAACACTA 
-250  GAGCCCATCC CCCAGCTCCG AAAAGCTTCC TGGAAATGTC CTTGTTATCA
-200  CTTCCCCTCT CGGGCTGGGC GCTGGGAGCG GGCGGTCTCC TCCGCCCCCG 
-150  GCTGTTCCGC CGAGGCTCGC TGGGTCGCTG GCGCCGCCGC GCAGCACGGC
Figure 3 Putative transcription factor binding sites in the PROS1 promoter. 
Computational analysis of bp -400 to -100 of the PROS1 promoter revealed the presence of
several putative transcription factor binding sites within this region. *Interspecies
conservation was above 95% for these sites. 
The protein-DNA complexes observed in incubations containing HepG2 nuclear extract
and radio-labeled oligonucleotide duplexes -359/-335, -298/-275, -253/-230, and -177/-146,
all displayed a similar pattern of retardation on poly-acrylamide gel. Computational analysis 
pointed out that all oligonucleotides, with the exception of -298/-275, contained putative 
binding sites for the ubiquitous transcription factor Sp1. Sp3, another member of the Sp-
family of transcription factors, has similar DNA-binding properties as Sp1 and thus often
binds to the same sites as Sp1. Four Sp3 isoforms exist with different molecular weights that
can all bind to the Sp1 consensus sequence. The resultant is the highly recognizable Sp1/Sp3
EMSA banding pattern (Figure 4) (41;42). The specificity of Sp-binding to the oligonucleotide
duplexes was confirmed in competition experiments with unlabeled wild type oligonucleotide
duplexes and the Sp-consensus oligonucleotide. Mutant oligonucleotides in which the putative 
Sp binding site had been modified did not compete for protein binding. Upon incubation with 
antibodies directed against either Sp1 or Sp3 a supershift of the specific bands, band a and
bands b and c, respectively, was observed (Figure 4, panels A, B, and C). These experiments
confirmed our hypothesis that all four oligonucleotide duplexes contained Sp-binding sites. 
Competition experiments demonstrated that not all Sp-binding sites in the PROS1 promoter
bind Sp1 with the same affinity (Figure 4, panels D and E). By addition of a 50-fold excess of 
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unlabeled competitor in the form of one of the three other duplexes to incubations with either
labeled duplex -177/-146 or -298/-275, the following order of binding affinity was 
established: -177/-146 > -253/-230 > -298/-275 > -359/-335. The oligonucleotide for which
the Sp-proteins displayed the highest affinity, -177/-146, was 8 bp longer than the other
oligonucleotides. The computational analysis showed that more than one Sp-binding site may
be located within this region. Moreover, the -177/-146 mutant oligonucleotide was still able to 
compete slightly for Sp1 binding (Figure 4, panel A). The higher affinity of Sp1 for -177/-146
may therefore be due to the presence of more than a single Sp-binding site.
All other oligonucleotide probe-protein complexes had a unique migratory behaviour.
Computational data (Figure 3) and a previous publication (33) indicated that the protein
complex attached to duplex -282/-258 could be the liver-specific transcription factor FOXA2.
EMSA competition experiments with the wild type oligonucleotide and a mutant 
oligonucleotide in which the putative FOXA2 binding site had been altered, confirmed this.
Moreover, incubation of the wild type oligonucleotide probe with a FOXA2-specific antibody
resulted in the disappearance of the FOXA2-specific band (Figure 5 panel A).
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Figure 4 Sp1 and Sp3 bind to multiple sites in the PROS1 promoter. 10 µg HepG2 
Nuclear Extract was incubated with a single ds oligonucleotide probe for 20 minutes. Protein-
DNA complexes were separated on 3% (panels C and D) or 5% (panels A and B) PAGE. The
dried gel was exposed to film. In panels A and B competition experiments were carried out
with a 50-fold excess of unlabeled wild type (wt) or Sp-consensus (cons) ds oligonucleotide.
Sp1 (panels A, B, and C) and Sp3 (panels A and B)-specific antibodies were added to the
reactions resulting in a supershift of the antibody-protein-oligonucleotide probe complex
(bands are indicated *1 for Sp1, *2 for Sp3). Panel D depicts a competition experiment in
which affinity of the Sp-proteins for the different oligonucleotides was investigated. Either
oligonucleotide -177/-146 or -298/-275 was labeled and a 50-fold excess of the other
(unlabeled) oligonucleotides was added. a: complex containing Sp1, b and c: complex
containing Sp3 isoforms. In Panel E the sequences of the PROS1 and Sp1 consensus ds 
oligonucleotides is depicted. The binding affinity of the four PROS1 oligonucleotides is 
estimated.
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Figure 5 FOXA2, CRE/ATF and NFY bind to the PROS1 promoter. 10 µg HepG2
Nuclear Extract was incubated with a single ds oligonucleotide probe for 20 minutes. Protein-
DNA complexes were separated on 3% (panel A) or 5% (panels B and C) PAGE. The dried
gel was exposed to film. Competition experiments were carried out with a 50-fold excess of
unlabeled wild type (wt) or mutant (mt) ds oligonucleotide. FOXA2 (panel A), CRE/ATF
(panel B) and NFY� (panel C)-specific antibodies were added to the reactions resulting in a 
supershift of the antibody-protein-oligonucleotide probe complex (bands are indicated with an
asterisk).
Computational analysis also revealed the presence of putative CREB/ATF and NFY sites
around positions -346 to -323 and -382 to -359, respectively. Protein-DNA complexes were 
obtained in incubations with HepG2 nuclear extract and labeled primers at these positions.
Evidence for binding of both families of transcription factors was subsequently established in
supershift assays with transcription factor-specific antibodies (Figure 5, panels B and C).
Effects of transcription factor binding site mutations on PROS1 promoter activity – The contribution
of each of the identified transcription factors in PROS1 transcription was assessed by site-
directed mutagenesis of their binding sites within the PROS1 promoter-reporter gene
constructs. First, it was confirmed that mutant oligonucleotide duplexes could not compete
for transcription factor binding and that mutant probes could not bind nuclear protein in 
EMSA experiments (Figure 4 panel A, panel B and Figure 5 panel A and results not shown).
Mutation of the Sp-binding sites had a pronounced effect on basal promoter activity. In the
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experiments depicted in Figure 6A, construct PS370 was modified to contain either one, three
or four mutated Sp-binding sites. Whereas alteration of site a (-177/-146) or b (-253/ 
-230) had a strong negative effect on promoter activity, mutation of site c (-298/-275) or d
(-359/-335) had a mildly positive effect. Mutation of site a or b alone resulted in a reduction
of promoter activity to 75% and 50% of the wild type PS370 construct, respectively. No 
further beneficial or deleterious effects were seen when mutation of either site a or b was 
combined with alteration of both Sp-binding sites c and d (mutants acd and bcd). The
quadruple mutant (abcd) and triple mutants, abc and abd, all displayed a residual promoter
activity of approximately 20% (background pGL3b activity was 9%). From these experiments
we conclude that Sp-binding sites a and b, but not c and d, are necessary for maximal PROS1
promoter activity under basal conditions. It may even be cautiously concluded that sites c and
d have an inhibitory influence on PROS1 transcription. Finally, the influence of Sp-binding 
site b on basal activity is greater than that of site a.
Basal expression of PROS1 construct PS370 or PS1062 in HepG2 was only slightly
influenced by mutation of the binding sites for FOXA2, CREB/ATF or NFY (Figure 6B).
The mutation in the FOXA2 binding site caused a slight decrease in PROS1 promoter activity,
whereas the NFY mutation caused a slight increase in promoter activity (p<0.05 for both
mutations). Mutation of the CREB/ATF binding site caused no measurable alteration in 
promoter activity. 
PROS1 promoter expression is stimulated by Sp1, Sp3, and FOXA2 -- Cotransfection of HepG2
cells with PS370 and the Sp1-expression vector resulted in a 2.4 fold induction of promoter
activity (Figure 7A). Sp3 had little or no effect on promoter activity. Cotransfections with 
triple mutants, in which only sites a, b, or c were still present, barely resulted in a decreased
inducibility of PS370 by Sp1 (2.44, 2.07, and 2.15 fold for bcd, acd and abd respectively). Site
a (mutant bcd) was sufficient for full Sp1 induction of PS370 and only a slight reduction of 
responsiveness to Sp1 was seen in triple mutants acd and abd. On the other hand, the triple 
mutant PS370abc and the quadruple mutant PS370abcd had low responsiveness comparable
to that of the empty vector pGL3basic (1.37, 1.58, and 1.35 fold stimulation respectively).
Apparently, Sp1-binding site d (-359/-335) is not able to mediate Sp1 induction of PROS1
promoter activity, indeed this site may even exert an inhibitory effect (1.37 fold stimulation
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Figure 6 Effect of site-directed mutagenesis of transcription factor binding sites on 
PROS1 promoter activity. HepG2 transient transfections with wild type and mutant PROS1
promoter-luciferase contructs were carried out. The mutated site(s) are indicated below the
bars. Luciferase expression of the wild type was set to 100% and promoter activity of the
mutants is expressed as a percentage of the wild type construct. The data are presented as the
means (± SD) of at least three different experiments in triplicate with two independent
plasmid preparations. (A) Sp-binding sites in PS370 were mutated as shown. *p<0.01, 
**p<0.001 relative to the wild type construct. (B) Binding sites for FOXA2, CRE/ATF and
NFY were mutated in the PS370 construct (FOXA2, CRE/ATF) and in the PS1062 construct
(FOXA2, CRE/ATF and NFY) as shown. *p<0.05. pb; pGL3basic. 
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versus 1.58 for the quadruple mutant). Upon alteration of all four binding sites, not all Sp1 
trans-activation potential was lost (1.58 vs. 1.35 background). This supports our earlier
assumption that an additional Sp-binding site may be present nearby site a (-177/-146) that 
was not mutated. Similar results were obtained with cotransfections in HeLa cells, albeit that
PROS1 promoter induction was more pronounced in this cell type (results not shown).
The activity of PROS1 promoter construct PS370 was stimulated slightly by cotransfection
with the liver-specific transcription factor FOXA2 in HepG2 cells (p=0.06) (Figure 7b). Upon
mutation of the FOXA2 binding site at position -282/-258 this trend was absent. The empty
vector, pGL3basic, was also strongly responsive to cotransfection with the FOXA2
expression vector. Cotransfections in HeLa cells produced similar results for the PROS1
constructs, but pGL3basic had an even higher background activity.
Figure 7 Cotransfections of HepG2 cells with PS370 variants and transcription factor 
expression vectors expressing Sp1, Sp3 or FOXA2. HepG2 transient transfections with
wild type and mutant PROS1 promoter-luciferase contructs were carried out. Luciferase
expression of the wild type co-transfected with the empty transcription factor expression 
vector was set to 100% and all other data are expressed as a percentage thereof. The data are 
presented as the means (± SD) of a representative assay done in triplicate. (A) Cotransfections
of PS370 variants with pCMV-Sp1 or pCMV-Sp3. (B) Cotransfections of PS370 variants with 
pcDNA3-FOXA2 *p<0.05. pb; pGL3basic.
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Chromatin immunoprecipitation locates Sp1 to the PROS1 promoter in vivo -- A PROS1-specific
PCR was performed on sheared HepG2 chromatin, which had been immunoprecipitated with
an Sp1-specific antibody, with primers encompassing promoter region -322 to -91 upstream 
from the PROS1 translational startcodon. As a positive control on the method, a PCR was 
performed on the GAPDH promoter after chromatin immunoprecipitation with the positive
control, TFIIB antibody. The PCR on the GAPDH promoter also served as a control for the 
specificity of the Sp1 antibody, since the GAPDH promoter contains two Sp1 binding sites in
the same region that was used for the TFIIB positive control PCR. The PROS1-specific PCR
product that was obtained (Figure 8) provides evidence for direct in vivo association of Sp1
with the PROS1 promoter in HepG2 chromatin.
Figure 8 Sp1 binds to the PROS1 promoter in vivo. ChIP assays were performed using
sonicated chromatin isolated from HepG2 cells and an antibody specific for Sp1, TFIIB, or a
non-specific IgG. The subsequently purified DNA samples were used as a template for PCR
with primers specific for GAPDH (lanes 2-6) generating a 166 bp gene-specific product or 
PROS1 (lanes 8-12), which generates a 231 bp fragment (bp -322 to -91). The following PCR 
results are shown: lanes 2 and 8, using DNA purified with the anti-Sp1 antibody; lanes 3 and 9,
using DNA purified with the anti-TFIIB antibody; lanes 4 and 10, using DNA purified with the
non-specific IgG; lanes 5 and 11, using untreated chromatin; lanes 6 and 12, H2O; and. Lanes 1, 
7 and 13 represent a 1-kb plus marker.
Discussion
Heterozygosity for PS deficiency is found in 0.2% of the general population and in 1-2% 
of patients with deep vein thrombosis (43-45). Whereas hereditary PS deficiency is relatively
rare, many other conditions lead to acquired PS deficiency. For instance, PS levels are strongly
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influenced by hormonal state, which is illustrated by decreased PS levels during pregnancy and 
oral contraceptive use (46;47). Conditions known to negatively influence PS levels are liver 
disease, and disseminated intravascular coagulation (16;48;49). Overall, the regulation of PS 
levels (free and C4BP-bound) in normal and pathophysiological circumstances is still poorly 
understood.
This paper reports on the transcriptional regulation of PROS1 by cell-specific and general
transcription factors. A proximal promoter fragment of 370 bp with maximal activity was 
identified through transient expression of PROS1 promoter-reporter constructs under basal
conditions in all cell lines. Larger PROS1 constructs had reduced activity in HepG2 and HeLa
cells, whereas promoter activity was maintained at a high level in the same constructs in 
Meg01 and HuH7 cells. The finding of a minimal promoter with a high level of activity in all 
cell types suggested that ubiquitous transcription factors are involved in the regulation of
PROS1 transcription under basal cell culture conditions. On the other hand, the finding of
differential activity of the longer constructs is an indication that also cell-specific transcription
factors may be involved in PROS1 transcription.
The hypothesis that PROS1 transcription is driven for a large part by general transcription
factors was confirmed by the identification of four binding sites for the ubiquitous
transcription factor Sp1 (41) in the first 370 bp of the PROS1 promoter. The affinity of Sp1 
for the four sites was estimated by EMSA competition experiments and was categorized as
follows; a (-177/-146) > b (-253/-230) > c (-298/-275) > d (-359/-335). Computational
analysis showed that multiple Sp1/3-binding sites may be situated in the region surrounding
site a, only one of which had been mutated during site-directed mutagenesis, however.
Mutagenesis of site b had the most deleterious effect on basal PROS1 promoter activity; 
PS370 activity in HepG2 cells was reduced by approximately 50% upon mutation of this site.
Mutation of site a resulted in a reduction of PS370 activity to 75% of that of the wild type
construct. Mutation of Sp-binding sites c or d had a slightly positive effect on PS370 promoter
activity. Alteration of all Sp-binding sites resulted in 20% residual promoter activity.
We also tested the effectiveness of mutation of Sp-binding sites a and b in a smaller
construct, namely PS261, and obtained similar results as for PS370 (40% (b) and 20% (ab)
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residual activity (results not shown)). In this respect our study is in accordance with that of 
Tatewaki et al (33), who previously identified site b as an Sp1 binding site. Upon mutation of
site b in a construct encompassing bp -282 to -161 of the PROS1 5’ region they demonstrated
a residual construct activity of approximately 15%. Site b is the only Sp-binding site present in 
the -282/-161 construct. This result is therefore best compared to the 20% residual activity of
PS261ab and PS370abcd in our study. The finding that alteration of sites c and d in 
combination with either site a or b in triple mutants acd and bcd did not result in an additional
effect on promoter activity over the single mutation of site a or b (Figure 5b) led us to
conclude that sites c and d are redundant in PROS1 transcriptional regulation by Sp1. The
increased activity of the single c and d mutants relative to the wild type promoter construct
suggests that these sites may nevertheless be important in PROS1 promoter regulation, most
likely through a different mechanism than trans-activation of the PROS1 promoter by Sp1
binding. For instance, steric hindrance by Sp1 binding at site c (-298/-275) could impede
simultaneous binding of FOXA2 at the overlapping site -282/-258 and vice versa. Sp1 has 
also been attributed a central role in transcriptional activation through histone acetylation and
the prevention of gene silencing through DNA hypermethylation (50-53). A third possible
explanation for the slight increase in promoter activity upon mutation of site c or d may be 
that these sites are bound with a higher affinity by Sp3 than by Sp1. Sp3 may act either as an
inhibitor or activator of transcription depending on cell type, DNA-binding site context, and
additional transcription factors that are present in the cell (41). In this case Sp3 may be
repressing PROS1 transcription through binding of Sp-binding sites c and d.
Cotransfection of Sp1 or Sp3 with PS370 triple mutant constructs confirmed that sites a
and b are essential in PROS1 transcriptional regulation by Sp1 (Figure 7). Mutant abd was
responsive to Sp1 in the same manner as mutant acd. This was an unexpected finding since in
basal activity experiments mutation of site c was found to have a stimulatory effect on PROS1
promoter activity (Figure 6). However, this finding indicates that site c may indeed be bound
with higher affinity by Sp3 under basal conditions, as suggested above. By addition of excess 
Sp1 in cotransfection experiments, most if not all Sp3 is most likely competed off of site c 
resulting in the observed induction of PS370abd promoter activity. 
In vivo chromatin immunoprecipitation of Sp1-PROS1 promoter complexes further
confirmed the relevance of Sp1 in PROS1 transcription. In an effort to further demonstrate in
100
Sp1 and Sp3 binding to and regulation of the Protein S gene promotor
vivo binding of transcription factors to the PROS1 promoter region, in vivo genomic 
footprinting of PROS1 promoter region -400 to -100 was attempted. Unfortunately, high 
levels of background signal in these experiments compromised the interpretation of the data.
We believe that these high background levels were due to the fact that the endogenous PROS1
promoter is not active in all cells, i.e. is not bound by transcription factors. This problem 
could probably be overcome if a major stimulator of PROS1 transcription was added to the
cell culture. To our knowledge such a compound has not yet been identified.
A previously identified binding site for the liver-specific transcription factor FOXA2 was
confirmed at position -282/-258 (33). In contrast to these earlier findings, mutation of the
FOXA2 site hardly resulted in reduced PROS1 promoter activity (Figure 7c). The different
construct sizes in both studies could cause the different effects of the mutations. As described
above, Tatewaki et al used a construct, which ranged from -282 to -161, thereby lacking several 
of the previously identified transcription start sites (32), whereas the construct used in this 
report is larger, spanning nucleotides -370 to -1 in relation to the PROS1 translational
startcodon. Cotransfection of HepG2 cells with FOXA2 and either PS370 or the PS370- 
FOXA2 mutant resulted in a slight induction of the wild type PS370, but not of the FOXA2
mutant construct. In addition, the empty vector pGL3basic was strongly responsive to
cotransfection with the FOXA2 expression vector. This complicated the interpretation of the 
data obtained with the PROS1 construct. We conclude that FOXA2 may not be an important
trans-activator of the PROS1 promoter in our model system. We identified three putative
FOXA2 binding sites within the first 100 bp upstream from the pGL3basic multiple cloning
site (mcs) and a single binding site between the mcs and the luciferase translational startcodon.
We therefore assumed that the cross-reactivity of pGL3basic was most likely due to FOXA2 
binding to the vector.
A CREB/ATF binding site was discovered and confirmed by EMSA-analysis in the 
PROS1 promoter at position -346/-323. Although no deleterious effect on basal PS370 
activity was observed by mutation of the binding site, this does not rule out a role for
CREB/ATF in the induction of PROS1 transcription under stimulatory circumstances. The
CREB/ATF family has at least 10 members, all of which bind to a DNA consensus sequence
called the CRE (reviewed in (54;55)). The finding of a CRE element in the PROS1 promoter,
suggests that changes in intracellular cAMP levels may be involved in the regulation of PS 
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levels in vivo. Transcription of many cellular genes is regulated by changes in cAMP levels in
response to extracellular stimuli, amongst which steroid hormones. This signalling pathway is
associated with the protein kinase A-dependent phosphorylation of nuclear proteins that
belong to the CREB/ATF family of transcription factors. It is tempting to speculate that
cAMP and CREB/ATF are the messengers involved in the estrogenic/progesteronic effects
on PS levels.
A binding site for the ubiquitous transcription factor NFY was found in the PROS1
promoter at position -382/-373 through primer walking and antibody supershift EMSA
experiments. NFY is primarily known as a transcriptional activator, although it has also been
shown to inhibit transcription (56;57). NFY is unable to activate transcription by itself, but
increases the activity of neighbouring enhancer motifs and participates in the correct 
positioning of other transcription factors at the start site. Mutation of the NFY binding site in 
PROS1 promoter construct PS1062 had a positive effect on promoter activity in HepG2.
Further research is needed to clarify the role of NFY and CREB/ATF in the transcriptional
regulation of the PROS1 promoter.
In conclusion, we show that constitutive expression of the minimal PROS1 promoter 
PS370 is mainly directed by Sp1/Sp3. The two most proximal Sp-binding sites of the total of
four binding sites that were identified in this study are pivotal in trans-activation of the PROS1
promoter by Sp1, whereas such a role for the two most distal sites could not be established.
Binding of either Sp1 or Sp3 to these last two sites may however be necessary for regulation
of PS transcription at a different level, which could not be revealed by the methodology used 
in this report. The PS370 minimal promoter was further shown to contain many transcription
factor binding sites, the most prominent of which were identified as sites binding transcription
factors Sp1/Sp3, FOXA2, CRE/ATF and NFY.
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Summary
The Protein C anticoagulant pathway is an essential mechanism for attenuating thrombin
generation by the membrane-bound procoagulant complexes tenase and prothrombinase. In
this pathway, Protein S (PS) serves as a cofactor for activated protein C (APC) in the
inactivation of coagulation factors VIIIa and Va. The primary site of PS synthesis is the liver. 
PS circulates in plasma in a free form and in complex with complement component 4b-
binding protein (C4BP), thus linking PS to the complement system. C4BP is a known acute 
phase reactant thereby also suggesting a relation between PS and the acute phase response.
Interleukin 6 (IL6), a major contributor to the acute phase response of hepatocytes, has been
shown to influence both PS and C4BP gene expression. We show here that IL6 upregulates
PS mRNA and protein levels in HepG2 cell culture and that it exerts this effect by induction 
of PS promoter activity through a direct interaction of Signal Transducer and Activator of 
Transcription 3 (STAT3) with the PS promoter at a region spanning nucleotides 229 to 207 
upstream from the translational start. A possible function for IL6-induced PS expression in 




The Protein C anticoagulant pathway is indispensable in maintaining the hemostatic
balance (1;2). In this pathway, Protein S (PS) functions as a non-enzymatic cofactor for
Activated Protein C (APC) in the inactivation of coagulation factors VIIIa and Va (3-6). The
clinical importance of PS became apparent by the association of venous thrombo-embolism
(VTE) with (partial) PS deficiency (7-9). The major source of circulating plasma PS is the
hepatocyte (10). In human plasma, PS circulates in an active free form (40%) and a C4b-
binding protein (C4BP)-bound inactive form (60%) (11-13). The acute-phase response (APR)
is characterized by a rapid increase of hepatic proteins, which serves to restore the
physiological balance and limit the deleterious effects of tissue injury and infection. In the
liver, synthesis of several plasma proteins, e.g. �1-antitrypsin, �2-macroglubulin, plasminogen, 
and fibrinogen, undergoes dramatic changes during the APR (reviewed by Ramadori et al (14)).
Several of these proteins are also involved in coagulation or fibrinolysis. The changes during 
the APR are mainly mediated by the action of cytokines, such as IL6, IL1�, and TNF�.
In vitro studies in cultured human hepatoma cell line HepG2, primary Human Umbilical
Vein Endothelial Cells (HUVECs), and in human microvascular endothelial cell line HMEC-
1, have shown an increased PS production upon IL6 stimulation (15-17). C4BP is an 
established acute phase reactant with 2-3 fold elevated plasma levels during inflammation (18-
21). The C4BP protein contains 6 or 7 identical �-chains and a single �-chain, although 17%
of the C4BP molecules lack the �-chain (13). PS is bound to C4BP via the �-chain. Several
studies have demonstrated similar or slightly increased total PS levels, but reduced free PS 
levels in plasma of patients during inflammation (22-24). The observed reduction in free PS 
levels has been explained as a direct consequence of an increase in the �-chain containing 
C4BP-form. Other studies, however, provide evidence for stable free PS levels during 
inflammation, showing only a rise in C4BP �-chain levels, but not in �-chain levels (21;25).
The observed discrepancy between the various studies may be explained by a differential
regulation of C4BP �- and �-chains in different subpopulations of patients during the APR 
(26).
The IL6 signalling pathway is well-defined (27-29). In short, IL6 is known to exert its 
stimulatory effect through IL6-responsive elements (IL6-RE) in the promoters of IL6-
responsive genes. Two types of IL6-REs have been identified in genes encoding acute phase 
proteins. Type I is a binding site for CCAAT/enhancer binding protein (C/EBP) � (NF-IL6,
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LAP), whereas the type II IL6-RE is bound by signal transducer and activator of transcription
3 (STAT3) (30). Whilst IL6 upregulates nuclear C/EBP� levels through both elevated
C/EBP� gene transcription and C/EBP� phosphorylation (29), increased nuclear STAT3
levels are mainly due to rapid STAT3 phosphorylation (28). C/EBP� and STAT3 have been
shown to affect IL6-induced transcription by binding to a.o. the promoters of the genes 
encoding C-reactive protein (CRP) (31;32), plasminogen (33), haptoglobin (34), and fibrinogen
(35). In this report we investigate the mechanism by which IL6 upregulates PS protein levels.
Two copies of the PS gene are located on chromosome 3. The active PS gene (PROS1)
shares 96% homology with the inactive pseudogene (PROS2) (36-38). Recently, constitutive
expression of the PROS1 promoter was shown to be regulated mainly by Sp1 in vitro, and to
contain binding sites for various other transcription factors such as the hepatocyte-specific
forkhead transcription factor FOXA2, which are possibly involved in tissue-specific or
induced expression of the PROS1 promoter (39). We confirmed earlier findings that PS is 
upregulated by IL6 in cultured HepG2 cells and complemented these with quantitative PS
mRNA data thereby identifying the regulatory mechanism as pre-translational. Subsequently,
we identified a region in the PS promoter spanning nucleotides 229 to 207 upstream from the
translational start that binds STAT3, one of the nuclear messengers of IL6.
Experimental Procedures 
Plasmids --- The generation of PROS1 promoter reporter constructs is described in Chapter
2. PROS1 promoter constructs were mutated at a putative STAT3 binding site by use of the
QuikChange XL Site-Directed Mutagenesis kit from Stratagene (La Jolla, CA), with forward
primer 5’-CCAGCTCCGAAAAGCCGCCTGGTGCTGTCCTTGTTATCAC-3’and reverse primer 5’-
GTGATAACAAGGACAGCACCAGGCGGCTTTTCGGAGCTGG-3’. Successful incorporation of the
mutations was confirmed by automated sequencing (Beckman).
Cell culture --- The human hepatoblastoma cell line HepG2 was purchased from the
American Type Culture Collection (ATCC, Manassas, VA). Cells were grown in Minimal 
essential medium (MEM), 10% Fetal Bovine Serum (FBS), 100 g/ml penicillin, 100 g/ml
streptomycin, and 1x MEM non-essential amino acids (all purchased from Gibco, Invitrogen).
For induction experiments, cells were washed twice with phosphate buffered saline, after
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which fresh medium was added that lacked FBS but contained 0.1% human serum albumin
and 5 or 100 ng /ml recombinant human IL6 (Strathmann)).
Preparation of nuclear extracts --- Nuclear extracts (NE) were prepared according to the
method of Dignam et al (40). The final nuclear extract buffer contained 20 mM HEPES (pH
7.9), 0.2 mM EDTA, 100 mM KCl, 0.5 mM DTT, 0.2 mM PMSF and a 1 x concentration of
an EDTA-free protease inhibitor cocktail (Roche, Mannheim, Germany). Nuclear extracts
were aliquoted and frozen at -80oC until further use. Protein concentration of the NE was
measured with the BCA assay (Pierce Biotech, Rockford, IL). Nuclear extracts were prepared
from HepG2 cells cultured in the absence or presence (30 minutes or 14 hours) of 100ng/ml 
IL6.
Immunological detection of STAT3 and C/EBP� --- Nuclear extracts (10 g protein) were 
fractionated on a denaturing 7.5% poly-acrylamide gel and transferred onto a nitrocellulose
membrane. After blocking for 1 hr in phosphate-buffered saline (PBS) containing 1% nonfat 
dry milk, 1% bovine serum albumin, and 0.05% Tween 20, the membrane was incubated for 1 
hr at room temperature with the first antibody. C/EBP� and p-STAT3 were detected with the
polyclonal antibodies sc-150G (1:1000) and sc-7993 (1:1000), respectively (Santa Cruz 
Biotech, CA, USA). As secondary antibody, HRP-conjugated rabbit anti-goat IgG was used at
a dilution of 1:1000. Enhanced chemoluminescence was used for detection by incubating the
membrane for 1 min with freshly mixed 1.25 mM 3-aminophtalhydrazide, 0.2 mM p-coumaric
acid, and 0.01% v/v H2O2 in 0.1M Tris pH 8.5.
Reporter gene assays --- Cells were transfected at 60-80% confluency. Each transfection was
performed in triplicate in 12-wells plates. All assays were conducted with two different DNA
preparations of each construct. Transfections were carried out using 3 l Tfx-20 lipids 
(Promega) per g transfected DNA. In each transfection, an equimolar concentration of
construct was used, supplemented with pUC13-MCS vector to obtain a fixed amount of 
transfected DNA. In pUC13-MCS the MCS had been removed by digestion with PvuII and
religation. Control vector pRL-SV40 (Promega), expressing the Renilla luciferase, was co-
transfected for correction of transfection efficiency in a 1:500 ratio to total transfected DNA.
The cell extracts were harvested at 24 hours (HepG2) after transfection. During induction
experiments, medium was aspirated and replaced by fresh medium with or without IL6 eight
hours after transfection and cell extracts were harvested 48 hrs after IL6 addition. Luciferase
activity was measured according to the Dual Luciferase Assay System Protocol (Promega).
Cells were lysed in 250 l Passive Lysis Buffer/well, after which 20 l was used to measure
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luciferase activity. Activity was measured using a Lumat LB9507 luminometer (Berthold, Bad
Wildbad, Germany).
PS measurements --- Total PS antigen levels in IL6-stimulated and unstimulated culture media
were determined by enzyme-linked immunosorbent assay (ELISA) as described previously
(41) with the following modifications. ELISA plates were coated with 10 g/ml goat anti-
human PS IgG (Kordia, Leiden, The Netherlands) overnight at 4oC. A second coating with 
2.5% ovalbumin (Sigma-ALDRICH, St. Louis, MO) at 37oC for 1 hour was performed to 
reduce background absorbance. Immobilized Protein S was detected with horseradish
peroxidase-conjugated rabbit anti-human IgG (Dako, Glostrup, Denmark). Absorbance at 450
nm was determined with an Organon Teknika plate reader (Turnhout, Belgium).
RNA-assays --- Total RNA was isolated from cell culture using Trizol reagent (Invitrogen)
according to the manufacturers recommendations. Samples were treated with RNAse-free
DNAse I (Amersham, Roosendaal, The Netherlands) after which RNA was purified with the
RNeasy mini kit (Qiagen, Hilden, Germany). PROS1 mRNA levels were determined by real-
time quantitative PCR analysis (QPCR). First, 1 g total RNA from each cell line was reverse
transcribed using Superscript II reverse transcriptase and random hexamers (Invitrogen).
1/20th of the obtained cDNA was subsequently used in a QPCR reaction with primers and 
probes specific for PROS1. The forward primer was 5’-TGCTGGCGTGTCTCCTCCTA-3’, the 
reverse primer was 5’-CAGTTCTTCGATGCATTCTCTTTCA-3’, the probe was TET-5’-CTTCCC
GTCTCAGAGGCAAACTTTTTGTC-3’-TAMRA. The primers and probe sequence locations and
lengths were determined by using the ABI Primer Express Program (Applied Biosystems, 
Foster City, CA). PROS1 QPCR reactions (Eurogentec) were performed in 0.5 ml thin-walled, 
optical-grade PCR tubes (Applied Biosystems) in a 50 l final volume, by addition of the
following components: 0.25 U AmpliTaq Gold DNA polymerase, 160 nM TaqMan probe,
300 nM of each primer, and 3 mM MgCl2. A QPCR of the internal standard, the
porphobilinogen deaminase gene (PBGD), was carried out in a similar fashion for each RNA 
sample with 4 mM MgCl2. For this QPCR the following primers and probe were used;
forward primer 5’-GGCAATGCGGCTGCAA-3’, reverse primer 5’-GGGTACCCACGCGATCAC-3’,
and probe TET-5’-CTCATCTTTGGGCTGTTTTCTTCCGCC-3’-TAMRA. An Applied Biosystems
Prism model 7700 instrument monitored the reactions. Thermal cycling conditions consisted 
of 10 min at 95oC followed by 50 cycles of 15 s at 95oC and 1 min at 60oC. Determinations of
cycle threshold (CT) were performed automatically by the instrument. The results are
expressed as fold transcript relative to the internal standard PBGD (=2�Ct).
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Electrophoretic Mobility Shift Assays (EMSA) --- EMSAs were performed in a 13 l binding 
reaction containing 10 g NE and 195 ng denatured herring sperm DNA. EMSA buffers were
purchased from Active Motif (Carlsbad, CA) and used according to the manufacturers
recommendations. Double-stranded (ds) oligonucleotides were end-labeled using �32P-ATP
and T4 polynucleotide kinase. The following ds oligonucleotides were used (only the sense
strand is given): -229/-207wt 5’-AAAAGCTTCCTGGAAATGTCCTTG-3’, -229/-207mt 5’-AAA
AGCCGCCTGGTGCTGTCCTTG-3’, STAT3cons 5’-GATCCTTCTGGGAATTCCTAGATC-3’,
C/EBP� cons 5’-TGCAGATTGCGCAATCTGCA-3’. Reaction mixtures were incubated on ice for 
20 min in the presence or absence of an unlabeled competitor. Subsequently the 32P-labeled ds 
probe was added and the incubation was continued for another 20 min. In antibody supershift
experiments, NE was incubated on ice 10 min with the 32P-labeled ds probe after which an 
anti-STAT3 or anti-C/EBP� antibody (sc-150x and sc-7993x, Santa Cruz Biotechnology) was 
added and the incubation was allowed to continue for another 10 min. Samples were loaded
on a 5% non-denaturing polyacrylamide gel, which was electrophoresed for 2 hrs at 200V, 
after which gels were vacuum-dried and exposed to X-ray film.
Results
IL6 induces PROS1 mRNA and PS protein levels in HepG2 --- PS circulates in normal plasma at
a concentration of about 0.33 M (13). Hepatocytes are the largest contributors to the
systemic levels of PS (10) therefore, hepatoma cell line HepG2 was used as a model system.
PS mRNA and protein levels under basal culture conditions were compared with those after
induction with 5 or 100 ng IL6 per ml culture medium (Figure 1). A dose-dependent increase
in PS mRNA and protein levels in HepG2 by IL6 became detectable after 16 hrs. Total
fibrinogen antigen levels were measured as a positive control. Fibrinogen is an established 
acute phase reactant (42-44), and its levels increased from 3.5 nM to 8.6 or 16.6 nM after 
induction with 5 or 100 ng/ml IL6 for 24 hours, respectively.
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Figure 1 Induction of PS mRNA and protein expression by IL6. In the top panel, the
expression of PROS1-derived mRNA in HepG2 cells is shown relative to that of the
housekeeping gene PBGD, encoding porphobilinogen deaminase. The incubation time (x-
axis) is plotted against the PROS1:PBGD transcript ratio (y-axis). The ratio of PROS1 over 
PBGD transcripts was determined by real-time quantitative PCR (qPCR). In the lower panel,
the production of PS over time is shown. The PS concentration in the culture medium was
determined by ELISA. All values represent the average of at least 3 pooled independent
experiments.
Phosphorylation of STAT3 is induced and maintained by IL6 in HepG2 cells --- The signal
transduction pathway of IL6 signal has two main cellular targets: the transcription factors 
STAT3 and C/EBP� that mediate most of the IL6-induced alterations in gene expression.
Strongly increased nuclear STAT3 levels stimulate transcription of target genes and are due to 
rapid STAT3 phosphorylation by janus kinases (JAKS) that are stimulated by binding of IL6
to its cognate receptor (28). As a consequence, induction of gene transcription by binding of
phosphorylated STAT3, which leads to dimerization, occurs rapidly after IL6 signalling. On 
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the other hand, increased C/EBP� activity is achieved by increased transcription of the
structural gene as well as by phosphorylation of the protein (29), hence increased trans-
activation of gene promoters by C/EBP� generally occurs later in time and lasts longer (45).
Therefore we tested nuclear extracts from HepG2 cells, which had been stimulated with IL6,
for the presence of both C/EBP� and phosphorylated STAT3 (Figure 2). Whereas C/EBP�
levels remained similar, phosphorylated STAT3 levels were increased at both time points 
tested, 30 minutes and 14 hours. The presence of strong STAT3 phosphorylation after 14 hrs
incubation with IL6 is in concordance with the sustained PROS1 mRNA induction.
Figure 2 Effect of IL6 treatment on several transcription factors. The effect of IL6
treatment on the transcription factors Sp1 (as an unchanged loading control), STAT3 and
C/EBP� is shown using Western blot analysis. Antibodies specific for Sp1, C/EBP� and the
phosphorylated form of STAT3 were used. 
An IL6 responsive element is present in the PROS1 promoter --- Subconfluent HepG2 cells were 
transfected with promoter-reporter gene plasmids containing a PROS1 5’ region of varying 
length, after which the cells were either induced with IL6, or grown further under basal 
conditions (Figure 3a). A PROS1 promoter region of 261 bp remained IL6-responsive.
However, transfections with the shortest promoter-reporter gene construct, PS197, did not
result in increased luciferase levels upon IL6 induction. These results indicate that an IL6-
responsive element within the PROS1 promoter is located between 261 and 197 bp upstream
from the translational startcodon. The stimulatory effect of IL6 on PS261 was not augmented 
with increasing promoter size. 
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Figure 3  Localization of the IL6-responsive element in the PROS1 promoter. (A)
Histogram showing PROS1 promoter activity, as assessed using luciferase constructs, in the
absence or presence of a physiological concentration of IL6 (5 ng/ml). A schematic
representation of each construct is shown on the left of the histogram. Statistical significance
was determined with the Student’s T-test. (B) Sequence of the PROS1 promoter between
-261 and -197 containing the IL6 responsive element. The ds oligonucleotide used in the
EMSA assays is indicated.
The IL6 response is mediated by binding of STAT3 to the IL6-RE in the PROS1 promoter --- 
Computational analysis using various databases on the internet such as MatInspector
professional (http://www.genomatix.com), Transfac (http://www.gene-regulation.com), and
tfsitescan (http://www.ifti.org) showed that both a STAT3 and a C/EBP� binding consensus
are located in the -261 to -197 bp region in the PROS1 promoter (Figure 3b). Increased 
binding of a protein complex to ds oligonucleotide probe -229/-207wt, was observed in 
extracts from IL6-treated HepG2 cells (Figure 4, left panel). The majority of this protein-
DNA complex was shifted with a STAT3 antibody, leaving a weak signal at the original
location. The mutated unlabeled ds oligonucleotide, -229/-207mt, was unable to compete with 
the PS wildtype probe for protein binding, whereas unlabeled ds oligonucleotides -229/-207wt
and STAT3cons containing the wild type and STAT3 consensus sequence were efficient
competitors (Figure 4). The C/EBP� consensus oligo did not influence protein binding to the
-229/-207 oligo probe. However, a slight shift from the original complex in nuclear extracts
from untreated HepG2 cells was observed with a C/EBP� antibody, suggesting that the
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residual band present in the STAT3 supershift might contain comigrating C/EBP�-probe
complexes (Figure 4, right panel).
Figure 4  EMSA of the IL6-responsive element in the PROS1 promoter. EMSA
(Electrophoretic Mobility Shift Assay) using a ds oligonucleotide representing the IL6-
responsive element and using nuclear extracts from HepG2 cells treated with or without 100
ng/ml IL6. The location of the IL6-specific band is indicated by an arrow. Non-labeled ds 
competitor oligonucleotides were used at 100 fold molar excess. wt = wild type, mt = 
mutant, cs1 is a STAT3 consensus oligonucleotide, cs2 is a C/EBP� consensus
oligonucleotide (see the experimental section for the sequences of the oligonucleotides).
Antibody 1 was a p-STAT3-specific antibody and antibody 2 was a C/EBP�-specific
antibody.
The expression of mutated promoter-reporter gene constructs in HepG2 cell culture was
analysed to investigate the contribution of STAT3 and possibly C/EBP� to transcriptional
upregulation of PS levels during IL6 induction. Although basal promoter activity remained 
unaltered upon mutation of the -229/-207 region, the mutations resulted in abolishment of 
the IL6 response in all promoter-reporter gene constructs (Figure 5). This underlines our
preliminary conclusion from the data obtained with the wild type PROS1-reporter gene
constructs that the site at -229/-207 is the only IL6-RE in the proximal PROS1 promoter.
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Figure 5  Activity of the PROS1 promoter after mutagenesis of the IL6-responsive
element. Histogram showing the luciferase activity of the wild type –370 construct and of 
three constructs with a mutated IL6-responsive element in the presence of a physiological
concentration IL6 (5 ng/ml).
Discussion
Plasma proteins that are upregulated during the APR can be roughly divided into three
major groups: proteins with an increased level of about 50% (e.g. ceruloplasmin and
complement factor-3), those with an increase of two-three fold (haptoglobin, fibrinogen,
C4BP), and a group of proteins which responds with a rapid increase of up to 5-fold to 1000-
fold (CRP and serum amyloid A (SAA)) (18;46-49). We found a 2-fold increase in PS levels in
medium after 48 hours incubation of HepG2 cell culture with 5 ng IL6 per ml medium
(Figure 1), which is in agreement with a previous report (15). Both PROS1 mRNA and PS 
protein levels were elevated up to 48 hours of IL6 stimulation. Protein S thus seems to belong
to the second category of acute phase proteins.
That not only PS protein levels but also PROS1 mRNA levels were upregulated by IL6
indicated that the mechanism by which IL6 upregulates PS levels was at the transcriptional 
level. Since IL6 induction is known to be mediated primarily by STAT3 and C/EBP�, we
tested the levels of these two transcription factors in IL6-induced nuclear extracts and found
that total C/EBP� levels remained unchanged throughout time, whereas phosphorylated
STAT3 levels were increased, also after prolonged IL6 stimulation (Figure 2). This result is in 
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concordance with the sustained higher PS levels in IL6-treated versus untreated HepG2 cell 
culture.
In this study we identified an IL6-RE in the PROS1 promoter at a region approximately
220 bp upstream from the PROS1 translational startcodon. This region contains both the
hallmarks of the STAT3 and the C/EBP� binding sites (Figure 3). We identified STAT3 as
the main transcription factor binding to the IL6-RE (Figure 4). C/EBP� may also bind to this 
region, but its contribution appears to be relatively minor. Mutation of the STAT3 binding site 
in the PROS1 promoter completely abolished the IL6 response in transfection experiments
with promoter-reporter gene constructs (Figure 5). This indicates that there are no additional
functional STAT3 or C/EBP� binding sites in the region investigated through which the IL6
effect is mediated. The putative overlap between the STAT3 and the C/EBP� binding sites
around position –220 makes it difficult to make definitive statements about the role of the 
latter protein in the induction of PROS1 transcription in HepG2 cells. Overlapping binding 
sites might constitute an efficient way to create an IL6-responsive element that is active both
at early and late time points of IL6 stimulation.
Although PROS1 is clearly IL6-responsive in HepG2 cell culture, patient studies indicate
that total systemic PS levels are only slightly increased or remain at a similar level during 
inflammation. Moreover, in a subpopulation of patients free PS levels are reduced during
inflammation due to increased C4BP �-chain levels (22). Also in patients with sepsis, free PS
levels (measured as PS activity) were decreased (50). In both circumstances, inflammation or
sepsis, IL6 is a major player and its induction of PS transcription does apparently not 
outweigh the above-mentioned in vivo effects. It could be argued that the effect on PS anti-
coagulant activity would even be worse in the absence of the mild induction of PROS1
transcription by IL6. Nevertheless, the possibility that the main function of PROS1
transcriptional regulation by IL6 may lie in another aspect of the inflammatory response
should also be considered. 
IL6 has been implicated in a variety of cellular processes with a diverse array of regulatory
roles. Dependent on the target cell, IL6 may induce various and sometimes contrasting
responses. For instance, IL6 has a pro-inflammatory function and it can induce cytotoxic
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effects, but it is also a cell survival factor. Several studies have demonstrated neuroprotective
effects of IL6, which are mediated by the stimulation of growth factors and STAT3 (51-55).
Recently, Liu et al reported a neuroprotective effect of intravenously injected PS on cortical
neurons during ischemic injury in mice (56). The authors speculated that PS may be working
through a similar mechanism as its structural homologue, growth arrest-specific gene 6
(GAS6), which induces cell survival through a signalling pathway mediated by the Tyro3/Axl
membrane receptor family. Stimulation of local PS synthesis by IL6 may therefore explain part
of the cell survival properties reported for IL6. In addition, increasing evidence suggests a 
function of PS in macrophage phagocytosis of apoptotic cells both directly (57;58) and
indirectly by directing complement to the surface of apoptotic cells (59;60). Exactly what this
new role for PS entails has not yet been fully clarified. Based on the cited literature, it seems 
plausible that the upregulation by IL6 of local and not systemic PS levels may contribute to 
processes such as the cell survival of cells in the inflamed region. Obviously, this hypothesis
needs to be tested in future research.
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Summary
For the first time we report the presence of a Protein S (PS) transcript resulting from
alternative splicing of PS pre-mRNA. The splice variant contains an additional 96 base pairs, 
which maintain the reading frame and originate from an additional exon between exons 1 and
2. The transcript predicts a protein (PSalt) with an additional stretch of 32 amino acids
between the pre- and propeptide containing four cysteine residues. The alternatively spliced
PS transcript was found in human liver and various cell lines, such as hepatoma cell lines
HepG2 and HuH7, megakaryocytic cell line Meg01, and human umbilical vein endothelial
cells (HUVEC), and was shown to be relatively abundant. The ratio of wild type transcript
versus the alternatively spliced variant was approximately 4 to 1 in human liver. Studies with 
Protein S expression vectors in COS-1 cells showed that the alternative transcript results in a
PS protein, which is retained within these cells. Western blot analysis of cell lysates indicated
that this protein S mostly forms high molecular weight aggregates within the cell that can be
partly resolved by treatment with a reducing agent. However, in non-transfected HepG2 cells
that contain the endogenous PSalt transcript, the high molecular weight species was not 





Protein S (PS), a vitamin K-dependent plasma glycoprotein, functions as a co-factor for
activated protein C (APC) in the proteolytic inactivation of coagulant factors VIIIa and Va by
APC (1-4). PS also exhibits direct APC-independent anticoagulant activity by inhibition of the
prothrombinase and tenase complexes (5-8). The primary source of circulating plasma PS is
the hepatocyte (9), although PS is produced constitutively at low levels by a variety of cell
types throughout the body (10-17). In human plasma, PS circulates in a free form (40%) and
in complex with C4b-binding protein (C4BP) at a concentration of approximately 0.35 µM
(18-20).
Partial PS deficiency was first reported to be associated with venous thrombotic disease in
1984 (21). The disorder inherits as an autosomal dominant trait with incomplete penetrance
(22). PS deficiency is classified in three types (23). Type I deficiency corresponds to low levels
of both free and total PS, type II PS deficiency is characterized by normal total and free PS 
levels, but reduced PS activity, and type III is defined by normal total PS levels, but low free 
PS levels and activity. Many abnormalities in the protein S gene (PROS1) have been described
underlying hereditary PS deficiency (reviewed in (24;25)). PS deficiency can also be acquired,
in which case it may be transient. Several non-genetic and environmental factors such as aging
(26) and hormonal status (contraceptive use) influence PS levels (27).
Protein S is synthesized as a single-chain preproprotein of 676 amino acids (aa). Pre- and
propeptide are consecutively removed from the aminoterminus of the preproprotein through
proteolytic processing, before secretion of the 635 aa long mature protein from the cell. The
signal peptide is first cleaved off by a signal peptidase during translocation of the nascent
preproprotein to the endoplasmic reticulum. The propeptide is necessary for �-carboxylation
of the N-terminal vitamin K-dependent Gla-domain which is rich in carboxy-glutamic acid
residues (28;29). In the trans-Golgi the propeptide is cleaved from the mature protein by a 
propeptidase or processing protease after completion of this process. The Gla-domain is
followed by a thrombin-sensitive region, which is connected to four epidermal growth factor
(EGF)-like domains. Whereas the C-terminal domain of other vitamin K-dependent plasma
proteins consists of a serine protease domain, the C-terminal domain of PS has two laminin
G-type repeats which share significant homology with sex hormone-binding globulin (30). 
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The PS genetic locus is located near the centromere on chromosome 3. It consists of an active
PS gene (PROS1) and an inactive pseudogene (PROS2), which share 96% homology in their
coding sequence. The promoter and the first exon are absent from PROS2, rendering it
inactive (31-33). 
We describe a protein S splice variant which was found in mRNA isolated from a human 
liver sample, hepatoma cell lines HepG2 and HuH7, megakaryocytic cell line Meg01, and
human umbilical vein endothelial cells (HUVECs). The splice variant contains an additional
96 nucleotides, resulting in a PS protein with 32 aa extra located between the pre- and
propeptide. Cloning of this alternative PS transcript in a eukaryotic expression vector and
subsequent expression thereof in COS-1 cells resulted in a PS protein (PSalt), which was not 
secreted, but instead accumulated within the cell, mainly in high molecular weight aggregates. 
Experimental procedures 
Plasmids --- The PS wild type in expression plasmid pZEM229R (pZEM229R-PSwt) was
described previously (34). The alternative PS splice variant was cloned in pZEM229R 
(pZEM229R-PSalt) as follows. First two overlapping PCR products were generated with one
splice variant-specific primer and one wild type-specific primer. In the first PCR, primer
PSwt(-14/+5), 5’-TCCGCGCCTTCGAAATGA G-3’, which is located in the first exon was used in
combination with alternative transcript-specific reverse primer PSalt(+171/+145) 5’-GCATAT
AGAATAGAAAAAATTGCATCC-3’. The second PCR was performed with forward primer PSalt
(+99/+120) 5’-TTTTATATACAACCGTGCATGC-3’ and reverse primer PSwt (+1123/+1103) 5’-
CCTCCAGTTGTGATTTTGGA-3’. The overlapping products were combined in a third PCR in
which only the outermost primers were used, thereby generating a 1233 bp final product. This
PCR product was digested with restriction enzymes BstBI and BlpI (New England Biolabs,
Beverly, MA). The 858 bp PSalt BstBI-BlpI fragment was cloned into the pZEM229R-PSwt
vector that had previously been linearized with BstBI and BlpI. The resulting pZEM229R-
PSalt was sequenced and checked for errors through automated sequencing on the Beckman
CEQ2000 system (Beckman Coulter, Fullerton, CA).
Human Liver Sample, Leukocytes and Monocytes --- A human liver sample was obtained from a 
deceased healthy donor and was a kind gift from E. de Wit at TNO Quality of Life, Leiden 
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(TNO). Leukocytes and monocytes were isolated from blood from healthy donors as 
previously described (35).
Cell culture --- The Cercopithecus aethiops (African green monkey) kidney cell line, COS-1, and
human hepatoma cell line, HepG2, were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). COS-1 cells were grown in Dulbecco’s modified Eagle's
medium (DMEM), HepG2 cells were grown in Minimal Essential Medium (MEM). Culture
media for both cell lines were supplemented with 10% Fetal Bovine Serum (FBS), 100 g/ml
penicillin, and 100 g/ml streptomycin (all cell culture reagents were purchased from
Invitrogen, Carlsbad, CA).
PS measurements --- Total PS antigen levels in culture media were determined by enzyme-
linked immunosorbent assay (ELISA) as described previously (36) with the following
modifications. ELISA plates were coated with 10 g/ml goat anti-human PS IgG (Kordia,
Leiden, The Netherlands) overnight at 4oC. A second coating with 2.5% ovalbumin (Sigma-
ALDRICH, St. Louis, MO) at 37oC for 1 hour was performed to reduce background
absorbance. Immobilized Protein S was detected with horseradish peroxidase-conjugated
rabbit anti-human IgG (Dako, Glostrup, Denmark). Absorbance at 450 nm was determined
with an Organon Teknika plate reader (Turnhout, Belgium). 
RNA-assays --- Total RNA was isolated from cell culture and human liver using Trizol 
reagent (Invitrogen) according to the manufacturers recommendations. Samples were treated
with RNAse-free DNAse I (Amersham, Roosendaal, The Netherlands) after which RNA was
purified with the RNeasy mini kit (Qiagen, Hilden, Germany). PS transcript levels were
determined by real-time quantitative PCR analysis (QPCR). First, 1 g total RNA from each
cell line was reverse transcribed using Superscript II reverse transcriptase and random
hexamers (Invitrogen). 1/20th of the obtained cDNA was subsequently used in a QPCR 
reaction with probes specific for the wild type or alternative PS and a single primer set. The
PS (+32/+51) forward primer was 5’-TGCTGGCGTGTCTCCTCCTA-3’, the PS (+186/+162)
reverse primer was 5’-CAGTTCTTCGATGCATTCTCTTTCA-3’, the PSwt probe was TET-5’-CCT
GTTGCTTGACAAAAGTTTGCCTCTGA-3’-TAMRA, the PSalt probe was TET-5’-AAGCCGACC
AATACAGAAATGCATGCCA-3’-TAMRA. The optimal primer and probe sequences were
determined using the ABI Primer Express Program (Applied Biosystems, Foster City, CA).
PROS1 QPCR reactions (Eurogentec, Seraing, Belgium) were performed in 0.5 ml thin-walled, 
optical-grade PCR tubes (Applied Biosystems) in a 50 l final volume, by addition of the
following components: 0.25 U AmpliTaq Gold DNA polymerase, 160 nM TaqMan probe,
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300 nM of each primer, and 3 mM MgCl2. A QPCR of the internal mRNA standard, the
porphobilinogen deaminase gene (PBGD), was carried out in a similar fashion for each RNA 
sample using 4 mM MgCl2. For this QPCR the following primers and probe were used;
forward primer 5’-GGCAATGCGGCTGCAA-3’, reverse primer 5’-GGGTACCCACGCGATCAC-3’,
and probe TET-5’-CTCATCTTTGGGCTGTTTTCTTCCGCC-3’-TAMRA. An Applied Biosystems
Prism model 7700 sequence detection instrument monitored the reactions. Thermal cycling
conditions consisted of 10 min at 95oC followed by 50 cycles of 15 s at 95oC and 1 min at 
60oC. Determinations of cycle threshold (CT) were performed automatically by the instrument.
The results are expressed as fold transcript relative to the internal standard PBGD (=2�Ct). PS
transcript levels were also determined by densitometric measurement of PCR product using 
the same PCR conditions and primers as described above. The PCR was allowed to continue
for 30, 33 or 36 cycles. The ratio of the alternative versus the wildtype PS transcripts was
determined with the Syngene densitometric tools (Syngene, Cambridge, UK).
Transient transfection --- For PS production purposes, COS-1 cells were cultured in 75 cm2
flasks. At 70% confluency cells were transfected with 7.2 pmol pZEM229R-PSwt or 
pZEM229R-PSalt and 100 l transfection reagent Tfx-20 (Promega). Mock transfections
contained 7.2 pmol pcDNA3 (Invitrogen) and 76 l Tfx-20. Eight hours after transfection,
cells were washed with phosphate buffered saline (PBS), after which cells were overlayed with 
10 ml Opti-MEM Glutamax production medium (Invitrogen) containing 10 mg/l vitamin K 
(Konakion, Roche), 100 g/ml penicillin, and 100 g/ml streptomycin. Conditioned medium
and cell lysates were harvested after a 10 hour incubation period. Three ml lysate buffer 
consisting of 2 mM CaCl2, 50 mM Tris/HCl (pH 7.6), 0.5% Nonidet P40, 20% glycerol, 0.5
mM phenyl methyl sulfonyl fluoride (PMSF) and 4 x complete EDTA-free protease inhibitor
cocktail (Roche, Mannheim, Germany), was used per 75 cm2 flask. For immunofluorescence
purposes, cells were grown to 70% confluency in 6 well plates, in which 18 mm glass dishes
had been placed. Transfection conditions were identical as described above, but scaled down
for transfections in 6 well plates. Eight hours after transfection cells were washed and medium
was replaced with Opti-MEM. Cells were allowed to grow for another 5, 10, 15 or 20 hours.
After the designated incubation time conditioned medium was aspirated and cells were
washed twice with PBS.
In situ immunofluorescent detection of PS --- Cells were fixed in situ with 3% formaldehyde
during a 30 min incubation period at 4oC. To allow penetration of antibodies into the cell,
cells were permeabilized with 0.1% Triton in PBS. The glass dishes, which were overgrown
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with cells, were then incubated at room temperature for 30 min with 50 l 10 g/ml primary
antibody (goat-anti-human PS IgG (Kordia, Leiden, The Netherlands)). 50 l 0.4 g/ml
FITC-conjugated secondary antibody (donkey-anti-goat IgG FITC (Santa Cruz)) was added
after an additional three PBS washes, and reactions were incubated for 30 min in the dark at 
room temperature. The glass dish was put on a microscopic slide and coverslips were
mounted over the sections with 2.5% 1.4-diazabicyclo-(2,2,2)-octane (DABCO).
Western Blot analysis --- Polyacrylamide gel electrophoresis was performed on 7.5%
SDS/PAGE under reducing and non-reducing conditions according to Laemmli (37). Protein
transfer to PVDF membranes (Millipore Corporation, Bedford, MA) was carried out
overnight through a wet blot system (Bio-Rad, Hercules, CA). Goat-anti-human PS IgG
(Kordia) was used to detect PS protein. Horseradish peroxidase (HRP)-conjugated rabbit-anti-
human PS IgG (Dako, Glostrup, Denmark) in combination with a chemiluminescent
peroxidase blotting substrate (SuperSignal West, Pierce, Rockford, IL) was used to visualize 
the immobilized antibodies.
Results
A novel transcript is produced from the PROS1 gene --- For the purpose of measuring PS protein
and transcript levels in cell culture medium and RNA isolates, we used a sensitive PS ELISA
and real-time quantitative PCR (QPCR), respectively. During optimisation of the real-time
PCR assay on human liver cDNA with primers located in PROS1 exon 1 and 2, the presence
of a second PCR product was noticed; the expected 154 bp wild type PS (PSwt) product and 
an additional product of approximately 250 bp. Purification and sequence analysis of the
unexpected product revealed that it was PS-specific and that the additional 96 base pairs
originated from intron A (Figure 1A). The sequence was compared with the human expressed
sequence tag (EST) database at the National Center for Biotechnology Information (NCBI,
http://www.ncbi.nlm.nih.gov). From a total of 32 PS-specific ESTs covering this region,
three entries contained (part of) the inserted sequence. The novel exon is located
approximately 1.3 kb upstream from exon 2 and is flanked by consensus splice sites (Figure
1B).
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Figure 1 Location and sequence of the alternative exon in PROS1. (A) Schematic
representation of the splice pattern of the standard and alternative transcript in the region of 
exons 1 and 2. The exons and introns are not shown to scale, the sequence coordinates are
based on GenBank accession number AC117474. The sequence shows the relevant part of the
alternative transcript. The nucleotide sequence of the alternative exon is shown in bold and is
underlined. The putative junctions between signal peptide and propeptide and between
propeptide and the mature protein have been indicated below the amino acid sequence. See
the main text for a discussion on propeptide processing. Nucleotide numbering starts at the A
of the startcodon, amino acid numbering starts at the first amino acid of the mature standard
protein. (B) Partial cDNA sequence of the PSalt transcript showing the position of the introns
and their splice consensus sequences.
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PS splice variant PSalt is present in various cell lines and human liver --- cDNA from human liver
and human hepatoma cell lines HuH7 and HepG2, megakaryocytic cell line Meg01, cervical
carcinoma cell line HeLa, Human Umbilical Vein Endothelial Cells (HUVECs), and freshly
isolated human leukocytes and monocytes was assayed for the presence of PSalt-encoding
mRNAs (Figure 2). PS transcripts were found in all cell lines and human liver. Unexpectedly,
low levels of the PSwt product were also found in reactions containing leukocytic and
monocytic cDNA. However, this product did not appear until 33 or more PCR cycles had
been performed. Therefore, we regard the potential of these cell types to produce PS mRNA
as negligible. Quantitative analysis of transcript ratios through real-time QPCR and 
densitometric measurement of PCR products revealed that PSalt-specific transcripts
represented approximately 20% of the total PS transcripts in the human liver sample (Table
1). Lowest PSalt transcript levels were found in cDNA isolated from HUVEC cells (0.3-
5.7%). Overall, the alternative transcript represented a significant fraction of the total PS-
specific mRNA pool in most cell types expressing PS. 
Figure 2 RT-PCR analysis of the standard and alternative transcripts in various cell 
types. First strand cDNA synthesis was primed using random hexamers and part of the
product was amplified for a varying number of cycles using Protein S-specific primers located
in exons 1 and 2. The products were separated on agarose gel. The lower panels represent a
separate experiment. 1; HuH7. 2; HUVEC. 3a; PBMC leukocytes donor 1. 4; HeLa. 5; human 
liver. 6; Meg01. 7; HepG2. 8; blank. 3b; PBMC leukocytes donor 2. 9; 95% pure monocytes
donor 3.
Recombinant PSalt protein expression --- The additional sequence in the PS splice variant was
determined to be in frame with the rest of the PSwt sequence and encoded an additional 32
amino acids. This stretch of amino acids is located between the pre- and propeptide, just
downstream of the predicted signal peptide cleavage site between the Ala and Asn-residues at
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 % PSwt or PSalt transcript per cell type 
Technique product HuH7 HUVEC HeLa Liver Meg01 HepG2
QPCR PSwt 90.8   99.7 73.0 72.9  81.0  93.8 
PSalt   9.2     0.3 27.0 27.1  19.0    6.2 
Densitometry PSwt 91.3  94.3 86.2 84.8  89.8  93.9 
PSalt   8.7     5.7 13.8 15.2  10.2    6.1 
Table 1 PS transcript composition per cell type. Transcript ratios were determined with
two different methods; quantitative real-time PCR (QPCR) and densitometric analysis of PCR
endproduct. In densitometric analysis a correction for product size was applied.
positions -50 and -49, respectively, and contains four cysteine residues (Figure 1A). This raised
several questions regarding the intracellular processing of PSalt. A full-length PSalt-encoding
cDNA was therefore cloned into a eukaryotic expression vector and protein expression of 
PSalt and Pswt was studied in COS-1 cells. COS-1 cells only produce very low levels of 
endogenous PS and readily produce high levels of protein from transfected expression 
vectors. PS levels were measured in conditioned media and lysates from COS-1 cells, which
had been transfected with either pZEM229R-PSwt or pZEM229R-PSalt (Table 2). In situ
immunofluorescent detection of PS confirmed the presence of PS protein in cells that had
been transfected with either construct (Figure 3). After a 5 hour transfection with PS
constructs, PSalt appeared to accumulate to a higher level within cells than PSwt. However,
after a 10 hour transfection period the observed difference in fluorescence intensity between
cells transfected with PSwt and PSalt had disappeared.
Incubation time 
(hr)




  -/- PSwt PSalt   -/- PSwt PSalt
10 0.028 1.037 0.030 0.076 0.222 0.423
20 0.045 1.612 0.055 0.089 0.264 0.573
30 0.048 1.865 0.066 0.103 0.232 0.460
Table 2 PS levels in COS-1 conditioned medium and cell lysate. Cells were grown in 75 
cm2 flasks. At 70% confluency cells were transfected with 7200 fmol pcDNA3 (-/-),
pZEM229R-PSwt (PSwt), or pZEM229R-PSalt (PSalt), and then cultured in 10 ml Opti-
MEM production medium for the designated incubation time.
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Figure 3 Immunofluorescent labeling of PS antigen in transfected COS-1 cells in situ.
COS-1 cells were transfected with expression constructs expressing either the standard
Protein S, PSwt, or the alternative Protein S, PSalt. Cells were grown on glass coverslips, 
fixed, permeabilized and stained with a PS-specific antibody 5 and 10 hrs after transfection.
PS-immunoreactivity was not present in medium from COS-1 cells that had been
transfected with pZEM229R-PSalt, whereas it was present in medium from COS-1 cells 
transfected with pZEM229R-PSwt (Figure 4a). PS antigen was detected in lysates from COS-1 
cells transfected with either the wild type or alternative construct. The PS protein in lysates
from pZEM229R-PSalt transfections had a much higher propensity to form high molecular
weight complexes. Some of the PSalt in these complexes could be reduced to the approximate
size of the monomeric protein by addition of DTT, presumably by reduction of 
intermolecular disulfide bonds present in the cysteine-rich extra segment in the alternative
protein (Figure 4b). The apparent molecular weight of the liberated PSalt appeared to be 
slightly greater than that of PS in lysates of cells transfected with PSwt, as is visible in the
immunoblot analysis in Figure 4b. The larger molecular weight of PSalt, in combination with 
its propensity to form aggregates, might indicate that the cysteine-rich domain is still present
at the aminoterminus of the protein, although another difference in post-translational
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processing could also cause the observed migratory shift. Unfortunately we do not know 
whether the PS identified in the cell lysates represents fully processed PS or an intermediate
form of PS, which still contains the propeptide. If the cysteine-rich domain is still present in
the intracellular PSalt, the propeptide which is C-terminal from the PSalt-specific sequence,
should also still be present in this protein. Interestingly, the high molecular weight complexes
were not detected in non-transfected HepG2 cells, that also express the PSalt-specific mRNA 
(Figure 4a).
Figure 4 Western blot analysis of wild type and alternative Protein S. (A) shows a blot 
with denatured, but non-reduced proteins. Note the intense staining of the high molecular
wight portion of the blot in the lane with PSalt and the absence of any staining in the lane
with the growth medium of Psalt-transfected cells. PSerl represents purified Protein S from
Enzyme Research Laboratories. HepG2 indicates lysate and medium from human HepG2
cells that show endogenous expression of Protein S and PSalt-encoding mRNAs. (B) shows a 
similar blot with reduced proteins. Note the somewhat higher molecular weight of the free 




We detected an alternatively spliced mRNA encoding a variant of the anti-coagulant
Protein S in human liver and various cell lines. The Protein S splice variant, PSalt, contains an
additional in-frame exon between the first two exons which encode the PS signal peptide
(exon 1) and the propeptide and the Gla-domain (exon 2). Our results demonstrate that the
additional 32 aa have a major impact on the maturation of the PSalt protein. The PSalt
mRNA comprises a significant fraction of the total PS mRNA in most cell types that were 
tested and, most significantly, in human liver. Human liver mRNA had the highest level of 
PSalt transcript, whereas mRNA isolated from HUVEC cells had the lowest PSalt content.
The difference between PSalt transcript levels in hepatocytic cell lines, HuH7 and HepG2, and
those found in human liver may occur through various processes. Firstly, differences in
growth conditions between cell culture and the in vivo liver may contribute to differences in 
levels of mRNA splice variants. Secondly, whereas mRNA from HuH7 and HepG2 culture 
contains only transcripts from a single origin, a human liver sample contains not only RNA
from hepatocytes, but also from other cell types. Cell type-specific PS pre-mRNA splicing 
may be influenced by differences in composition of the spliceosome and splicing regulators,
thereby resulting in different levels of mRNA splice variants (38;39).
Previously, we identified a transcription start site (TSS) in HUVECs, which is not 
employed for transcriptional initiation in other cell types (40). It is tempting to speculate that
the TSS location in the PROS1 promoter is somehow involved in the lower level of 
alternative splicing in these cells, as it has been shown that usage of different TSSs may lead
to different splicing patterns downstream (41-44). However, alternative splicing of pre-
mRNA is mostly due to the usage of multiple alternate promoters, leading to the
incorporation of different first exons in the mature mRNAs. In the case of the PROS1
transcripts in HUVECs, it is just the length of the 5’ untranslated region (5’UTR) of the first
exon that is different in the mRNAs.
Recombinant human PSalt was expressed by COS-1 cells, in which it was retained in large 
aggregates, whereas recombinant human PSwt was readily secreted into the medium. We
believe that the accumulation of recombinant PSalt protein within the cell is a consequence of 
the altered sequence and folding of the region normally encoding the prepropeptide of
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Protein S. In addition, some specific properties of the COS-1 cells may be responsible for the
observed results, as similar high molecular weight complexes were not detected in HepG2
cells that apart from normal PS also should express PSalt from endogenous mRNAs. The 
presence of an extra sequence in this region of Protein S is not predicted to affect the cleavage
site of the signal peptide. However, the cleavage site of the propeptide may be less accessible
to the peptidase responsible for its cleavage, because of an altered three-dimensional structure 
of this region. This is expected to be mainly due to intra- or intermolecular disulfide bond 
formation by the four cysteine residues contained within the alternative peptide sequence. In
addition, the �-carboxylase complex may not be able to bind efficiently to the propeptide,
because of steric hindrance by the cysteine-rich stretch located directly upstream. Fluorescent
in situ antibody staining showed that at longer transfection times (10 hours) the observed
difference in fluorescence intensity between cells that had been transfected with PSwt or PSalt
had disappeared. Possibly, PSalt was actively degraded within the cell.
The high molecular weight complexes, which were found in immunoblot assays of lysates 
from COS-1 cells transfected with pZEM229R-PSalt, could be partly dissociated by addition
of DTT. This may be explained if the cysteines within the alternative protein sequence form
intermolecular disulfide bridges. We could not exclude the possibility that the observed
complexes contained proteins other than PSalt, leaving open the possibility that PSalt interacts
with other proteins within the cell. Cultured HepG2 cells contain both normally and
alternatively spliced PS mRNA and secrete fully processed PS in medium. In contrast to what
was observed in the lysates of COS-1 cells transfected with PSalt the lysates of HepG2 cells
did not contain high molecular weight PS antigen. Whether this is related to differences
between COS-1 cells and HepG2 cells or to the simultaneous presence of wt presence will 
need further investigation.
Alternative exons have been found in the same position in mRNAs from the Factor VII 
and Protein Z genes, which encode two other liver-expressed Vitamin K-dependent
coagulation factors (45;46). The length and sequence of these exons is completely different,
suggesting that it is mainly their location that matters. The significance of these findings has
not yet been studied. GAS6 is a platelet protein with a domain structure highly similar to PS. 
No similar alternative transcripts have been reported for the GAS6 mRNA. However, the first
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intron of PROS1 is 46 kb long, whereas that of the GAS6 gene is only 91 bp in length, leaving
no room for alternative splicing within the latter intron.
The presence of an alternative transcript resulting in a non-secreted form of PS suggests 
that alternative splicing might be used to regulate PS plasma levels in vivo and thus may
contribute to the intraindividual variation in PS levels. However, it is as yet unknown whether 
this alternative splicing event is modulated in vivo. This awaits further investigations.
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General Discussion and Conclusions
7.1 This Chapter
The association of familial protein S (PS) deficiency in the 1980s with an increased risk for 
venous thrombosis was followed by an extensive search for mutations in the PROS1 gene. In 
contrast to the FV gene in which a single point mutation, FV Leiden, is responsible for over 
90% of the APC-resistant phenotype, many different PROS1 gene abnormalities were found
to contribute to low PS levels. At the same time other studies investigated the causes and
clinical significance of acquired PS deficiencies. Population-based studies revealed that PS 
levels are influenced by gender, oral contraceptive use, trauma, autoimmune disease, and liver 
disease, among others. 
In functional studies, PS anticoagulant activity has been thoroughly investigated and the
emerging functions of PS apart from those as an anticoagulant, e.g. in inflammation and
apoptosis, present a wide area for ongoing and future research. Remarkably, not much interest
has been shown in the transcriptional regulation of the PS gene. 
This thesis describes our investigations into the transcriptional regulation of the protein S
gene (PROS1) promoter. In this final chapter the results and conclusions from the preceding
experimental chapters are integrated and discussed in a wider context. We will discuss the
functions of the transcription factors that were found to bind to the PROS1 promoter. Also,
the use of in vitro studies, such as transfection studies, as a model system for the study of gene
regulation will be discussed in light of our recent findings.
7.2 Basal expression of PROS1
About 50% of the promoter regions of a wide variety of genes is located in CpG islands,
regions in which there is an abundance of CpG dinucleotides (1;2). The PROS1 promoter
region fits the characteristics of this category of promoters. Transcription from GC-rich
promoters is generally initiated from multiple weak start sites that are distributed over a region
of about 100 nucleotides (1;3) and it has been shown that binding of the ubiquitous




The main sites for initiation of PROS1 transcription were identified in Chapter 2. This had
been a long outstanding issue for various reasons. Different unique transcriptional start sites
had been reported in literature (6-8) and many 5' cDNA ends have been deposited at the
databases at the National Center for Biotechnology Information (NCBI). Whereas most
reported PROS1 cDNA start sites are located directly upstream from the first exon, a single
cDNA was reported with a start in the first intron (9). Also, the results of PS primer extension
experiments with total liver RNA led Ploos van Amstel et al to suggest that an additional exon
from which transcription of PROS1 could start, might be present upstream from what is now 
known as exon 1 (10). Recently, Kimura et al (2) showed that transcription from over 60% of 
all CpG-containing promoters may be directed from more than one promoter. In addition, 
they showed that these putative alternative promoters (PAPs), which are defined by a spacing
of more than 500 bp between start sites, may be used in a tissue-specific manner.
We determined the sites for PROS1 transcriptional initiation by RNA ligase-mediated rapid 
amplification of cDNA ends (RLM-RACE). With this technique we circumvented the
problems of previous studies, since only full-length mRNAs were isolated and many mRNA 
products could be analysed (11). We did not find evidence for an alternative PROS1 promoter
in the cell types used for our studies, nor did we find a start in the first intron of PROS1.
However, PS is also synthesized by Leydig cells in the testis (12), an organ that was shown to
frequently contain tissue-specific PAPs (2). It would therefore be interesting to determine the
PROS1 transcription start sites in Leydig cells. 
With the identification of three main transcription start sites (-147, -117, -100) and many
additional unique sites in human liver, human umbilical vein endothelial cells (HUVEC), and
cell lines HepG2, HuH7, Meg01 and HeLa we showed that initiation of PROS1 transcription
is directed from multiple start sites. Since then, Kimura et al have largely confirmed our results
(2) by also identifying -147 as the major start site among many others. The different start site 
distribution per cell type, and the presence of an additional frequent start at -200 in HUVEC 
indicates that start sites may be used in a cell type-specific manner. The PROS1 start sites at -
200 and -100 form the center of an Inr, a cis-element which recruits the basal transcription
machinery to the promoter (4;13;14). In Chapter 3 we demonstrated transcriptional activation
of the PROS1 promoter by Sp1 and we extended this finding in Chapter 4 where we
identified four, possibly five, functional Sp1 binding sites in the PROS1 promoter. Especially
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the two most proximal Sp1 binding sites were shown to be crucial for PROS1 trans-activation
in vitro. One of these sites may consist of two overlapping Sp1 sites.
Sp1 belongs to the superclass of transcription factors with a zinc-coordinating DNA-
binding domain. Sp family members (Sp1-Sp5) contain three zinc fingers through which they
bind and trans-activate DNA. Sp1 can form homotypic multimers (Sp-Sp), but it can also
interact with various classes of other nuclear proteins, such as factors belonging to the general 
transcription machinery, AP1, NFkB, steroid receptors and many more (for reviews on Sp 
transcription factors (15-19)). It is possible that the multiple Sp1 and Inr pairs collectively
generate the array of PROS1 start sites that were observed in Chapter 2. Figure 1A shows the 
Sp1-binding sites relative to the main start sites. Start site -200 is located directly downstream 
to three of the four Sp1-sites whereas the other sites are downstream to all Sp1 sites. 
Sp1 has been shown to mediate transcription initiation not only by acting in concert with
the basal transcription factors but also by contributing to the maintenance of the 
hypomethylated state of CpG islands (20;21). The mechanism for this Sp1-mediated
prevention of CpG methylation has thus far not been clarified. Methylation of CpG 
dinucleotides generally results in a loss of transcriptional activity by preventing the binding of
transcription factors (22). Next to specific transcription start site usage, m5-CpG-methylation
of the PROS1 promoter, may thus be a mechanism through which tissue-specific PROS1
transcriptional activity is regulated. A hypothetical model is shown in Figure 1B. Preliminary 
experiments that were not included in this thesis suggested a difference in the degree of
PROS1 promoter methylation between cell types. Future research will point out if and how 
Sp1 is involved in determining the degree of methylation of the PROS1 promoter.
In Chapter 4, the two most proximal Sp1-binding sites in the PROS1 promoter, -177/-146
and -253/-230 were shown to be indispensible for promoter activity whereas mutation of sites 
-298/-275 and -359/-335, did not negatively influence PROS1 promoter activity. The latter 
two sites therefore do not seem functional. On the other hand, these sites may be involved in 




Figure 1 Schematic model for basal PROS1 transcription. (A) Sp1 binding to the PROS1
promoter relative to the transcription start sites, (B) Methylation of CpG dinucleotides results
in loss of transcriptional activity. Note that this is a schematic representation of the PROS1
promoter region, in fact 43 putative methylatable CpGs are located in the CpG island region.
Many Alu-repeats are located in the region between 6 kb and 1 kb upstream of the PROS1
translational startcodon. The Figure is adapted from a Figure by G. Brock
(http://otir.nci.nih.gov/tech/slides-brock/slide-brock.html#title)
Another interesting issue concerning Sp1 is that, whereas Sp1 trans-activated the PS370
construct ~25 fold in HeLa cells, in HepG2 PS370 trans-activation was only ~2.5 fold 
(Chapters 3 and 4). This may be caused by a difference of endogenous Sp1 levels between 
these two cell types, which was not tested. On the other hand, these data indicate that Sp1 
may be regulating PROS1 activity in a cell-specific manner as well as at the constitutive level,
either alone but more likely by interacting with (other) cell-specific transcription factors.
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7.3 Induced expression of PROS1
7.3.1 Liver-specific expression of PROS1
In our pilot study in Chapter 3 we found that liver-specific transcription FOXA2
(HNF3�) was a strong inducer of PROS1 promoter activity. In Chapter 4 we confirmed the
presence of a previously identified FOXA2 binding site at position -282/-258 (23). In contrast
to what was reported in the earlier study, mutation of this site resulted only in a slightly
reduced basal activity of the PS370 promoter-reporter gene construct. An explanation for this
discrepancy may be sought in a difference in PROS1 promoter fragment length in the
promoter-reporter gene construct in the two studies. Whereas we used a construct
encompassing the first 370 bp proximal to the translational startcodon (-370/-1), Tatewaki 
and coworkers used a smaller PROS1 promoter that ranged from -282 to -162. Cotransfection
of HepG2 cells with FOXA2 and either PS370 or the PS370 FOXA2 mutant resulted in a
slight induction of the wild type PS370, but not of the FOXA2 mutant construct. We
concluded that FOXA2 may not be an important trans-activator of the PROS1 promoter in 
our model system.
7.3.2 Inflammation 
PS levels were upregulated in HepG2 cell culture by IL6 and Oncostatin M (OSM) (24).
IL6- but not OSM-upregulated PS levels were downregulated by TNF�. The transcriptional 
mechanism of PS induction by IL6 was studied in Chapter 5. We identified an IL6-responsive
element (IL6-RE) at -229/-207 in the PROS1 promoter to which transcription factor STAT3
binds. When binding of STAT3 is prevented by mutation of the IL6-RE, all IL6
responsiveness was lost.
STAT3 may be the sole factor mediating the effects of IL6 on PROS1. On the other hand, 
the STAT3 binding site is imperative for the IL6 response but the response may be influenced
by other transcription factors. In the fibrinogen � gene promoter for instance, a FOXA2
binding site just upstream from the IL6-RE was shown to augment IL6-induced transcription
(25). A functional FOXA2 binding site is located in the PROS1 promoter approximately 30
base pairs upstream from the IL6-RE at -275/-265 (Chapter 4, (23)). In preliminary
experiments in HepG2 we found however that IL6-induced PS370 activity is only slightly
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positively influenced by cotransfection of FOXA2. This argues against a prominent role for
FOXA2 in IL6-mediated PROS1 transcription.
In Chapter 3, another known mediator of the IL6 response, C/EBP�, was shown to 
stimulate PROS1 transcription in HeLa cells. Even though the IL6-RE in PROS1 contains the
consensus for a C/EBP� binding site in addition to the STAT3 consensus, we could not 
establish a strong interaction of C/EBP� with the IL6-responsive element, as detected by
EMSA analysis (Chapter 4). Moreover, PROS1 promoter-reporter gene plasmids with a
mutated IL6-RE are still trans-activated by C/EBP� in cotransfection studies in HeLa cells 
(Figure 2), which indicates that C/EBP� mediates its effects on the PROS1 promoter most
likely through other C/EBP� sites or through another, as yet unidentified, mechanism. In 
conclusion, we found no evidence for the involvement of C/EBP� in the IL6-mediated
stimulation of PROS1 transcription in HepG2 cells. 
Figure 2 Induction of PROS1 promoter activity by C/EBP� in HeLa cells. 375 fmol 
PROS1 construct and 25 ng expression vector was transfected into 60% confluent HeLa cell
culture in 12 well plates. Total ng of transfected DNA was equalized by addition of pUC 
vector. Cells were grown for 48 hours after which cells were lysed and luciferase activity was
measured. Each bar represents the average of three independent transfections. The exact
mutations in the IL6-RE are described in Chapter 5. 
The effects of IL6, OSM and TNF� on PS synthesis suggested that PS may function in the
(anti-) inflammatory pathway. However, even though systemic total PS levels were increased
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in patients during inflammation, free PS levels remained unchanged (26-28) or were even
marginally reduced (29-32). It may be, however, that PS not so much mediates the effects of
IL6 at the systemic level but instead is more important in mediating local IL6 effects through
a local rise in PS levels. Support for such a hypothesis comes from the recent finding that
intravenously injected PS has a neuroprotective effect on cortical neurons during ischemic 
injury in mice (33). The authors speculated that PS may be working through a similar
mechanism as its structural homologue, growth arrest-specific gene 6 (GAS6), which induces
cell survival through a signalling pathway mediated by the Tyro3/Axl membrane receptor
family. In addition, increasing evidence suggests a function of PS in macrophage phagocytosis
of apoptotic cells both directly (34;35) and indirectly by directing complement to the surface
of apoptotic cells (36;37). Based on the cited literature, it seems plausible that the upregulation
by IL6 of local and not systemic PS levels may contribute to survival of cells in the inflamed 
region. Obviously, this hypothesis needs to be tested in future research.
7.3.3 Unresolved Challenges
C/EBP�
In the pilot study in Chapter 3 C/EBP� was found to be one of the major inducers of 
PROS1 transcriptional activity. Moreover, C/EBP� was first identified as the nuclear factor
mediating IL6 effects (NF-IL6). We, therefore hypothesized that C/EBP� would be the factor
mediating the effects of IL6 on PROS1 transcription. To the contrary, in Chapter 5 we 
identified STAT3 and not C/EBP� as the main IL6-signal transducer. This left us with the
unresolved molecular mechanism of C/EBP�-induced PROS1 transcription.
We attempted to dissect the interaction of C/EBP� with the PROS1 promoter. In HeLa
cells C/EBP� induced PROS1 promoter activity ~7 fold, whereas in HepG2 C/EBP� only 
stimulated the PROS1 promoter ~2 fold (Chapter 3 and unpublished data). Surprisingly, in
HepG2 PROS1 promoter activity was stimulated more by the dominant negative variant of 
C/EBP�, liver inactivating protein (LIP, unpublished results). This variant lacks the trans-
activation domain (38;39) and has no effect in HeLa. C/EBP� has a restricted expression
pattern and is present in HepG2 but not in HeLa cells. Varying the C/EBP� versus LIP ratio in
these cell types resulted in opposite patterns of PROS1 promoter induction; in HeLa C/EBP�
induced PROS1 promoter activity and this induction was increasingly inhibited by increasing
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amounts of LIP whereas in HepG2 LIP induced PROS1 promoter activity and this induction
was increasingly inhibited by increasing amounts of C/EBP�. Due to the complexity of the
cell-specific aspects and the failure to obtain a reliable functional assay for the detection of
C/EBP�, we were not able to resolve this intriguing issue in the course of this project. 
Female hormones
Estrogens markedly affect the coagulation system, with increased levels of procoagulant
factors VII, IX, X, XII and XIII, and reduced concentrations of the anticoagulant factors PS
and antithrombin. The impact of female hormones on coagulation is underlined by the fact 
that women on oral contraceptives (OC) and hormone replacement therapy have an increased
risk to develop venous thrombosis (reviewed in (40)). Gender and OC use are thus
determinants of plasma PS levels, with women having lower levels than men and women 
using OC having lower levels than women who do not use OC (41;42). The mechanism
through which PS levels are decreased has not been investigated but functional estrogen
response elements (ERE) have been identified in the promoters of coagulation factors VII 
(43) and XII (44). The ERE in the factor VII promoter was shown to repress transcription, 
whereas the factor XII promoter was activated by estrogen.
To investigate the possible presence of a negatively acting ERE in the PROS1 promoter we 
performed several pilot experiments. In the pilot study in Chapter 3, PS370 activity was 
inhibited by cotransfection in HeLa with the androgen receptor but not with the constitutively
active estrogen receptor (ER). In a second experiment we measured endogenous PS levels in
HepG2 culture medium after stimulation with 17�-estradiol and transfection with wild type
and constitutively active ERs and found no significant effect (results not shown). In 
conclusion, we did not find evidence for an effect of ER and/or estrogen on PROS1
transcription.
On the other hand, both a nuclear factor Y (NFY) binding site and a cAMP-response 
element (CRE)-binding protein (CREB)/activating transcription factor (ATF) binding site
were discovered and confirmed by EMSA analysis in the PROS1 promoter in Chapter 4.
NFY is primarily known as a transcriptional activator, although it has also been shown to
inhibit transcription (45;46). NFY was shown to prevent ER-mediated trans-activation of the 
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factor XII promoter in NIH-3T3 and HepG2 cells (47). CREB/ATF transcription factors
bind promoter regions of many genes in response to changes in intracellular cAMP levels,
which are regulated by extracellular stimuli, amongst which steroid hormones (48;49). It is 
tempting to speculate that NFY and CREB/ATF are somehow involved in the regulation of
PROS1 transcripton by estrogens. For now however, the mechanism of estrogen-mediated
inhibition of PROS1 transcription in vivo remains obscure. 
7.4 In vitro studies as a model for in v vo gene transcription; how 
representative are they? 
i
7.4.1 General issues
Plasmid DNA generated in E. coli culture lacks structural features of endogenous DNA
such as a chromatin structure and CpG methylation. Transfection studies are thus useless for
investigating the effect of these features on promoter activity and the lack of a chromatin
structure and CpG methylation should be taken into account when analysing results. Instead,
plasmid DNA is (super-) coiled and generally has prokaryotic dam (GmATC) and/or dcm
(CmC(A/T)GG) methylation patterns which do not occur in eukaryotes. The effect of dam and
dcm methylation on promoter activity, was studied by Allamane et al (50) who found that 
luciferase expression from a reporter gene plasmid is surprisingly greater when it is dam and 
dcm methylated than when it is unmethylated. This study showed that methylation affects
promoter activity and therefore most likely transcription factor binding. Transcription factor
binding was not studied however and, regretfully, no other studies have been published on the
subject.
The luciferase assay system is wellsuited for establishing the effects of endogenous
transcription factors on the promoter under investigation, although it should never be
forgotten that it remains a model system, in which some aspects of promoter regulation, as 
discussed in the previous paragraph, cannot be investigated. However, cotransfection
experiments with vectors expressing a transcription factor pose special challenges. These
mainly have to do with the selection of the negative controls and the internal standard.
Negative controls for both the transcription factor and for the promoter-reporter construct,
e.g. pGL3basic, should be included. Generally, the empty expression vector or the
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transcription factor cloned in the opposite direction is used as negative control for the
transcription factor. In our hands some empty expression vectors, which mostly contain the
strong cytomegalovirus (CMV) promoter, had a profound effect on promoter-reporter gene
activity (see e.g. Figure 2 in this chapter). This is usually attributed to so-called squelching; the
preferential binding of endogenous transcription factors to the CMV promoter at the cost of
the weaker PROS1 promoter. Although this usually leads to a lower promoter activity of the
promoter under investigation, squelching may also stimulate the activity of a promoter, for
instance when the cotransfected CMV promoter is bound by a negative factor. This effect can
make it difficult to establish if an observed effect is caused by the transcription factor or by
the CMV promoter that is regulating it. One should therefore never rely on just cotransfection
experiments. They should be considered as pilot experiments that should be backed up by
EMSA experiments and functional promoter assays using constructs in which the binding site
of the implicated transcription factor has been mutated. We have followed this approach as
often as possible.
Another problem of the cotransfection experiments is that the luciferase production from 
the "promoter-less" pGL3basic vector was sometimes strongly induced by the transcription
factors (see Figure 2 in this chapter and Figure 7B in Chapter 4), presumably by the presence
of spurious transcription factor binding sites in the bacterial sequences. This problem is not
easily circumvented and we have been very cautious not to over-interpret the data whenever
pGL3basic was induced by a co-transfected transcription factor, as was the case for the
FOXA2 cotransfections.
A final problem has to do with the normalisation of the different experiments.
Transfection efficiency may differ strongly from one experiment to another. Therefore
normalisation is required to make the data from different experiments comparable. This is
accomplished by cotransfection of an internal standard, a plasmid that encodes Renilla 
luciferase, another type of luciferase with different substrate requirements. The internal
standard is an expression vector containing one of three promoters of variable strength
(CMV>SV40>TK) upstream from the Renilla luciferase gene. Again, the addition of most
transcription factor expression vectors influenced the production of Renilla luciferase, 
probably by the same mechanisms that have been previously delineated for the PROS1
promoter. As a consequence, the internal standard could not be used to correct for
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transfection efficiency and we had to assume that within a single experiment transfection
efficiency was similar for all wells.
These problems have been circumvented by other scientists as follows: firstly, pGL3basic
(or any other negative vector control) was mostly simply left out, secondly, wild type 
promoter activity in the absence of a co-transfected expression plasmid was not shown (only
plus expression vector and empty expression vector), and lastly, the internal luciferase
standard was omitted and/or transfection efficiency was estimated by �-galactosidase activity
or cotransfection of a different internal standard. Whether these solutions are justified is open
for discussion. 
7.4.2 PROS1-specific issues 
In Chapter 2 we determined PROS1 transcription start sites for transcription directed
from the endogenous PROS1 gene in HepG2 cells as well as start sites from PROS1
promoter-reporter gene constructs that were transiently expressed in HepG2 cells. The
starting points of transcripts derived from construct DNA were highly diverse and largely did
not correspond to the starts found for the endogenous PROS1 gene. Studies with TATA-box
driven promoters have shown that transcription from promoter-reporter gene constructs is
still directed from the correct start sites (51;52), however for TATA-less promoters this issue 
had not been previously addressed. The reason for this is unknown. Maybe such studies have
not been conducted or researchers failed to report the (disappointing) results or results were
not accepted by scientific journals. Whatever the reason, the de-regulated transcriptional
initiation from TATA-less promoter-reporter constructs raises the question whether this 
model system is suitable for studying all the characteristics of this type of promoter.
The results presented in Chapters 3 through 5 show that (co-)transfections are useful for 
the detection of large scale effects of transcription factors on promoter activity (e.g. Sp1).
However, one has to keep in mind that an endogenous pool of transcription factors is always 
present and that the composition thereof differs per cell type. This is illustrated well by the
fact that in Chapter 3 Sp1 trans-activated the PS370 construct ~25 fold in HeLa cells whereas 
in HepG2 PS370 trans-activation was only ~2.5 fold. It would be interesting to compare the
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results from EMSA experiments done with HepG2 nuclear extracts in Chapter 4 with the
same experiments done with nuclear extracts from HeLa cells.
7.5 Alternative splicing of PROS1
The alternative PROS1 transcript, PSalt, that was found in human liver and various cell
lines in Chapter 6 contains an additional in-frame exon between the first two exons, which
encode the PS signal peptide (exon 1) and the propeptide and the Gla-domain (exon 2). Our
results demonstrated that the additional 32 amino acids have a major impact on the 
maturation of the PSalt protein. Recombinant human PSalt was expressed by COS-1 cells, in
which it was retained in large aggregates, whereas recombinant human PSwt was readily
secreted into the medium. We believe that the accumulation of recombinant PSalt protein 
within the cell is a consequence of the altered sequence and folding of the region normally 
encoding the prepropeptide of Protein S. 
Even though HepG2 cells contained relatively large endogenous amounts of the alternative
transcript, high molecular weight aggregates were not found in HepG2 cell lysates. The reason
for this may be two-fold. First, the alternative mRNA may not be translated into protein. 
Second, the aggregates may be specific for COS-1 cells in which the recombinant alternative
transcript was expressed. Future experiments will have to provide further insight into the
relevance of our finding. Thus far, we do not know if the observed transcript is translated into 
protein in the cell lines in which it is expressed. If PSalt is indeed synthesized to the same
extent as its mRNA, the accumulation of PSalt protein in the cell might restrict PS synthesis,
thereby influencing systemic PS levels. Expression of the recombinant protein in a more
relevant cell line, such as the hepatocytic cell line HepG2, would be a first step into 
understanding these processes. In this respect one could think of titration experiments in 
which ratios of transfected PSwt versus PSalt are varied. Also, in order to follow the protein
maturation process in more detail, pulse chase experiments can be performed. Finally, the
development of a PSalt-specific antibody would aid greatly in determining its in vivo 
relevance.
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7.6 Implications of the findings presented in this thesis for the scientific
community and for patients suffering from deep vein thrombosis.
Importance of our findings to the scientific community 
According to Rezende et al (53) research into the cis-acting elements governing PROS1
transcription has to date been hampered by a controversy regarding the presence of possible
additional exons upstream to what is currently considered as exon 1. We clarified this issue
and showed that no additional 5' exons are present in any of the PROS1 transcripts that we
isolated in our experiments. With the identification of the exact start sites for PROS1
transcriptional initiation another long outstanding issue was resolved. These findings will 
certainly simplify future research into the PROS1 promoter.
Subsequent identification of the ubiquitous transcription factor Sp1 as a major player in the
basal transcriptional regulation of PROS1, through at least four and possibly five direct
binding sites for Sp1 in the promoter, may explain why PROS1 is transcribed at low levels by a 
large variety of cells throughout the body. Using cotransfection experiments, we found
evidence that liver-specific transcription factors FOXA2, HNF6, C/EBP� and DBP positively 
influence PROS1 transcription. A partially different set of transcription factors was found to 
bind to the PS promoter in EMSA experiments. The discrepancies in the results may be the 
result of the limitations of the various test systems that are routinely employed, as was 
discussed in this chapter. No evidence was found for a direct interaction of the steroid
hormone receptors; the estrogen, androgen or glucocorticoid receptors. Therefore, the
mechanism by which female sex hormones downregulate PS plasma levels remains 
unresolved.
In experiments conducted in HepG2 cell culture, we showed that PS levels are positively
influenced by IL6 through a direct interaction of the transcription factor STAT3 with the
PROS1 promoter. The changes in PS levels are most likely not of importance to plasma PS 
levels in vivo, since no major changes in PS levels have been reported during inflammation. 
However, locally upregulated PS levels at the site of inflammation may be of importance in 
light of the recently reported functions of PS in controlled cell death.
The full significance of our finding of an alternative PS transcript still needs to be 
determined. This transcript comprises 5 to 20% of the total transcripts, dependent on the cell
type, suggesting an important in vivo role. Recombinant protein expression in COS1 cell 
culture pointed out that the alternative protein, which contains an additional 32 amino acid 
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stretch in between the pre- and propeptide of the immature PS protein, is retained within the 
cell and forms aggregates, possibly with other proteins. In the future, coexpression
experiments with standard PS constructs in HepG2 cells need to be performed to determine if 
absolute and relative expression levels of PSalt affect its fate.
Importance of our findings to patients
The present research was mainly aimed at resolving several basic scientific issues regarding 
the regulation of transcription of the important anticoagulant Protein S. A thorough
understanding of the transcriptional regulation of PROS1 will contribute to a better 
understanding of how PS levels are regulated at the genetic level and may in the future provide
important insights into as yet unexplained partial PS deficiencies. The present results can be 
used as a steppingstone in that direction. In addition, the role of the alternative exon in 
PROS1 needs to be further explored, since similarly positioned exons occur in other 
coagulation genes.
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The goal of our research was to obtain more insight into the way in which Protein S (PS)
expression is regulated. PS is a Vitamin K-dependent plasma protein with an important 
anticoagulant role. It is the cofactor of Activated Protein C (APC), which inactivates factors
Va and VIIIa. PS is present in the circulation in two forms, as a free protein and bound to 
C4b-binding protein (C4BP). Only free PS is functional as an APC cofactor. A deficiency of
free PS is associated with the development of deep venous thrombosis, which leads to
obstruction of a blood vessel. This occurs most frequently in the deep veins of the leg. When
(part of a) thrombus detaches, it travels via the heart to the lungs, leading to a pulmonary
embolism, a complete or partial blockage of lung arteries.
A PS deficiency can be inherited or acquired. Inherited deficiency is relatively rare and
occurs in 2-8% of the families with a hereditary propensity to thrombosis (thrombophilia). An
acquired deficiency, which may be temporary in nature, occurs more frequently and may be
caused by oral contraceptive use (female sex hormones), liver disease and diffuse intravascular
coagulation (DIC). These effectors may directly or indirectly lower PS expression by altering
transcription or by changing other factors, respectively. Knowledge of the transcriptional
regulation of the gene encoding PS, PROS1, should enable us to understand the fluctuations
in PS levels in various circumstances.
Careful study of the DNA sequence directly upstream of the translational start of PROS1
showed that it does not contain a TATA box. The TATA box is a transcriptional element that
directs initiation of transcription to a clearly defined start site at a fixed distance downstream
from it. Genes without a TATA box often have several transcription start sites (TSSs) and 
may even contain multiple promoters. The use of these promoters and/or start sites is usually
cell type-specific. Because PS is mainly produced by liver cells, but to a lesser extent also by
other cell types, I investigated in Chapter 2 the TSSs of PROS1 transcripts in various cell
types to determine their cell type-specificity. The mRNA was isolated from liver cells (human
liver and the cell lines HepG2 and HuH7), megakaryocytes (cell line Meg01), and endothelial
cells (human umbilical vein endothelial cells; HUVECs). These cell types share as a common
property that they could in principle contribute to PS plasma levels, because they are in direct
contact with blood and are known to be capable of PS expression. Epithelial cells (the HeLa
cell line) were originally included as a negative control, but appeared to be capable of a low 
level of PS expression during the course of the studies. In addition, the activity of PROS1
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promoter fragments cloned in luciferase reporter gene constructs was determined by 
transfection in the same cell lines. In these constructs, luciferase expression is entirely
dependent on the strength of the PROS1 promoter fragment. If the activity of the PROS1
promoter would be mainly determined by cell-specific transcription factors, the relative
strength of the various promoter constructions should be cell type-dependent. In contrast, if
ubiquitous factors were responsible for the bulk of the promoter activity, then one would 
expect the activity of the various constructs to be similar in all cell lines.
All cell types express endogenous PROS1 transcripts with TSSs at 100, 117 and 147 bp 
upstream from the startcodon. The various start sites are used at a different frequency among
the cell lines, however. The HUVECs also showed an additional start site at 200 bp upstream 
of the translational start. These results show that the exact distribution of the start sites varies
among the different cell types. This type of cell type specific regulation of transcription is
probably caused by differences in the set of transcription factors in each cell type. We
obtained no evidence for the existence of alternative PROS1 promoters. The possible 
existence of additional transcription start sites in intron 1 was also excluded.
A PROS1 promoter with maximal activity was identified using in vitro studies with PROS1
promoter reporter-gene constructs. The maximally active promoter contained 370 bp 
upstream of the startcodon in all cell types. This region is present in construct PS370. Only 
small differences were found in the expression pattern of the various promoter constructs in 
the cell types used. Whereas the activity of the constructs in HepG2, HeLa and HUVEC cells
decreased with an increasing length of the PROS1 promoter fragment, the longer PROS1
promoter constructs in the Meg01 and HuH7 cell lines retained a relatively high activity.
Contrary to our expectations, the maximally active promoter fragment still had an activity 
of 40% in HepG2 cells following deletion of all identified transcription start sites from the 3'
end by exonuclease treatment. When we subsequently determined the TSSs in the parental
PS370 construct, start sites were found to be apparently randomly spread over the PROS1
promoter fragment. This is probably caused by a less stringent regulation of transcription
initiation in our model system in comparison with the endogenous gene.
The results described in Chapter 2 indicate that the basal activity of the PROS1 promoter
is regulated in approximately the same way in all cell types. The small differences in the
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types to determine their cell type-specificity. The mRNA was isolated from liver cells (human
liver and the cell lines HepG2 and HuH7), megakaryocytes (cell line Meg01), and endothelial
cells (human umbilical vei  endothelial cells; HUVECs). These cell types share as a common
property that they could in principle contribute to PS plasma levels, because they are in direct
contact with blood and are known to be capable of PS expression. Epithelial cells (the HeLa
cell line) were originally included as a negative control, but appeared to be capable of a low 
level of PS expression during the course of the studies. In addition, the activity of PROS1
171
promoter fragments cloned in luciferase reporter gene constructs was determined by 
transfection in the same cell lines. In these constructs, luciferase expression is entirely
dependent on the strength of the PROS1 promoter fragment. If the activity of the PROS1
promoter would be mainly determined by cell-specific transcription factors, the relative
strength of the various promoter constructions should be cell type-dependent. In contrast, if
ubiquitous factors were responsible for the bulk of the promoter activity, then one would 
expect the activity of the various constructs to be similar in all cell lines.
All cell types express endogenous PROS1 transcripts with TSSs at 100, 117 and 147 bp 
upstream from the startcodon. The various start sites are used at a different frequency among
the cell lines, however. The HUVECs also showed an additional start site at 200 bp upstream 
of the translational start. These results show that the exact distribution of the start sites varies
among the different cell types. This type of cell type specific regulation of transcription is
probably caused by differences in the set of transcription factors in each cell type. We
obtained no evidence for the existence of alternative PROS1 promoters. The possible 
existence of additional transcription start sites in intron 1 was also excluded.
A PROS1 promoter with maximal activity was identified using in vitro studies with PROS1
promoter reporter-gene constructs. The maximally active promoter contained 370 bp 
upstream of the startcodon in all cell types. This region is present in construct PS370. Only 
small differences were found in the expression pattern of the various promoter constructs in 
the cell types used. Whereas the activity of the constructs in HepG2, HeLa and HUVEC cells
decreased with an increasing length of the PROS1 promoter fragment, the longer PROS1
promoter constructs in the Meg01 and HuH7 cell lines retained a relatively high activity.
Contrary to our expectations, the maximally active promoter fragment still had an activity 
of 40% in HepG2 cells following deletion of all identified transcription start sites from the 3'
end by exonuclease treatment. When we subsequently determined the TSSs in the parental
PS370 construct, start sites were found to be apparently randomly spread over the PROS1
promoter fragment. This is probably caused by a less stringent regulation of transcription
initiation in our model system in comparison with the endogenous gene.
The results described in Chapter 2 indicate that the basal activity of the PROS1 promoter
is regulated in approximately the same way in all cell types. The small differences in the
endogenous TSSs and in the expression pattern of the various promoter constructs point at
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some cell-specific regulation via start site choice, but argue against a major influence of these
variables on the basal activity.
Chapter 3 describes a pilot study into the inducibility of the maximally active PS370-
promoter described in Chapter 2 by a number of carefully selected transcription factors. Co-
transfection of the PS370 construct and expression vectors encoding a transcription factor in
HeLa cells showed that PROS1 promoter activity was increased 24- and 15-fold by the
ubiquitous transcription factors Sp1 and Sp3, respectively. In addition, the liver-specific
transcription factors C/EBP� and FOXA2, and to a lesser extent HNF6 and DBP, had a
stimulatory effect on the activity of PS370. A detailed study of the PROS1 promoter sequence
in PS370 and its conservation in various mammalian species resulted in the localisation of 
evolutionary conserved consensus binding sites for C/EBP�, STAT, FOXA2 and
transcription factors of the Sp-family.
The results of this pilot study were partially confirmed in Chapter 4, in which it was
shown that FOXA2, Sp1 and Sp3 do indeed bind to the predicted locations in the PROS1
promoter sequence. Four Sp1 binding sites were found at 177-146 bp, 253-230 bp, 298-275 
bp and 359-335 bp upstream of the translational start site. The presence of the FOXA2
binding site at position 282-258 bp upstream of the startcodon had already been demonstrated 
by another group and could be confirmed. We also observed binding of the transcription
factors NFY (at 382-359) and CREB/ATF (at 346-323) to the promoter sequence. Analysis of 
the functionality of the identified transcription factor binding sites via mutagenesis showed
that the Sp1 binding sites at 177-146 and 253-230 were required for full basal activity of the
PS370 construct in HepG2 cells. In constructs in which these sites had been mutated, the 
promoter activity of the PS370 construct was reduced to 70 and 50% of the wild-type
construct, respectively. Alteration of just the sites at 298-275 and 359-335 had no negative
effect, but a mutant in which all four Sp1-sites had been mutated had a remaining activity of 
just 20%.
Cotransfection of HepG2 with an Sp1 expression vector and the fourfold PS370-Sp1 
mutant demonstrated that this mutant, despite its strongly decreased basal activity, could still 
be induced by Sp1, which indicates that not all functional Sp1 sites in the PS370 construct had
been identified. Most likely, there is an additional non-mutated Sp1 binding site in the
sequence 177-146. Finally, the Sp1-PROS1 promoter interaction that was demonstrated in vitro
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was confirmed by chromatin immunoprecipitation (ChIP) experiments using an antibody
directed against Sp1.
Mutations in the binding sites of the transcription factors FOXA2, CREB/ATF and NFY
only had a marginal negative effect on the basal expression of the luciferase reporter gene
under the control of the PROS1 promoter. Cotransfection of HepG2 cells with the PS370 
FOXA2 mutant and a FOXA2 expression vector resulted in a decreased response of the
mutant relative to the wild-type construct, but the interpretation of the data was complicated
by the fact that the control vector without the PROS1 promoter was strongly stimulated by
FOXA2.
The results of Chapter 4 confirm those of Chapter 2. The basal PROS1 transcription is
indeed regulated by an ubiquitous transcription factor, i.e. Sp1. The transcription factors that
are presumably responsible for the high expression in the liver have not yet been identified,
however. It is very well possible that part of this tissue-specific expression is caused by
epigenetic modulation of the PROS1 promoter via methylation and histone modification.
Despite various attempts to study promoter methylation, we have not yet been able to obtain 
unequivocal results.
Another interaction between a transcription factor and the PROS1 promoter described in
Chapter 3 was that between PS370 and C/EBP�. C/EBP� is known as the transcription
factor that mediates the signalling of the inflammatory mediator interleukin 6 (IL6). STAT3 is
a second nuclear factor that transduces the signal of IL6. In response to the binding of IL6 to
its receptor on the cellular membrane, both STAT3 and C/EBP� are phosphorylated.
Subsequently, they enter the nucleus and stimulate the transcription of various genes by
binding to their promoters. In the case of STAT3, phosphorylation is the only mode of 
activation, whereas the transcription of the C/EBP�-gene itself is also upregulated by IL6. In
Chapter 5, we investigated the effects of IL6 on PS levels in the medium of cultured HepG2
cells. We confirmed the results of other investigators, who previously showed that PS levels
rise in cell culture upon stimulation by IL6. We subsequently demonstrated that this effect can 
also be detected at the level of the PROS1 mRNA, which indicates that it is most likely caused 
by an effect on the promoter activity. The level of phosphorylated STAT3 (p-STAT3) in the




The goal of our research was to obtain more insight into the way in which Protein S (PS)
expression is regulated. PS is a Vitamin K-dependent plasma protein with an importa t 
a ticoagulant role. It is the cofactor of Activated Protein C (APC), which inactivates factors
Va and VIIIa. PS is present in the circulation in two forms, as a free protein and bound to 
C4b-binding protein (C4BP). Only free PS is functional as an APC cofactor. A deficiency of
free PS is associated with the development of deep venous thrombosis, which leads to
obstruction of a blood vessel. This occurs most frequently in the deep veins of the leg. When
(part of a) thrombus detaches, it travels via the heart to the lungs, leading to a pulmonary
embolism, a complete or partial blockage of lung rteries.
A PS deficiency can be inherited or acquired. Inherited deficiency is relatively rare and
occurs in 2-8% of the families with a hereditary propensity to t romb sis (thrombophilia). An
acquired deficiency, which may be temporary in nature, occurs more frequently and may be
caused by oral contraceptive use (female sex hormones), liver disease and diffuse intravascular
coagulation (DIC). These effectors may directly or indirectly lower PS expression by altering
transcription or by changing other factors, respectively. Knowledge of the transcriptional
regulation of the gene encoding PS, PROS1, should enable us to understand the fluctuations
in PS levels in various circumstances.
Careful study of the DNA sequence directly upstrea  of the translatio al start of PROS1
showed that it does not contain a TATA box. The TATA box is a transcriptio al element that
directs initiation of transcription to a clearly defined start site at a fixed distance downstream
from it. Genes without a TATA box often have several transcription start sites (TSSs) and 
may even contain multiple promoters. The use of these r moters and/or start sites is usually
cell type-specific. Because PS is mainly produced by liver cells, but to a lesser extent also by
ot er cell types, I investigated in Chapter 2 the TSSs of PROS1 transcripts in various cell
types to determine their cell type-specificity. The mRNA was isolated from liver cells (human
liver and the cell lines HepG2 and HuH7), megakaryocytes (cell line Meg01), and endothelial
cells (human umbilical vein endothelial cells; HUVECs). These cell types share as a common
property that they could in principle contribute to PS plasma levels, because they are in direct
contact with blood and are k own to be capable of PS expression. Epit elial cells (the HeLa
cell line) were originally included as a negative control, but appeared to be capable of a low 
level of PS expression during the course of the studies. In addition, the activity of PROS1
171
was confirmed by chromatin immunoprecipitation (ChIP) experiments using an antibody
directed against Sp1.
Mutations in the binding sites of the transcription factors FOXA2, CREB/ATF and NFY
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indeed regulated by an ubiquitous transcription factor, i.e. Sp1. The transcription factors that
are presumably responsible for the high expression in the liver have not yet been identified,
however. It is very well possible that part of this tissue-specific expression is caused by
epigenetic modulation of the PROS1 promoter via methylation and histone modification.
Despite various attempts to study promoter methylation, we have not yet been able to obtain 
unequivocal results.
Another interaction between a transcription factor and the PROS1 promoter described in
Chapter 3 was that between PS370 and C/EBP�. C/EBP� is known as the transcription
factor that mediates the signalling of the inflammatory mediator interleukin 6 (IL6). STAT3 is
a second nuclear factor that transduces the signal of IL6. In response to the binding of IL6 to
its receptor on the cellular membrane, both STAT3 and C/EBP� are phosphorylated.
Subsequently, they enter the nucleus and stimulate the transcription of various genes by
binding to their promoters. In the case of STAT3, phosphorylation is the only mode of 
activation, whereas the transcription of the C/EBP�-gene itself is also upregulated by IL6. In
Chapter 5, we investigated the effects of IL6 on PS levels in the medium of cultured HepG2
cells. We confirmed the results of other investigators, who previously showed that PS levels
rise in cell culture upon stimulation by IL6. We subsequently demonstrated that this effect can 
also be detected at the level of the PROS1 mRNA, which indicates that it is most likely caused 
by an effect on the promoter activity. The level of phosphorylated STAT3 (p-STAT3) in the
nucleus of the HepG2 cells increased following incubation with IL6, while that of C/EBP�
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remained at the same level. This indicated that the observed effects were most likely mediated
by STAT3.
The sequence element in the PS370 construct that could mediate the IL6-response
contains a consensus binding site for both C/EBP� and STAT3 at 229-207 bp upstream of
the start site of translation. Mutation of this site in several PROS1 promoter constructs
resulted in the simultaneous disappearance of both binding sites and prevented stimulation of
the promoter by IL6. Protein-DNA binding assays subsequently showed that STAT3 could
indeed bind to the normal sequence, but not to that of the mutant, and that this interaction
was much more obvious after stimulation of the cells with IL6. Binding of C/EBP� to this
sequence could not be detected, however. Moreover, the C/EBP� consensus sequence was
not capable to compete for protein binding to the PROS1 promoter sequence, whereas the
STAT3 consensus-sequence was capable of doing so. In addition, only a small part of the
protein-DNA complex in the gel was supershifted by a C/EBP� antibody, whereas incubation
with an anti-STAT3 antibody resulted in a nearly complete supershift of the DNA-protein
complex. This made clear that STAT3 plays an important role in the reaction of the PROS1-
promoter toward IL6. A role of C/EBP� could not entirely be discounted, however, on the 
basis of the results obtained in Chapter 3.
During inflammation the plasma levels of total Protein S are unaltered or slightly elevated,
whereas free Protein S levels are slightly reduced to unchanged. An induction of plasma PS
levels that is expected on the basis of our experiments, is probably counteracted by a
simultaneous increase of the levels of the C4BP that is also stimulated by IL6. The induction
of PS by IL6 is therefore probably not so much relevant to the levels of PS in plasma, but
much more to local PS levels in tissues.
PS is synthesized as a preproprotein. The pre- and propeptide are removed during the
subsequent maturation of the protein inside the cell. Chapter 6 describes the discovery of an
alternative PROS1 transcript encoding 32 additional amino acids in between the pre- and
propeptide of the immature protein. The novel transcript was detected during the
optimalisation of a quantitative PCR aimed at the detection of the normal PROS1 mRNA.
The transcript was present in all cell types tested, also in human liver. The alternative
transcript was converted to cDNA and cloned. The expression and size of the resulting
alternative PS (PSalt) was compared to that of standard PS following transfection of both
constructs in COS-1 cells. The alternative protein accumulated in the cell, whereas the
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standard protein was secreted into the culture medium as expected. Western blot analysis
indicated that the remaining PSalt was possibly larger than the standard protein, which
suggested that the additional amino acids in between the  pre- and propeptide disrupted the
removal of these two peptides during the maturation of PSalt. PSalt did not just accumulate 
in the cell, it also formed aggregates that were easily detectable on Western blot.
The implications of these finding are unclear for the time being, since PSalt-aggregates
were not observed  in lysates of HepG2 cells that also produce significant levels of the
alternative transcript. Possibly, the alternative PROS1 mRNA is degraded before it is 
translated into protein. In that case, alternative splicing of PROS1 transcripts may be used to
regulate the levels of standard PS. Alternatively and perhaps more likely, PSalt might be more
efficiently processed when it is expressed at relatively low levels in combination with standard 
PS in professional PS-expressing cells, such as HepG2 cells.
The regulation of PROS1 transcription was the focus of the research presented in this 
thesis. Our results provide novel insights into the transcriptional regulation of this gene and
thereby contribute to the basic knowledge required to understand the regulation and 
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Het doel van het hier gepresenteerde onderzoek was om meer inzicht te verkrijgen in de
wijze waarop de productie van Proteïne S (PS) geregeld wordt. PS is een eiwit in het
bloedplasma dat een belangrijke rol speelt in de bloedstolling. Het is een helper (cofactor) van
geactiveerd Proteïne C (APC). APC beperkt overmatige stolling door de stollingsfactoren Va
en VIIIa onwerkzaam te maken. PS komt in bloed in twee vormen voor, als vrij eiwit en
gebonden aan C4b-bindend eiwit (C4BP). Alleen de vrije vorm is functioneel als cofactor van 
APC. Een tekort aan vrij PS in het bloed draagt bij aan de ontwikkeling van diep veneuze
trombose. Dit is een aandoening waarbij een bloedstolsel ontstaat in een ader (vene),
waardoor de bloedbaan verstopt raakt. Dit komt het meest voor in de diepe venen van het 
been en staat bekend als een trombosebeen. Wanneer het stolsel of een stukje daarvan loslaat,
kan het via het hart in de longen terechtkomen en een longembolie, een gehele of gedeeltelijke
afsluiting van longslagaderen, veroorzaken.
Een tekort aan PS (een deficiëntie) kan aangeboren of verworven zijn. Een aangeboren
deficiëntie is vrij zeldzaam en komt slechts voor in 2-8% van de families met een erfelijke
tromboseneiging (trombofilie). Een verworven deficiëntie, die van voorbijgaande aard kan 
zijn, komt vaker voor en kan onder meer door pilgebruik (vrouwelijke geslachtshormonen),
leverziekte en diffuse intravasale stolling (DIS) worden veroorzaakt. Het effect van deze
factoren op PS spiegels kan direct (op het niveau van de PS productie) of indirect (door
beïnvloeding van andere factoren) zijn. Het belangrijkste gereguleerde proces tijdens de
eiwitproductie is doorgaans de transcriptie, waarbij een gen wordt overgeschreven in 
boodschapper RNA (mRNA), dat vervolgens in eiwit vertaald (getransleerd) wordt. De 
mRNA productie wordt geregeld door de promoter van een gen, die vlak voor de start van het
gen gelegen is. De mate van transcriptie wordt bepaald door specifieke eiwitten, zogenaamde
transcriptiefactoren, die aan de promoter binden en zo de transcriptie reguleren. Kennis van
de transcriptionele regulatie van het gen dat codeert voor PS, PROS1, zal een bijdrage leveren 
aan ons begrip van de fluctuaties in PS spiegels in verschillende situaties.
Zorgvuldige bestudering van de DNA-volgorde in en rond de PROS1-promoter wees uit
dat PROS1 geen TATA-box heeft. De TATA-box is een DNA-element dat de transcriptie laat
starten op een vast punt. Genen zonder TATA-box kennen vaak meerdere transcriptiestart-
punten en hebben soms zelfs verschillende promoters. Het gebruik van deze promoters en/of
startpunten is doorgaans celtype-specifiek. Omdat PS met name geproduceerd wordt door 
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levercellen, maar in mindere mate ook door andere cellen, onderzocht ik in Hoofdstuk 2 de
startplaatsen van PROS1 transcripten in verschillende soorten cellen om zo te bepalen of de
transcriptie startplaatsen van PROS1 celtype-specifiek zijn. Het mRNA werd geïsoleerd uit
levercellen (menselijke lever en de cellijnen HepG2 en HuH7), megakaryocyten (cellijn
Meg01), en vaatwandcellen (humane vasculaire endotheelcellen uit navelstreng). Deze
celsoorten hebben als gemeenschappelijke kenmerk dat zij in principe kunnen bijdragen aan
plasma PS spiegels, omdat zij in direct contact staan met het bloed. Epitheliale cellen (cellijn
HeLa) werden oorspronkelijk in de studie als een negatieve controle opgenomen, maar tijdens
de studie bleek dat ook deze cellen in geringe mate PS produceren. Daarnaast werd de
activiteit van PROS1 genconstructen bepaald. In deze constructen regelt de PROS1 promoter
de transcriptie van een reporter-gen, dat codeert voor een gemakkelijk te meten eiwitproduct,
in ons geval luciferase. De mate van luciferaseproductie is een maat voor de 
promoteractiviteit. Deze promoter-reportergenconstructen werden door middel van
transfectie in de eerder genoemde cellijnen ingebracht. Indien de PROS1 promoter gedreven 
wordt door celspecifieke transcriptiefactoren dan zou de relatieve sterkte van de
promoterconstructen per celsoort moeten verschillen. Als PROS1 transcriptie gereguleerd
wordt door algemeen voorkomende factoren dan zou de relatieve promoteractiviteit van de
verschillende constructen in alle cellijnen nagenoeg gelijk moeten zijn. 
Alle celsoorten blijken eigen (endogene) PROS1 transcripten te bevatten met een
transcriptiestartplaats op 100, 117 en 147 basenparen (bp) voor de vaste startplaats van 
eiwitsynthese (translatie). De frequentie van gebruik van deze startplaatsen verschilde echter
per celsoort. Ook bleken vaatwandcellen uit de navelstreng een extra startplaats van het
PROS1 transcript te vertonen op 200 bp voor de translationele start. Deze resultaten tonen
aan dat de exacte verdeling van startpunten van PROS1 transcripten in de bestudeerde 
celsoorten varieert. Deze vorm van celsoortspecifieke regulatie van transcriptie wordt
mogelijkerwijs veroorzaakt door verschillen in de samenstelling van de groep eiwitten in de
celkern die gezamenlijk de transcriptie reguleren. Voor alternatieve PROS1 promoters werd
geen bewijs gevonden en ook een eerder geopperde mogelijkheid dat PROS1 transcriptie
vanuit het eerste intron geïnitieerd zou kunnen worden, werd uitgesloten.
Een PROS1 promoter met maximale activiteit werd geïdentificeerd door middel van in vitro 
studies met PROS1 promoter-reportergenconstructen. De maximaal actieve promoter werd
voor alle celsoorten vastgesteld op een lengte van 370 bp stroomopwaarts van de 
translationele start, zoals aanwezig in het PROS1 promoterconstruct PS370. Er worden slechts
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kleine verschillen gevonden in het expressiepatroon van de promoterconstructen in de
geselecteerde celsoorten. Terwijl de activiteit van de constructen in HepG2, HeLa en HUVEC
cellen met toenemende lengte van het PROS1 promoterfragment sterk afnam, behielden de 
langere PROS1 promoterconstructen in de cellijnen Meg01 en HuH7 een relatief hoge
activiteit.
Tegen de verwachting in behield het maximaal actieve promoterfragment in HepG2 cellen
40% van zijn activiteit nadat alle gebruikelijke transcriptie startpunten vanaf de 3' kant waren
verwijderd. Toen vervolgens de transcriptie startplaatsen bepaald werden op het PS370
construct bleek dat deze verschilden van de startpunten gevonden voor de transcriptie van het
endogene PROS1, zoals dat op de chromosomen van de HepG2 cellen aanwezig was. Hieruit
werd geconcludeerd dat transcriptie vanaf de getransfecteerde promoterconstructen vanuit
veel meer punten werd geïnitieerd. Vermoedelijk wordt dit veroorzaakt door de minder
nauwkeurige regulatie van transcriptie initiatie in het modelsysteem in vergelijking met het
volledige gen in zijn normale chromosomale omgeving.
De bevindingen in Hoofdstuk 2 wijzen uit dat de basale activiteit van de PROS1 promoter
in alle celsoorten min of meer op een zelfde wijze is gereguleerd. De kleine verschillen in 
transcriptie startplaatsen van het endogene PROS1 en het expressiepatroon van de 
verschillende promoterconstructen in de verschillende cellijnen wijzen wel op een mogelijke
celspecifieke regulatie van transcriptie via de startlocatie, maar spreken een grote invloed
daarvan op de basale activiteit tegen.
Hoofdstuk 3 bevat een verkennende studie naar de induceerbaarheid van de in
Hoofdstuk 2 gevonden maximaal actieve promoter PS370 door verschillende zorgvuldig
geselecteerde transcriptiefactoren. Cotransfectie van HeLa cellen met het PS370 construct en
expressievectoren met daarin een gen coderend voor een transcriptiefactor, wees uit dat 
PROS1 promoteractiviteit respectievelijk 24- en 15-maal gestimuleerd werd door de alom 
aanwezige transcriptiefactoren Sp1 en Sp3. Ook de leverspecifieke transcriptiefactoren
C/EBP� en FOXA2 en in geringere mate HNF6 en DBP hadden een positieve invloed op de 
PS370 activiteit. Nauwkeurige bestudering van de PROS1 DNA-volgorde (sequentie) in PS370 
en de conservering daarvan tussen verwante diersoorten, resulteerde in de lokalisatie van 
evolutionair goed bewaard gebleven consensus bindingsplaatsen voor onder andere C/EBP�,
STAT, FOXA2 en transcriptiefactoren van de Sp-familie. 
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De resultaten van de verkennende studie werden bevestigd in Hoofdstuk 4, waarin door 
middel van de bestudering van eiwit-DNA interacties aangetoond werd dat FOXA2, Sp1 en
Sp3 inderdaad op de gevonden locaties binden aan de PROS1 promotersequentie. Vier Sp1
bindingsplaatsen werden gevonden die op 177-146 bp, 253-230 bp, 298-275 bp en 359-335 bp
stroomopwaarts van de translationele start werden gelokaliseerd. De aanwezigheid van een
FOXA2 bindingsplaats werd al eerder door een andere groep aangetoond op 282-258 bp
stroomopwaarts van de translationele start en kon worden bevestigd. Tevens werd een
interactie van de transcriptiefactoren NFY (op 382-359) en CREB/ATF (op 346-323) met de 
promoter waargenomen. Analyse van de functionaliteit van de gevonden 
transcriptiefactorbindingsplaatsen middels mutagenese wees uit dat Sp1 bindingsplaatsen 177-
146 en 253-230 van groot belang zijn voor de basale activiteit van het PS370 construct in 
HepG2 cellen. In constructen waarin deze bindingsplaatsen gemuteerd waren was de basale
PS370 activiteit gereduceerd tot respectievelijk 70 en 50% van die van het onveranderde
construct. Mutatie van uitsluitend de bindingsplaatsen op 298-275 en 359-335 had geen
negatief effect, maar een mutant waarin alle vier de Sp1-posities werden gemuteerd had een
restactiviteit van slechts 20%.
Cotransfectie van HepG2 cellen met een Sp1 expressievector en de viervoudige PS370-Sp1 
mutant liet echter zien dat deze mutant ondanks de afgenomen basale activiteit nog door Sp1
geïnduceerd kan worden, hetgeen er op duidt dat niet alle functionele Sp1 bindingsplaatsen in
het PS370 construct werden geïdentificeerd. Hoogstwaarschijnlijk is een extra niet-gemuteerde
Sp1 bindingsplaats aanwezig in de sequentie 177-146. De in vitro aangetoonde interactie tussen
Sp1 en de PROS1 promoter werd tenslotte bevestigd door een chromatine immunoprecipitatie
(ChIP) met een antilichaam specifiek voor Sp1.
Mutaties in de bindingsplaatsen voor de transcriptiefactoren FOXA2, CREB/ATF en 
NFY hadden niet of nauwelijks een negatief effect op de basale expressie van het luciferase
reporter-gen onder de controle van de PROS1 promoter. Cotransfectie van HepG2 cellen met
de PS370 FOXA2 mutant en een FOXA2 expressievector resulteerde weliswaar in een
afgenomen respons van de mutant ten opzichte van het normale construct, maar de
interpretatie van de data werd bemoeilijkt door het feit dat de controle vector zonder PROS1
promoter ook sterk op FOXA2 reageerde. 
De resultaten in Hoofdstuk 4 bevestigen die van Hoofdstuk 2. De basale PROS1
transcriptie wordt inderdaad gereguleerd door een alomtegenwoordige transcriptiefactor,
namelijk Sp1. De transcriptiefactoren verantwoordelijk voor de hoge leverspecifieke expressie 
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van PS werden echter vooralsnog niet geïdentificeerd. Het is goed mogelijk dat een deel van
deze weefselspecifieke expressie wordt veroorzaakt door zogenaamde epigenetische
modulering van de PROS1 promoter middels promotermethylering en histonmodificatie.
Ondanks pogingen om promotermethylering aan te tonen is het vooralsnog niet gelukt
hieromtrent een eenduidig resultaat te verkrijgen.
Een andere interactie die naar voren kwam uit de studie in Hoofdstuk 3 was die tussen
PS370 en C/EBP�. C/EBP� staat bekend als de transcriptiefactor die de signalering van de
ontstekingsmediator interleukine 6 (IL6) bewerkstelligt. STAT3 is de tweede nucleaire factor
die IL6-effecten medieert. In reactie op binding van IL6 aan de zijn receptor op de 
celmembraan worden zowel STAT3 als C/EBP� gefosforyleerd, waarna ze de kern ingaan en
verschillende genen aanzetten tot (versterkte) transcriptie door aan hun promoters te binden.
Voor STAT3 is deze fosforylering de enige manier van activatie, terwijl de transcriptie van het 
C/EBP�-gen zelf ook door IL6 wordt opgereguleerd. In Hoofdstuk 5 onderzochten wij het 
effect van IL6 op PS spiegels geproduceerd door gekweekte HepG2 cellen. Wij bevestigden
de resultaten van andere onderzoekers, die eerder hadden gevonden dat PS spiegels in 
celkweek inderdaad toenemen tijdens stimulatie met IL6. Vervolgens toonden we aan dat dit
effect ook zichtbaar is op het niveau van het PROS1 mRNA en dus hoogstwaarschijnlijk 
wordt veroorzaakt door een direct effect op promoteractiviteit. In onze experimenten nam de
concentratie van gefosforyleerd STAT3 (p-STAT3) toe in de kern van HepG2 cellen na 
incubatie met IL6, terwijl die van C/EBP� gelijk bleef. Dit duidde erop dat de waargenomen
effecten waarschijnlijk gemedieerd werden door STAT3.
De DNA-volgorde in het PS370 construct waardoor de IL6-respons gemedieerd zou
kunnen worden, bevat een consensus bindingsplaats voor zowel C/EBP� als voor STAT3 op
229-207 bp stroomopwaarts van de start van translatie. Nadat deze bindingsplaats in 
verscheidene PROS1 promoterconstructen gemuteerd was, waardoor zowel de C/EBP� als de 
STAT3 bindingplaatsen verdwenen waren, reageerde de promoter niet meer op de toevoeging
van IL6. Eiwit-DNA bindingsassays toonden aan dat STAT3 inderdaad kan binden aan de 
normale sequentie, maar niet aan die van de mutant, en dat deze interactie versterkt wordt
door stimulatie van de cellen met IL6. Voor C/EBP� werd een dergelijke interactie echter niet
waargenomen. De C/EBP� consensussequentie was bovendien niet in staat binding van het
eiwit aan de PROS1 promoter sequentie te voorkomen, terwijl de STAT3 consensussequentie
dat wel kon. Bovendien verschoof slechts een deel van het eiwit-DNA complex in de gel na
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toevoeging van een C/EBP� antilichaam, terwijl incubatie met een tegen STAT3 gericht
antilichaam resulteerde in een nagenoeg complete verschuiving van het eiwit-DNA complex.
Hierdoor is duidelijk geworden dat STAT3 een belangrijke rol speelt bij de reactie van de 
PROS1-promoter op IL6. Een rol van C/EBP� kan echter niet volledig worden uitgesloten
op basis van de resultaten in Hoofdstuk 3.
Tijdens ontsteking zijn de totale PS spiegels in het plasma van patiënten nagenoeg 
onveranderd tot licht verhoogd, terwijl vrije PS spiegels soms gereduceerd zijn of ook gelijk 
blijven. Een potentiële geringe inductie van plasma PS spiegels door IL6, zoals verwacht mag 
worden op basis van onze experimenten, wordt hoogstwaarschijnlijk tenietgedaan door de 
gelijktijdige stijging van de spiegel van C4BP, dat ook geïnduceerd wordt door IL6. Het belang
van de inductie van PS door IL6 moet dan wellicht ook niet gezocht worden in een effect op 
de plasma PS spiegels, maar meer op lokaal (weefsel)niveau.
PS wordt aangemaakt als een prepro-eiwit, waarvan het pre- en propeptide verwijderd 
worden tijdens de verdere rijping van het eiwit in de cel. Hoofdstuk 6 beschrijft de
ontdekking van een alternatief PROS1 transcript dat codeert voor 32 extra aminozuren tussen
het pre- en propeptide van het onvolwassen eiwit. Dit transcript werd gevonden tijdens de
optimalisatie van een kwantitatieve PCR voor het normale PROS1 mRNA. Het nieuwe
transcript was aanwezig in alle celsoorten die getest werden, waaronder een sample van een
humane lever. Het alternatieve transcript werd gekloneerd en de expressie en grootte van het 
resulterende alternatieve PS (PSalt) werd vergeleken met die van het standaard PS na
transfectie van beide constructen in COS-1 cellen. Het alternatieve eiwit hoopte zich op in de
cel, terwijl het standaard PS product, zoals verwacht, werd uitgescheiden. Western blot analyse
gaf aan dat het alternatieve eiwit dat in de cel aanwezig bleef mogelijk groter was dan het
standaard product. Dit suggereerde dat de extra aminozuren tussen het pre- en propeptide de
afscheiding van deze twee peptides in het rijpingsproces van PSalt verstoorde. Niet alleen
bleef het alternatieve PS in de cel, het vormde ook aggregaten die zichtbaar waren op een 
Western blot.
De implicaties van deze bevindingen zijn vooralsnog onduidelijk, aangezien aggregaten met 
het alternatieve PS eiwit niet in lysaten van HepG2 cellen werden gevonden, die het
alternatieve transcript ook produceren. Mogelijkerwijs wordt het alternatieve PROS1 transcript
afgebroken voordat het omgezet wordt tot eiwit. In dat geval bestaat de mogelijkheid dat 
vorming van het alternatieve transcript in vivo gebruikt wordt om de synthese van het 
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standaard PS te reguleren. Een andere en misschien meer waarschijnlijke mogelijkheid is dat 
PSalt efficiënter wordt verwerkt wanneer het in relatief lage hoeveelheden worden
geproduceerd in de aanwezigheid van standaard PS en/of in cellen die gewend zijn PS te
produceren, zoals HepG2 cellen.
De regulatie van PROS1 transcriptie stond centraal in het onderzoek dat in dit proefschrift
beschreven is. Dit proefschrift geeft nieuwe inzichten in die transcriptie en draagt daardoor bij
aan de basiskennis die noodzakelijk is voor het begrijpen van de regulering en de 
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